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Abstract 
Chk1 is a conserved protein kinase which is activated in response to multiple 
exogenous and endogenous genotoxic stresses. In response Chk1 mediates 
several cell cycle checkpoint responses which are important components of the 
cellular DNA damage response (DDR) pathway and as such are important in 
maintaining genome integrity throughout the cell cycle. The aim of this study 
was to investigate the potential role that Chk1 may play in the maintenance and 
progression of malignant melanoma using both in vitro and in vivo models; and 
to determine if Chk1 inhibition could be a viable therapeutic approach to 
malignant melanoma treatment.  
Initially I investigated the importance of Chk1 in the cells of origin for 
melanoma; melanocytes. In this thesis I have examined the importance of Chk1 
on melanoblast proliferation and survival during development. I demonstrated 
that targeted deletion of Chk1 in the melanoblasts of developing mice causes 
complete loss of these cells from the developing embryo. This manifests itself as 
complete lack of a pigmented coat in adult mice. Chk1 deleted melanoblasts 
exhibit DNA damage as marked by γH2AX. 
To examine the role of Chk1 in melanoma maintenance and progression I utilized 
cell lines generated from a murine model of metastatic melanoma in allograft 
nude mouse experiments and investigated how the conditional genetic deletion 
of Chk1 in this model affects disease progression. Using this model I showed that 
complete loss of Chk1 during tumour development caused a profound reduction 
in the proliferation potential of melanoma tumour formation with a concurrent 
significant increase in survival time in these mice. In addition I also showed that 
hemizygous deletion of Chk1 during tumour development exerts a more modest 
but nevertheless measurable effect on melanoma tumour formation, however 
with no demonstrable effect on survival time.  
To further understand how the loss of Chk1 leads to cell death and how this may 
be beneficial for the treatment of melanoma I utilised a specific allosteric 
inhibitor of Chk1 in human melanoma cell lines. I found that Chk1 inhibition led 
to collapse of replication forks in S-phase cells resulting in the generation of DNA 
damage specifically in S-phase cells, leading to a cell death signal characterised 
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by cleavage of PARP and Annexin V positivity. I also showed that Chk1 inhibition 
has significant toxicity in vitro in all metastatic melanoma cell lines; however 
there is a broad range of relative toxicities to Chk1 inhibition between cell lines. 
Further in vivo analysis also showed that Chk1 inhibition caused a measurable 
reduction in the tumour growth rate of subcutaneously injected metastatic 
melanoma cells in CD1 nude mice. 
Overall the work presented here provides evidence that Chk1 is essential for 
both melanocyte and melanoma cell survival with the essential function of Chk1 
being in S-phase of the cell cycle, and that Chk1 inhibition may be a viable 
therapeutic option for melanoma therapy. 
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1 Introduction 
1.1 Cell cycle and Checkpoints 
1.1.1 The Cell Cycle 
The eukaryotic cell cycle is an evolutionarily conserved process, from unicellular 
organisms to complex multicellular organisms, that regulates cell division. The 
majority of cells in the human body are not actively cycling. These cells are 
either in a reversible withdrawal from cell cycling known as G0, which happens 
in response to high cell density or in the absence of growth factor stimulation 
(Tessema et al, 2004), or in a permanent withdrawal from cell cycling becoming 
either terminally differentiated or senescent. Differentiation is the 
normal process by which a less specialized cell develops or matures to become 
more distinct in form and function whereas senescence is a stress induced 
response.   
The cell cycle consists of four sequential phases; G1-S-G2 and M. The most 
dynamic phases are S-phase, when DNA replication occurs, and M-phase, when 
the cells divide into two identical daughter cells. These are bridged by two gap 
phases that govern the readiness of cells to enter S and M-phases (Tessema et al, 
2004). During G1, which follows mitosis, the cells are sensitive to both positive 
and negative cues from growth factor signalling networks. Progression through 
the cell cycle is mediated by the cyclin-dependant kinase (CDK) family of 
serine/threonine kinases and their regulatory partners’ cyclins (Morgan, 1997; 
Nurse, 2000; Vermeulen et al, 2003). Active CDKs comprise a protein kinase 
subunit whose catalytic activity is dependent on association with a regulatory 
cyclin subunit. The abundance of different cyclins is regulated by protein 
synthesis and degradation in a cell cycle-dependant manner which regulates 
their association with CDKs to control different stages of cell division (Johnson & 
Walker, 1999; Sherr, 1996). The different combinations of cyclins and CDKs work 
together by phosphorylating downstream targets to alter their activity. CDK-
cyclin complexes are negatively regulated by a complex network of proteins 
including phosphatases, the INK4 and CIP/KIP family of proteins and through 
proteolysis (Elledge, 1996; Lee M et al, 2001). 
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The cyclin D-CDK4/6 and cyclin E-CDK2 complexes drive G1 progression through 
the restriction point, which commits a cell to the cell cycle. Cyclin D is produced 
in response to extracellular growth signals and binds to CDK4/6, which in turn 
phosphorylates the retinoblastoma (Rb) protein (Winston and Pledger 1993). 
Hyper-phosphorylated Rb dissociates from E2F transcription factors allowing 
them to become active. Active E2F promotes transcription of genes including the 
S-phase cyclins (E and A) and enzymes required for DNA replication such as DNA 
polymerase.  Cyclin E thus produced binds to CDK2, forming the cyclin E-CDK2 
complex, which pushes the cell from G1 to S phase (Blomen & Boonstra, 2007; 
Schafer, 1998).   
S-phase is initiated by the cyclin A-CDK2 complex which phosphorylates proteins 
of the pre-replication complexes. This phosphorylation serves two purposes, to 
activate each assembled pre-replication complex and to prevent new complexes 
from forming (Kelly & Brown, 2000; Nishitani & Lygerou, 2002). This ensures that 
every portion of the cells genome is replicated only once (Blow & Hodgson, 
2002). The cyclin B-CDK1 complex regulates entry into mitosis. Activation of the 
cyclin B-CDK1 complex causes breakdown of the nuclear envelope and initiation 
of prophase (Nigg, 2001). Its subsequent deactivation causes the cell to exit 
mitosis. Passage through the cell cycle and transition from one phase to the next 
is tightly monitored by sensor mechanisms. These mechanisms are called 
checkpoints which act to maintain the correct order and integrity during cell 
division, and as such are critical in the maintenance of genome integrity 
(Elledge, 1996; Hartwell & Weinert, 1989; Nyberg et al, 2002).  
1.1.2 Checkpoint function and control 
Cells are constantly exposed to DNA damage arising from a variety of internal 
and external sources, and to replicative stress. To protect the integrity of their 
genomes cells have developed a variety of different repair mechanisms which 
are equipped to deal with specific lesions (Christmann et al, 2003; Sancar et al, 
2004). These include non-homologous end joining and homologous recombination 
to deal with double stranded breaks and base excision repair to deal with single 
or short patches of nucleotide damage (Christmann et al, 2003; Morita et al, 
2010). However in order for DNA repair to occur normal progression through the 
cell cycle needs to be temporarily suspended. This allows time for recognition of 
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the lesion, recruitment of various repair proteins and the repair process to 
proceed without error. Checkpoint proteins are central to this process, which 
act by either preventing entry into or halting progression at specific phases of 
the cell cycle (Sancar et al, 2004) (Figure 1.1). Key players in these checkpoint 
responses are the ATM-Chk2 and ATR-Chk1 pathways (Reinhardt & Yaffe, 2009; 
Smith et al, 2012). Activation of these pathways is crucial for the proper co-
ordination of checkpoint and DNA repair processes. They also play key roles in 
initiating apoptosis or cellular senescence in the presence of extensive DNA 
damage which cannot be repaired.  
 
 
Figure 1.1: Multiple DNA damage and replication checkpoints in vertebrate cells. 
DNA damage and DNA synthesis inhibition evoke multiple, mechanistically distinct, checkpoint 
responses in vertebrate cells that are controlled by the ATM/Chk2 and ATR/Chk1 pathways. In 
response to DNA damage cells can delay entry to S-phase (G1/S checkpoint), slow the replication 
of damaged DNA (Intra-S checkpoint) or prevent entry to mitosis while damage persists (G2/M 
checkpoint). When DNA synthesis is inhibited distinct checkpoint responses are triggered that 
serve to stabilise stalled replication forks, suppress the firing of latent replication, and delay the 
onset of mitosis until DNA replication is complete (S/M checkpoint). 
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1.1.2.1 DNA damage and G2/M checkpoint 
When DNA damage is acquired during the G2-phase of the cell cycle, the G2/M 
checkpoint is activated in order to prevent entry of the damaged cell into 
mitosis. This is imposed by blocking activation of the mitotic cyclin B-CDK1 
complex which is required for breakdown of the nuclear envelope and initiation 
of prophase. DNA damage triggers a rapid cascade of phosphorylation events 
involving the ATM/Chk2 pathway (upon IR induced DNA DSBs) or ATR/Chk1 
pathway (upon UV induced tracts of ssDNA) kinases. Inhibition of the cyclin B-
CDK1 complex is achieved through the addition of inhibitory phosphorylation on 
threonine 14 and tyrosine 15 (T14/Y15), which is imposed by the Wee1 kinase 
(Den Haese et al, 1995; Rowley et al, 1992). The Wee1 kinase is a direct target 
of the Chk1 kinase which phosphorylates and activates Wee1 in the presence of 
DNA damage (Lee J et al, 2001). Activation of the cyclin B-CDK1 complex is 
achieved through removal of the inhibitory phosphorylation (T14/Y15), which is 
accomplished by the CDC25 family phosphatases. Upon DNA damage these 
phosphatases are inhibited to prevent removal of the inhibitory phosphorylation. 
The CDC25A and CDC25C phosphatases are direct targets of Chk1 and Chk2. In 
response to DNA damage active Chk1 and Chk2 can phosphorylate CDC25A on 
serine 123 which primes it for ubiquitination and rapid degradation by the 
proteasome (Falck et al, 2002). Concurrently active Chk1 can also phosphorylate 
CDC25C on serine 216 which causes it to binds to 14-3-3 proteins, causing its 
subsequent exportation from the nucleus (Peng et al, 1997). Collectively these 
mechanisms prevent activation of the mitotic cyclin B-CDK1 complex resulting in 
cell cycle blockage in G2-phase. Other kinases such as p38 have also been 
implicated in carrying out this function (Astuti et al, 2009; Thornton & Rincon, 
2009). Transcriptional programmes regulated by p53 and Brca1 can also 
contribute to sustaining G2/M checkpoint arrest (Kastan & Bartek, 2004). 
1.1.2.2 DNA replication arrest and S/M checkpoint 
When DNA synthesis is inhibited distinct checkpoint responses are triggered that 
serve to stabilize stalled replication forks, suppress the firing of latent 
replication origins, and to delay the onset of mitosis until DNA replication is 
complete. The ATR/Chk1 pathway plays a major role in all these responses. 
Upon inhibition of DNA synthesis, for example through nucleotide pool depletion 
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or by direct damage to the replicating DNA, long tracks of ssDNA are produced. 
These tracks of ssDNA recruit and activate ATR which subsequently activates 
Chk1 (Choi et al, 2010). As in the G2/M checkpoint, Chk1 prevents the entry of 
cells with incomplete DNA replication into mitosis by inhibition of the cyclin B-
CDK1 complex. Chk1 had also been implicated in the maintenance of stalled 
replication forks and suppression of origin of firing (Broderick & Nasheuer 2009; 
Zachos et al, 2005). The CDC45 protein plays a central role in the regulation of 
both the initiation and elongation stages of DNA replication, and is thought to be 
the main target of the Chk1-depedent S/M checkpoint (Bailis et al, 2008; Liu et 
al, 2006). CDC45 interacts with the replication factors MCM5 and MCM7, which is 
required for DNA replication (Hardy, 1997). Chk1 activity negatively regulates 
the association of CDC45 and MCM7 at origins of replication via a CDC25A/CDK2-
independent pathway, and as such suppresses origin of firing during DNA damage 
(Liu et al, 2006).  
1.1.2.3 DNA damage and the G1/S checkpoint 
When DNA damage is acquired during the G1-phase of the cell cycle, the G1/S 
checkpoint is activated in order to prevent the damaged cells from initiating 
DNA replication. This is imposed by blocking activation of the S-phase cyclin E-
CDK2 complex which is required for the initiation of DNA replication by 
promoting CDC45 loading on chromatin, an attractant for DNA polymerase onto 
pre-replication complexes (Kneissl et al, 2003; Mimura & Takisawa, 1998). 
Blockage of the cyclin E-CDK2 complex is carried out by two mechanisms, which 
cause a rapid and sustained induction of the G1/S checkpoint respectively. DNA 
damage triggers a rapid cascade of phosphorylation events involving the 
ATM/Chk2 pathway (upon IR induced DNA DSBs) or ATR/Chk1 pathway (upon UV 
induced tracts of ssDNA) kinases. Inhibition of the cyclin E-CDK2 complex is 
achieved through the addition of inhibitory phosphorylation on threonine 14 and 
tyrosine 15 (T14/Y15). Activation of Chk1/Chk2 maintains this inhibition by 
phosphorylation of CDC25A phosphatase, which primes CDC25A for ubiquitination 
and rapid destruction by the proteasome (Falck et al, 2002). The absence of 
CDC25A phosphatase activity ‘locks’ the CDK2 kinase in its inactive form. 
Maintenance of the G1/S arrest after DNA damage requires new protein 
synthesis. As in the rapid response the ATM/ATR and Chk2/Chk1 kinases play a 
pivotal role through the phosphorylation and stabilisation of p53 (Maclaine & 
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Hupp, 2009; Shieh et al, 2000). Phosphorylation of p53 prevents its binding to 
MDM2, a specific inhibitor of p53 and a p53 ubiquitin ligase. This leads to 
accumulation of a stable and transcriptionally active p53 protein which results in 
the induction of the p21 protein, an inhibitor of CDKs (Mirza et al, 2003). When 
accumulated to a threshold level, p21 can bind to and inhibit all cyclin E–CDK2 
complexes, and thereby secure the maintenance of the G1 arrest.  
1.2 DNA damage response pathway 
The DNA damage response (DDR) pathway consists of a highly complex collection 
of signal transduction processes which orchestrate together to allow the correct 
coordination and induction of DNA damage repair processes, cell cycle 
checkpoints and apoptosis/senescence. The DDR pathway is critical for the 
maintenance of genome integrity and as such plays a central role in the 
evolution of cancer. In fact inherited defects in DNA damage responses can 
predispose to cancer by enhancing the accumulation of oncogenic mutations. 
Key players’ among the DDR are the ATM/Chk2 and ATR/Chk1 signalling 
pathways, which are evolutionary conserved.  
1.2.1 The ATM/Chk2 pathway 
The ATM/Chk2 pathway is primarily activated in response to radiation and 
genotoxins which cause DNA DSBs, with weak, if any, activation following agents 
that block DNA replication without inducing damage (Matsuoka et al, 2000). ATM 
is a large serine/threonine kinase that belongs to the family 
of Phosphatidylinositol 3-kinase-related kinases (PIKKs). ATM phosphorylates 
numerous protein substrates, key of which is the serine/threonine kinase Chk2. 
ATM is recruited to and activated primarily at DNA DSBs in conjunction with the 
Mre11: Rad50: Nbs1 (MRN) sensor complex (Lee & Paull, 2005; Suzuki et al, 1999) 
(Figure 1.2). The exact nature of the primary signal that triggers ATM activation 
following DNA DSBs remains unknown; however it does not appear to be limited 
to the immediate vicinity of the damage and may be linked to long-range 
alterations in chromatin structure (Bakkenist & Kastan, 2003). The relationship 
between MRN and ATM activation at DNA DSBs is exemplified by human disorders 
resulting from mutation in these genes. Hypomorphic mutations in the Nbs1 and 
Mre11 genes lead to the genetic instability disorders Nijmegen breakage 
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syndrome and Ataxia-like disease respectively. These clinically resemble ATM 
deficiency which causes the genetic disorder ataxia-telangiectasia (A-T) that is 
characterized by cerebellar degeneration, immunodeficiency, radiation 
sensitivity, chromosomal instability and cancer predisposition.  
In undamaged cells ATM is thought to be kept in an inactive state by the 
formation of homo-dimers. In response to DNA DSBs these inactive homo-dimers 
are rapidly induced to auto-phosphorylate in trans. This results in dissociation of 
the homo-dimers to form monomers which are partially active (Bakkenist & 
Kastan, 2003). Although it is unclear how this auto-phosphorylation is induced it 
is not directly dependant on sites of DNA DSBs but more on a rapid change 
induced by DSBs which change some aspect of higher-order chromatin structure, 
and that this chromatin alteration initiates ATM activation (Bakkenist & Kastan, 
2003).  The first auto-phosphorylation site to be identified was serine 1981 
(S1981). Modification of this residue has been shown to be tightly linked with 
activation of ATM under most circumstances (Bakkenist & Kastan, 2003). 
However this residue is not essential for ATM activation in mice (Pellegrini et al, 
2006). Further studies have identified two additional auto-phosphorylation sites, 
S367 and S1893, which may contribute to ATM activation. ATM has also been 
shown to undergo acetylation which is mediated by the TIP60 acetyl-transferase. 
This modification may also play a role in the full activation of ATM (Lavin & 
Kozlov, 2007). Full activation of ATM monomers is induced by interactions with 
members of the MRN complex (Lee & Paull 2007; Uziel et al, 2003). This not only 
allows for full activation of ATM but also recruits ATM to sites of DNA DSBs where 
it can act locally on its substrates. Local substrates include the variant histone, 
H2AX, forming the DNA damage associated γ-H2AX histone mark (Fernandez-
Capetillo et al, 2004), the Nbs1 member of the MRN complex, BRAC1 and CtIP 
which are important in initiating homologous recombination (HR) repair, MDC1, 
p53BP1 (Kastan & Lim, 2000; Lavin, 2008), the cohesin SMC1 (Kitagawa et al, 
2004) and the downstream effector kinase Chk2 (Lukas et al, 2003). In addition, 
ATM acts on other substrates which do not necessarily concentrate at sites of 
damage. For example, ATM plays an important role in activating the p53 
response to DNA damage both by phosphorylating p53 itself and its stability 
regulators, MDM2 and MDMX (Chen et al, 2005; Lavin & Kozlov, 2007) and there 
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is increasing evidence that ATM also has substrates and functions in the 
cytoplasm (Lavin, 2008).  
ATM activates Chk2 by phosphorylation on a specific threonine (T) residue, T68. 
This residue is located within an N terminal serine/ threonine-glutamine (SQ/ 
TQ) rich motif (Ahn et al, 2000). Once phosphorylated, the SQ/ TQ motif of one 
Chk2 molecule is recognized by the phosphopeptide-binding Fork-head 
associated (FHA) domain of another, leading to transient homo-dimerization, 
intermolecular activation loop auto-phosphorylation, and full activation (Ahn et 
al, 2002; Cai et al, 2009; Oliver et al, 2006).Once activated, Chk2 is thought to 
dissociate from sites of damage and disperse as a monomer throughout the 
nucleus to act on multiple substrates involved in cell cycle progression, 
apoptosis, and gene transcription. (Lukas et al, 2003). Known substrates of Chk2 
include the p53 tumour suppressor protein (Chehab et al, 2000; Shieh et al, 
2000) and its regulator MDMX (Chen et al, 2005), CDC25 family phosphatases 
(Blasina et al, 1999; Chaturvedi et al, 1999; Matsuoka et al, 1998), the BRCA1 
tumour suppressor (Lee J et al, 2000) and transcription factors such as FOXM1 
(Tan et al, 2007) and E2F1 (Stevens et al, 2003).  
1.2.2 The ATR/Chk1 pathway 
The ATR/Chk1 pathway is activated most strongly when DNA replication is 
impeded, for example as a result of nucleotide depletion or replication blocking 
DNA damage lesions such as those inflicted by ultraviolet (UV) light (Abraham, 
2001). ATR, like ATM, is a large serine/threonine kinase that belongs to the 
family of PIKKs. ATR phosphorylates numerous protein substrates, key of which is 
the serine/threonine kinase Chk1. ATR is recruited to and activated at tracts of 
single-stranded DNA (ssDNA) in association with its partner protein ATRIP, which 
interacts directly with ssDNA in complex with Replication Protein A (RPA) (Figure 
1.2). Tracts of ssDNA can be generated by several mechanisms. Firstly when 
replication is blocked, DNA polymerases become uncoupled from the replicative 
helicase (Byun et al, 2005) causing the generation of tracts of ssDNA through 
unwinding of the DNA double helix. These structures can also be generated 
through the action of nucleotide excision repair (NER) or at dysfunctional 
telomeres. Finally they can also be generated at sites of DNA DSBs as a result of 
nucleolytic strand resection. Conversely, replication of damaged DNA can result 
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in DSBs when leading-strand DNA polymerases encounter single strand nicks or 
abasic sites. As a result, the ATM/Chk2 and ATR/Chk1 pathways are frequently 
activated simultaneously in cells exposed to diverse genotoxic stresses, including 
ionizing radiation and cytotoxic chemotherapy agents. Upon generation these 
tracts of ssDNA rapidly become coated with the trimeric ssDNA-binding protein 
complex, RPA, which interacts with ATRIP through the 70kD RPA1 subunit (Zou & 
Elledge, 2003). 
Like ATM, there is evidence that ATR activation involves auto-phosphorylation. 
Upon DNA damage the ATR-ATRIP complex is recruited to RPA-coated tracts of 
ssDNA, where ATR is induced to auto-phosphorylate in trans on a single site, 
T1989 (Liu et al, 2011). This phosphorylation is crucial for full activation of ATR, 
and is dependent on RPA, ATRIP and ATR kinase activity, but not on the ATR 
mediator TopBP1 (Liu et al, 2011). In addition, efficient ATR activation and 
downstream phosphorylation of Chk1 depends on the actions of two mediator 
proteins, TopBP1 and Claspin. TopBP1, which is recruited to ssDNA-RPA via the 
PCNA-like Rad9: Rad1: Hus1 checkpoint clamp (Delacroix et al, 2007), contains a 
domain that stimulates ATR activity, although exactly how this occurs is unclear 
(Kumagai et al, 2006; Mordes et al, 2008). Claspin, which associates with active 
replication forks (Lee J et al, 2003), is phosphorylated in an ATR-dependant 
manner within a short repeated motif. Phosphorylated Claspin then binds to and 
recruits Chk1 (Jeong et al, 2003) to ssDNA-RPA complexes, bringing it into close 
proximity with active ATR (Kumagai & Dunphy, 2003) and enabling ATR to 
phosphorylate Chk1 directly. Recently studies have revealed a requirement for 
two additional mediators, Timeless and Tipin (Timeless-interacting protein); 
both for normal replication and for ATR-Chk1 activation in response to 
replication stress (Kondratov & Antoch, 2007). Timeless binds to both ATR and 
Chk1 whereas Tipin can interact with Claspin (Kemp et al, 2010). Recent data 
indicate that like ATRIP, Tipin binds to a specific subunit of the RPA complex 
(although RPA2 rather than RPA1) and is required for stable association of both 
Timeless and Claspin with tracts of ssDNA-RPA (Kemp et al, 2010). In addition to 
checkpoint activation, Timeless and Tipin also seem to be required for 
replication fork stabilization and restart (Errico et al, 2007). As with ATM, ATR is 
also thought to act on many other substrates in addition to Chk1, including 
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BRCA1, mini-chromosome maintenance (MCM) proteins, and components of the 
RPA complex (Cimprich & Cortez, 2008). 
ATR phosphorylates Chk1 directly at multiple S/T-Q sites within the C-terminal 
regulatory domain, most notably at S317 and S345. Phosphorylation of these 
sites, and in particular S345, is essential for Chk1 biological activity, although 
exactly how these modifications regulate Chk1 catalytic remains poorly 
understood (Niida et al, 2007; Walker et al, 2009). ATR-mediated 
phosphorylation is reported to stimulate Chk1 kinase activity by relieving 
inhibition by the C-terminal regulatory domain (Oe et al, 2001; Walker et al, 
2009); however it may also promote release of Chk1 from chromatin (Smits et al, 
2006). Chk1 also undergoes auto-phosphorylation during activation (Kumagai et 
al, 2004), however this does not occur within the activation loop (Chen et al, 
2000), and the exact target sites and functional consequences of this 
modification have not yet been fully established. Once activated, Chk1 is 
thought to dissociate from Claspin to act on both nuclear and cytoplasmic 
substrates (Lukas et al, 2003). Known substrates of Chk1 include CDC25A (Falck 
et al, 2002), CDC25C (Blasina et al, 1999), and Wee1 (Lee J et al, 2001), which 
are important regulators of cell cycle transitions. Chk1-mediated 
phosphorylation inhibits the activity of both CDC25A and CDC25C under 
conditions of genotoxic stress, although by different mechanisms; 
phosphorylation of CDC25A targets the protein for degradation (Falck et al, 
2002), whilst phosphorylated CDC25C is sequestered in an inactive form through 
association with 14-3-3 proteins (Peng et al, 1997). Wee1 kinase activity, by 
contrast, is stimulated by Chk1 mediated phosphorylation (Lee J et al, 2001). 
Chk1 is also thought to modulate recombination by phosphorylating Rad51 
(Sorensen et al, 2005) and BRCA2 (Bahassi et al, 2008), and to mediate DNA 
damage-induced repression of gene transcription through phosphorylation of 
histone H3 (Shimada et al, 2008). Although predominantly nuclear, a proportion 
of active Chk1 also localizes at the centrosome, where it is thought to control 
the timing of activation of the mitotic cyclin B-CDK1 complex, and thus the 
onset of mitosis, both after damage and during unperturbed cell cycles (Kramer 
et al, 2004). In contrast to ATM and Chk2, ATR and Chk1 are thought to be active 
at low levels even during unperturbed cell cycles, particularly during S-phase 
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(Syljuasen et al, 2005), potentially explaining why they are essential in many 
cell types.  
 
 
 
 
Figure 1.2: Activation of the ATM/Chk2 and ATR/Chk1 pathways. ATM and ATR are activated 
in response to DNA DSBs and ssDNA respectively, although ATR can also be activated in 
response to DNA DSBs by ATM-dependent strand resection. In response to DSBs ATM, in 
conjunction with the MRN complex, CtIP and BRCA1, stimulates nucleolytic strand resection to 
generate tracts of ssDNA. These tracts of ssDNA act as platforms for the recruitment of ATR-
ATRIP leading to Chk1 activation and also initiating HRR.  
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1.3 Checkpoint pathway alterations in cancer 
Genomic instability occurs in most human cancers, and the importance of 
maintaining the integrity of our genomes is highlighted by both inherited and 
sporadic loss-of-function mutations which occur in DNA damage response genes, 
resulting in human cancer predisposition syndromes and cancer. Examples of 
both have been seen to affect the ATM/Chk2 pathway, whereas mutations in the 
ATR/Chk1 pathway are rarer.  
Homozygous germline loss-of-function mutations affecting ATM cause the human 
disease syndrome Ataxia telangiectasia (A-T), characterised by 
immunodeficiency, neurodegeneration, hypersensitivity to radiation and 
spontaneous predisposition to cancer (Shiloh & Kastan, 2001). As with A-T 
humans, ATM knockout mice are predisposed to lymphomas and are sensitive to 
radiation (Xu et al, 1996). Interestingly although A-T is a recessive condition 
individuals which are heterozygous for ATM mutations also show an increased 
incidence of cancer, which may be related to medical and occupational exposure 
to radiation (Briani et al, 2006; Swift et al, 1991). Furthermore cells taken from 
heterozygous individuals show sensitivity to radiation in vitro that is 
intermediate between those seen from A-T patients and normal individuals 
(Swift et al, 1991). Somatic mutations affecting ATM have also been documented 
in sporadic lymphoid malignancies and lung adenocarcinomas (Ding et al, 2008; 
Gumy-Pause et al, 2004). The importance of DNA damage signalling is further 
emphasised by mutations in members of the MRN complex, which is important in 
sensing damage and activating ATM. Hypomorphic mutations affecting the Nbs1 
and Mre11 genes give rise to the human conditions Nijmegen breakage syndrome 
and Ataxia-like disorder respectively, which both share clinical similarities with 
A-T (Stewart et al, 1999; Varon et al, 1998). Similarly mice with hypmorphic 
mutations of Nbs1 and Rad50 also show predisposition to cancer (Bender et al, 
2002; Kang et al, 2002; Williams et al, 2002).  
Mutations in downstream targets of ATM; including the important effector kinase 
Chk2, BRCA1 and p53 also show functional significance in cancer development. 
Studies have established that individuals who are heterozygous for mutations in 
Chk2 suffer from a statistically significant increase in the incidence of breast, 
prostate and other cancers (Antoni et al, 2007). However tumours that arise in 
Chapter 1  30 
 
these Chk2 heterozygous individuals do not consistently lose the remaining allele 
of Chk2, indicating that Chk2 is not functioning as a classical tumour suppressor 
protein (Antoni et al, 2007). Interestingly Chk2 knockout mice develop normally 
and are not prone to spontaneously cancer development (Takai et al, 2002). 
However they are more sensitive to chemical-induced skin carcinogenesis 
showing both an increase in tumour burden and tumour growth rate (Hirao et al, 
2002). Humans that are heterozygous for the BRCA1 and BRCA2 genes show an 
increased incidence of breast and ovarian cancers (O’Donovan & Livingston, 
2010). Tumourigenesis in these individuals is attributed to functional 
inactivation of the remaining allele of BRCA1/2 (Collins et al, 1995; Neuhausen & 
Marshall, 1994). The functional consequence of this is loss of HR-mediated DNA 
repair in these cells. This is demonstrated by tumours that arise in susceptible 
individuals which show deficiency for HR repair, whereas the normal surrounding 
tissue remains proficient in HR (Turner et al, 2005). Inherited mutations in p53 
cause the human condition Li-Fraumeni syndrome, which is characterised by 
multi-organ cancer predisposition including sarcomas and cancers of the breast, 
brain and adrenal glands (Birch, 1994). Mice that are knockout for p53 develop 
normally however they are predisposed to a wide variety of cancers, primarily 
lymphomas and sarcomas, by 6 months of age (Donehower et al, 1992).  
 
Homozygous germline hypomorphic mutations affecting ATR cause the human 
disease Seckel Syndrome, characterised by a wide range of symptoms including 
growth retardation and microcephaly. Interestingly these individuals do not show 
an increased incidence of cancer (Kerzendorfer & O’Driscoll, 2009). In mouse 
models of Seckel syndrome degenerative and premature ageing-like phenotypes 
are observed, demonstrating that ATR is critically important in normal 
development, stem cell survival and tissue homeostasis. Similarly to humans 
with Seckel syndrome, these mice do not show predisposition to cancer (Murga 
et al, 2009; Ruzankina et al, 2007). Consistent with this somatic mutations 
affecting ATR are not widely found in cancers (Heikkinen et al, 2005), with the 
exception of rare sporadic stomach and endothelial tumours with microsatellite 
instability (Menoyo et al, 2001; Vassileva et al, 2002; Zighelboim et al, 2009). 
This shows that in general loss of ATR function does not perturb genomic 
stability in such a way as to promote carcinogenesis.  
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Germline mutations in Chk1 have thus far not been implicated in any human 
disease and somatic mutations affecting Chk1 in human cancers is very rare, 
with rare exceptions in tumours displaying microsatellite instability (Bertoni et 
al, 1999; Menoyo et al, 2001). This may be explained by the observation that 
Chk1 knockout in mice is embryonic lethal (Liu et al, 2000). However the 
development of a conditional Chk1 knockout mouse model, whereby Chk1 can be 
deleted in a tissue specific manner has enabled the study of Chk1 during 
carcinogenesis. Studies have shown that homozygous loss of Chk1 is deleterious 
for tumour formation including in mammary tumour formation on both a p53 null 
background (Fishler et al, 2010) and a WNT-1 transgene model (Liu et al, 2000), 
and in chemical-induced skin carcinogenesis (Tho et al, 2012). These data 
suggest that Chk1 is essential for tumour cell survival. Interestingly studies have 
also shown that while complete loss of Chk1 function is detrimental to tumour 
formation heterozygous loss of Chk1 can promote tumourigenesis. In mammary 
tumour formation on both a p53 null background and a WNT-1 transgene model 
heterozygous deletion of Chk1 enhanced tumour formation (Fishler et al, 2010; 
Liu et al, 2000), whereas in chemical-induced skin carcinogenesis Chk1 
heterozygous deletion increased the progression of benign papilloma to 
malignant carcinoma (Tho et al, 2012). These data show that Chk1 
hemizygousity, at least in some systems, can promote tumourigenesis.  
The functional consequences on cell survival and cancer development induced by 
alterations in the ATM/Chk2 and ATR/Chk1 pathways are very different. While 
impairment or complete loss of function of the ATM/Chk2 pathway is compatible 
with cell survival, it comes at the cost of cancer predisposition. This is a result, 
at least in part, of loss of genome stability resulting in more rapid accumulation 
of oncogenic mutations. In contrast impairment or complete loss of function of 
the ATR/Chk1 pathway appears incompatible with cell survival in most cell 
types, presumable because it controls aspects of DNA replication that are 
essential for cell proliferation and survival, and which lead to cell death if 
dysfunctional.  
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1.3.1  DNA damage signalling as a barrier to tumourigenesis 
Maintenance of genomic integrity is fundamental to continued life, and which is 
maintained by the DDR pathway. This is a complex cellular network of dynamic 
and mutually co-ordinated transduction pathways which elicit DNA repair, cell 
cycle arrest, senescence and cell death. As a consequence of this important role 
the DDR pathway has emerged as a powerful anti-cancer barrier which blocks 
malignant progression (Halazonetis et al, 2008). The initial observation for this 
phenomenon came from clinical specimens of human breast and lung carcinomas 
harvested before the patients had received any treatment. These samples 
displayed constitutively activated DNA damage checkpoint signalling as 
determined by phosphorylation of Chk2 at T68 (DiTullio et al, 2002). This was 
further emphasised by studies which showed that in contrast to normal human 
tissue, tumour specimens from various tissues often showed constitutive 
activation of DNA damage signalling as demonstrated by the presence of 
activated phosphorylated forms of ATM, Chk2, p53 and γH2AX and 53BP1 foci 
(Bartkova et al, 2005; Gorgoulis et al, 2005). Interestingly the observed DDR 
pathway activation was at its peak level in early stage tumours with attenuation 
in later malignant stages. Furthermore it was noted that in these early pre-
invasive lesions DDR pathway activation preceded the occurrence of mutations 
or loss of expression of DDR pathway components such as ATM, Chk2 and p53 
(Bartkova et al, 2005; Gorgoulis et al, 2005). On the basis of these results it was 
postulated that the DDR machinery serves as an inducible barrier to constrain 
tumour development in its early stages. This is achieved by inducing cellular 
senescence or cell death. It was also postulated that this may exert a selective 
pressure for specific mutations which could over-ride this effect such as p53. 
These earlier observations were subsequently supported by further studies. In 
vitro cell culture models driven by ras, mos, cdc6, cyclin E and Stat5 oncogenes 
and in vivo mouse model experiments with ras-driven mouse epithelial tumours 
have demonstrated that activated oncogenes evoke a robust DDR pathway 
activation leading to the establishment of cellular senescence in diverse cell 
types including primary fibroblasts, lymphocytes and epithelial cells (Bartkova et 
al, 2006; Di Micco et al, 2006; Mallette et al, 2007; Mallette & Ferbeyre, 2007). 
Experimental blockage of oncogene-induced DNA damage signalling through 
siRNA mediated knockdown of targets such as ATM resulted in escape from 
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senescence and increase in DNA synthesis. This observation was equal in degree 
to that achieved by knockdown of p53 (Bartkova et al, 2006; Di Micco et al, 
2006).  
Accumulating evidence suggests that replicative stress may be the underlying 
trigger of oncogene-induced DDR pathway activation and senescence. It has been 
shown that in cells exposed to oncogenic stimuli the ATR/ATRIP module engages 
with RPA coated tracts of ssDNA, resulting in both S-phase and G2-phase arrest 
(Bartkova et al, 2005; Gorgoulis et al, 2005). Other studies have also 
documented co-localisation of oncogene-evoked DDR foci with replication foci, 
as marked by the presence of proliferating cell nuclear antigen (PCNA) in S-
phase cells (Bartkova et al, 2006). DNA combing, a technique used to produce an 
array of uniformly stretched DNA that is then highly suitable for nucleic acid 
hybridization studies, has shown that oncogenes induce aberrant replication 
forks coupled with premature termination. Such replication forks are unstable 
and can collapse leading to DNA breakage (Branzei & Foiani, 2005). The exact 
mechanism by which oncogenes induce replicative stress remains unclear; 
however deregulation of CDK activity is a potential candidate.  Tightly 
coordinated activation and deactivation of CDK- cyclin complexes is essential for 
the proper transitioning of the cell cycle including initiation of DNA synthesis. 
The action of many oncogenes and tumour suppressor genes is to ultimately 
deregulate CDK activity thus amplification of CDK activity as a result of 
oncogenic signalling could lead to aberrant DNA replication and thus DNA 
damage (Blow & Gillespie, 2008). An example of this is Ras-oncogenes which 
affect CDK activity by up-regulating cyclin D1 and down-regulating p27, a CDK 
inhibitor (Takuwa, 2001).  
Cellular senescence has been shown to critically dependant on two powerful 
tumour suppressor pathways; the p53 and pRb/p16Ink4a pathways. Escape from 
oncogene-induced replicative stress resulting in cellular senescence had mainly 
been attributed to mutations in one or both of these pathways (Beausejour et al, 
2003). The importance of this in tumour progression is highlighted by the fact 
that in humans a significant proportion of cancers harbour mutations in the p53 
and pRb pathways. Inactivation of either p53 or p16 has been shown to prevent 
Ras-induced arrest in mouse cells in vitro (Kamijo et al, 1997; Serrano et al, 
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1997). More recently an in vivo model of prostate cancer shows p53-dependant 
growth arrest induced by PTEN inactivation, which is reversed upon loss of p53 
resulting in aggressive invasive cancer (Chen et al, 2005).  
1.3.2 Checkpoint suppression as a therapeutic target 
Although drugs which target pathways important in tumour development, such 
as Imatinib, a bcr-abl inhibitor in chronic myeloid leukaemia, and Vemurafenib, 
a B-Raf inhibitor in melanoma (Hauschild et al, 2012) are starting to be used in 
the clinic, the main treatment for most cancers still focuses on radiation and 
genotoxic chemotherapy. These agents cause massive amounts of DNA damage, 
and as such will be potent activators of the DDR pathway. As a result in recent 
years much interest has been focused on the cellular DDR and whether it can be 
manipulated for therapy; including proteins involved in both DNA repair such as 
DNA-PK, BRCA1 and PARP and DNA damage checkpoint proteins such as ATM, 
ATR, Chk2 and Chk1 (Ljungman, 2009). The ATR/Chk1 pathway in particular is an 
attractive target as unlike ATM and Chk2 which are frequently mutated in both 
familial and sporadic cancer, ATR and Chk1 are very rarely mutated. In addition 
the ATR/Chk1 pathway has been shown to be essential for both S-phase and G2-
phase cell cycle arrest following replicative stress and DNA damage, whereas the 
ATM/Chk2 pathway appears to be less crucial.  
A large proportion of cancers are thought to have an inactivated p53 pathway 
(Zhou & Bartek, 2004), plus a significant proportion have been shown to have 
defects in the ATM/Chk2 pathway (Bartkova et al, 2005; Bartkova et al, 2006; 
Gorgoulis et al, 2005). As a consequence many cancer cells will be deficient for 
the G1/S checkpoint, which hampers the tumour cells ability to arrest in 
response to genotoxic stress. Thus it has been postulated that such G1/S 
checkpoint-deficient cancer cells become more reliant on Chk1 in order to 
respond to DNA damage than the surrounding normal tissue (Dai & Grant, 2010; 
Zhou & Bartek, 2004). Therefore the initial strategy for Chk1 inhibition focused 
on preferentially sensitizing tumour cells to DNA damaging agents in combination 
therapy.  
Inhibition of Chk1 using either siRNA depletion or the selective chemical 
inhibitor, UCN-01, has been shown to potentiate cell killing by a wide range of 
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genotoxic agents, including IR, alkylating agents, nucleoside analogues, 
cisplatin, and topoisomerase inhibitors (Carrassa et al, 2004; Cho et al, 2005; 
Ganzinelli et al, 2008; Hirose et al, 2001; Karnitz et al, 2005; Koniaras et al, 
2001; Wang et al, 1996; Yu et al, 2002). In many, although not all, of these 
studies Chk1 inhibition resulted in a greater degree of sensitization in tumour 
cells that were deficient for p53 than in their proficient counterparts, consistent 
with the idea that loss of G1 arrest indeed creates a therapeutic index. More 
selective inhibitors of Chk1, such as AZD7762, PF-00477736, XL844 and SCH 
900766, have been developed which all showed promising preclinical activities in 
combination with a wide range of DNA damaging agents including IR, 
gemcitabine and camptothecin in both in vitro and in vivo analysis (Ashwell et 
al, 2008; Dai & Grant, 2010). These studies showed evidence for amplified levels 
of damage, mitotic catastrophe with damaged or incompletely replicated DNA, 
and increased levels of apoptosis (Carrassa et al, 2004; Cho et al, 2005; 
Ganzinelli et al, 2008; Hirose et al, 2001; Karnitz et al, 2005; Koniaras et al, 
2001; Wang et al, 1996; Yu et al, 2002). However more recent studies have also 
shown that Chk1 inhibitors may have potential as single agents in some cancer 
types (Brooks et al, 2012; Davies et al, 2011a; Ferrao et al, 2012), and in 
combination with other inhibitors which target important cell cycle proteins 
such as Wee1 (Aarts et al, 2012; Carrassa et al, 2012; Davies et al, 2011b). In 
single agent studies Chk1 inhibition was more selective in both myc-driven 
cancer cells and those which displayed high levels of replicative stress, and was 
associated with collapse of DNA replication forks and increased levels of 
apoptosis.  
Together these studies demonstrate that Chk1 is a valuable target in the 
treatment of cancer whose pharmacological inhibition can both potentiate 
tumour cell killing by a wide range of genotoxic agents and exhibit potency as a 
single agent. Much remains to be understood about the mechanisms involved in 
chemo-sensitization however; Chk1 inhibition can clearly both amplify the 
extent of damage inflicted by a given agent and promote the formation of more 
lethal lesions, for example by triggering stalled replication fork collapse to form 
DSBs. In addition, evidence suggests that damage escalation as a result of Chk1 
inhibition can enhance tumour cell killing both by conventional routes, for 
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example by increasing apoptosis, but also by triggering novel mechanisms such 
as premature entry to mitosis with un-replicated DNA. 
1.4 Melanocytes 
Melanocytes are a specialised cell type which resides predominantly in the skin, 
where they are found in the basal layer of the epidermis in humans and in the 
hair follicles of animals with hair. However they can also be found in the eye, 
inner ear, meninges, bones and heart. Melanocytes comprise only 5-10% of the 
cells present in the basal layer of the epidermis; however despite this they are 
phenotypically prominent. The principle function of melanocytes is their ability 
to produce the pigment melanin, contained within membrane-bound organelles 
termed melanosomes, which are exported to the surrounding keratinocytes in 
the skin or to newly synthesised hair. Melanin is important in providing photo-
protection from UV-induced DNA damage and thermoregulation to cells in the 
skin, the bodies’ main barrier to the external environment.  
1.4.1 Early embryonic development 
Melanocytes develop from neural-crest (NC) precursor cells during 
embryogenesis. NC-cells are pluripotent cells that arise from the dorsal-most 
point of the neural tube between the surface ectoderm and the neural plate 
(Erickson & Reedy, 1998). In addition to melanocytes they also give rise to 
sensory neurons, glial cells, osteocytes, chrondocytes and craniofacial tissue (Le 
Douarin et al, 2004). The development of NC-cells (NCC) into mature 
melanocytes has been well studied showing that they first develop into bi-
potential glial-melanocytes lineage progenitors before becoming un-pigmented 
precursors called melanoblasts and finally maturing into differentiated 
melanocytes (Dupin et al, 2000) (Figure 1.3). Development of a mouse model 
whereby the LacZ reporter gene is expressed from the melanocyte specific 
promoter, Trp2, has enabled dissection of the migratory path taken by the 
melanocytes during embryogenesis (Mackenzie et al, 1997). In mice, 
melanoblasts differentiate at embryonic day 8.5 (E8.5) migrating along the 
dorsolateral pathway and eventually diving ventrally through the dermis. By 
E14.5 they exit from the underlying dermis and populate the epidermis and 
developing hair follicle (Mackenzie et al, 1997). Numerous signalling pathways 
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and transcription factors tightly regulate melanocyte migration and 
differentiation during embryogenesis (White & Zon, 2008). These proteins and 
pathways provide and integrate spatial and temporal signals to create the proper 
environment for normal development. Defects in these pathways cause 
hypopigmentation arising from lack of melanocyte cells.   
1.4.1.1 Mitf 
The importance of the Microphthalmia-associated transcription factor (Mitf) in 
melanocyte development is highlighted by the human diseases Tietz syndrome 
and Waardenburg Type IIa syndrome; both characterised by deafness and 
reduced pigmentation. Mitf belongs to the myc-related family of basic helix-
loop-helix leucine zipper (bHLH-Zip) transcription factors (Moore, 1995; 
Steingrimsson et al, 2004). Like other bHLH-Zip factors it binds to the canonical 
E box sequence (CA[T/C]GTG) (Steingrimsson et al, 2004). Mitf regulates the 
melanocyte lineage, at least in part, through the transcriptional activation of 
genes related to pigment cell function including DCT, Tyrosinase, Tyrp1, c-Kit, 
AIM1 and MC1r (Aoki & Moro, 2002; Du & Fisher, 2002; Tsujimura et al, 1996; 
Yasumoto et al, 1995). These genes play central roles in melanin production, and 
as such mutations in these genes in mice have been found to be associated with 
lack of pigmentation due to defects in melanin synthesis rather than an absence 
of viable melanocytes (Guyonneau et al, 2004). However Mitf mutant mice and 
zebrafish have been shown to be completely devoid of both embryonic and adult 
melanocytes suggesting that Mitf plays an important role in melanocyte survival 
as well as pigmentation (Hodgkinson et al, 1993; Lister et al, 1999). Studies have 
shown that Mitf mutant mice lack melanoblasts at early stages prior to their 
migration from the neural tube (Hornyak et al, 2001). This apparent apoptotic 
cell death of melanoblasts is due, at least in part, to disruption in the expression 
of Bcl-2, an anti-apoptotic protein. Mitf has been shown to be a direct 
transcriptional activator of Bcl-2 expression, and therefore promotes cell 
survival by up-regulation of Bcl-2 (McGill et al, 2002). The importance of this is 
demonstrated by the observation that overexpression of Bcl-2 is able to rescue 
the apoptotic phenotype seen in Mitf mutant melanocytes (McGill et al, 2002).  
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1.4.1.2  c-Kit 
c-Kit is a receptor tyrosine kinase that is expressed on the surface of early 
embryonic melanoblasts during development. c-Kit is activated by its ligand SCF, 
which leads to activation of the Ras/MAPK pathway. One consequence of this is 
to induce post-translational modification of Mitf (Hemesath et al, 1998; Wu et 
al, 2000) indicating its role in differentiation. Melanocyte migration and 
localisation during embryogenesis is strongly correlated with SCF expression. In 
the absence of functional c-Kit or SCF melanoblasts remain fixed laterally to the 
dorsolateral neural tube with no migration beyond this point, and ultimately 
disappear (Wehrle-Haller & Weston, 1995). Analysis of humans, mice and 
zebrafish bearing mutations in either c-Kit or its ligand SCF demonstrate its 
importance in the survival, proliferation and migration of melanoblasts during 
development (Jordan & Jackson, 2000; Mackenzie et al, 1997; Wehrle-Haller & 
Weston, 2003). The human disease piebaldism, which is characterised by white 
de-pigmented areas of skin, is caused by a heterozygous mutation in c-Kit 
(Giebel & Spritz, 1991; Spritz, 1994). Mouse models whereby either c-Kit or SCF 
harbour mutations exhibit varying degrees if pigmentation defects associated 
with a reduced number of melanocytes (Brannan et al, 1991; Geissler et al, 
1988). In sparse mutant zebrafish, which corresponds to c-Kit, melanoblasts are 
formed normally but they subsequently die by 11 days post-fertilisation, 
revealing a role in melanoblast survival (Parichy et al, 1999). These melanoblasts 
also show a defect in migration, with a greater degree located closer to the site 
of origin than in wild-type animals (Parichy et al, 1999). 
1.4.1.3  Wnt 
The first evidence that Wnt signalling was important in melanocyte development 
came from the Wnt1/Wnt3a knockout mice which have almost no detectable 
melanocytes (Ikeya et al, 1997). Studies in zebrafish suggest that Wnt/β-catenin 
signalling controls the fate decision of bi-potential glial-melanocyte stem cells; 
overexpression of β-catenin lead to increased numbers of melanocytes but with 
a reciprocal reduction in neuron and glial cells whereas inhibition of β-catenin 
signalling caused NCC to adopt a neural rather than pigment cell fate (Dorsky et 
al, 1998). In culture studies of mouse cells showed that directed gene transfer of 
Wnt1 and β-catenin into NC-precursor cells caused an increase in the both the 
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number of differentiated melanocytes and their pigmentation levels (Dunn et al, 
2000). Further studies have shown that this occurs in an endothelin-dependant 
manner, but with two distinct mechanisms for Wnt1 and Wnt3a (Dunn et al, 
2005). Wnt3a or β-catenin overexpression causes an increase in melanocyte 
numbers by biasing the fate of NCC towards the melanocyte lineage, whereas 
overexpression of Wnt1 does not alter the fate of NCC but instead acts through 
paracrine signalling on melanoblast precursors to increase the number that 
become melanocytes (Dunn et al, 2005). Interestingly in the mouse, conditional 
deletion of β-catenin in pre-migratory NCC prevents the generation of both 
melanocytes and sensory neurons (Hari et al, 2002), showing that Wnt/β-catenin 
signalling in vivo controls both sensory and melanocyte lineage formation. This 
has been shown to be due to two sequential waves of Wnt/β-catenin signalling; 
β-catenin activation in pre-migratory NCC promotes the formation of sensory 
neurons at the expanse of all other cell lineages, however β-catenin activation 
in later migratory NCC promotes the formation of melanocytes while other 
lineages are suppressed (Hari et al, 2012). Wnt1/Wnt3a triggers the canonical β-
catenin pathway, resulting in β-catenin-induced transcription at TCF/LEF 
promoter/enhancer elements. Wnt signalling is thought to drive the 
differentiation of the melanocyte lineage, as least in part, through its direct 
transcriptional up-regulation of Mitf (Takeda et al, 2000). Mitf in turn has been 
shown to interact with LEF1, where they act synergistically to increase the 
transcription of melanocyte specific-target promoters (Schepsky et al, 2006; 
Yasumoto et al, 2002).   
1.4.1.4 Snail/Slug and Sox10 
Snail and Slug are zinc-finger transcription factors that bind to E-box motifs and 
which have been associated with the human diseases piebaldism (Tachibana et 
al, 2003) and Waardenburg Type IIa syndrome (Sanchez-Martin et al, 2003). Mice 
with Slug mutations display a phenotype similar to piebaldism with 
depigmentation of the ventral trunk, tail and feet, and white forelock (Perez-
Losada et al, 2002). The earliest known response to signals that induce NCC 
during embryogenesis is the expression of Snail/Slug transcription factors 
(LaBonne & Bronner-Fraser, 1999). Before migration of NCC from the neural 
plate can occur they must undergo an epithelial-to-mesenchymal transition 
(EMT) in which down-regulation of cell adhesion molecules such as E-cadherin 
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allows for movement to occur (Acloque et al, 2009; Kalluri & Weinburg, 2009). 
The Snail and Slug family of transcription factors have been shown to be 
important in this process by direct transcriptional repression of E-cadherin (Cano 
et al, 2000). In fact, onset of Snail transcription coincides with migration of NCC 
from the neural plate. In Xenopus repression of Slug leads to reduced expression 
of both Slug and Snail in late stage embryos, which is associated with the 
inhibition of NCC migration and the reduction or loss of many NCC derivatives 
(Carl et al, 1999; LaBonne & Bronner-Fraser, 2000). This phenotype is rescued by 
overexpression of either Slug or Snail that leads to an excess of melanocytes 
(Carl et al, 1999; LaBonne & Bronner-Fraser, 2000). Snail/Slug expression is 
important at two distinct phases where it contributes to both cell fate and 
migration. Inhibition at early stages of embryogenesis prevents formation of NC 
precursor cells, whereas inhibition at later stages interferes with NCC migration 
(LaBonne & Bronner-Fraser, 2000).  
Sox10 is a transcription factor that belongs to the SOX (SRY-related HMG-box) 
family of transcription factors, which are involved in the development and 
normal physiology of numerous tissues, including melanocytes (Harris et al, 
2010). Mutations in Sox10 are associated with the human disease Waardenburg 
Type IV, a combination of both Waardenburg syndrome and Hirschsprung disease 
(Bondurand et al, 2007). Mice which express a dominant negative Sox10 are a 
model for Waardenburg Type IV (Herbarth et al, 1998; Southard-Smith et al, 
1998). These mice exhibit an increased number of apoptotic cells in the NCC 
migratory pathway early in development with an almost complete loss of NCC at 
later stages (Hou et al, 2006; Pottorf et al, 2001; Southard-Smith et al, 1998). 
Sox10 has been shown to play a key role in the transcriptional control of Mitf 
(Lang & Epstein, 2003; Lee M et al, 2000; Potterf et al, 2000; Verastegui et al, 
2000), and as such has the ability to regulate a number of genes related to 
pigment cell function including DCT, Tyrosinase and Tyrp1 (Jiao et al, 2004; 
Murisier et al, 2007). These genes play central roles in melanin production. 
Consistent with this primary NCC cultures generated from Sox10 mutant mice 
have an absence of Mitf expression (Hou et al, 2006). However, although Sox10 is 
thought to act primarily through the regulation of Mitf, overexpression of Mitf 
was not able to induce the expression of Tyrosinase or to rescue pigmentation in 
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the absence of Sox10 (Hou et al, 2006), therefore demonstrating that Sox10 also 
acts independently of Mitf.  
1.4.1.5 Endothelins 
The initial observation that endothelin signalling was important in melanocyte 
development came from the endothelin-B receptor (EDNRB) and endothelin-3 
(ET3) knockout mice which both have almost a complete lack of pigmentation 
(Baynash et al, 1994; Hosoda et al, 1994). EDNRB is a G-protein coupled receptor 
which is activated by binding of its ligand ET3. Upon activation EDNRB signals to 
numerous pathways inducing activation of PKC, MAPK, Raf1, p90 ribosomal S6 
kinase, CREB and cAMP protein kinase (Bohm et al, 1995; Imokawa et al, 1996; 
Imokawa et al, 1997; Sato-Jin et al, 2008). EDNRB signalling has also been shown 
to regulate the melanocyte specific transcription factor Mitf at both the 
transcriptional and translational level (Sato-Jin et al, 2008). EDNRB/ET3 
signalling plays various roles in melanocyte development including promoting the 
survival, proliferation, differentiation and migration of committed melanocyte 
precursors (Saldana-Caboverde & Kos, 2010). Animal studies have shown that 
EDNRB signalling is only critically required  from E10 to E12.5 in mice in order to 
develop a normal pigmentation pattern, with loss at this time leading to 
complete loss of melanocytes from adult mice (Lee H et al, 2003; Shin et al, 
1999). In this model it was shown that the phenotype caused by loss of EDNRB 
could be rescued by activating EDNRB as late as E10, therefore indicating that 
endothelin signalling is not necessary for the initial specification of mammalian 
NCC but rather for the dispersal and survival of melanoblasts (Shin et al, 1999).  
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Figure 1.3: Neural-Crest differentiation. Stages of differentiation from a neural-crest precursor 
cell to a fully differentiated melanised melanocyte, with the important pathways for each stage 
 
1.4.2  Adult melanocytes 
The skin is one of the most regenerative organs known in both human and animal 
biology. On any given day millions of new epidermal skin cells and hair are 
generated, both of which are pigmented in an identical fashion to their 
predecessors by melanocytes. During the final stages of development 
melanocytes are correctly localised to the base of newly formed hair follicles 
and to niches in the basal layer of the epidermis, where they will be able to 
exert their functions during the lifespan of the organism. In the hair follicle the 
new developing hair shaft becomes pigmented due to the transfer of melanin 
from melanocytes located in the bulb of the hair follicle. In the skin melanocytes 
transfer melanin to the surrounding keratinocytes forming the basis of skin 
pigmentation. In mice the skin is often (although not exclusively) non-
pigmented.  
1.4.2.1 Melanocyte function and pigmentation 
The most obvious function of melanocytes is the manufacture and distribution of 
pigment, melanin, which is packaged into specialised organelles called 
melanosomes and transferred to the surrounding keratinocytes in the skin and 
newly formed hair in hair follicles. While most melanocytes are found in the skin 
and hair of organisms it can also been found in the RPE and iris of the eye, the 
inner ear where they are essential for hearing and in certain parts of the central 
nervous system.  While pigmentation in nature performs a wide range of 
purposes in humans it acts primarily to protect the skin from UV-induced DNA 
damage (Abdel-Malek et al, 2010). This is achieved by melanin which forms a 
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cup over the nuclei of keratinocytes thereby creating a physical barrier to 
protect the cellular DNA (Meredith & Sarna, 2006). This cup of melanin also acts 
as a ‘sink’ for reactive oxygen species. There are two types of melanin, 
red/yellow pheomelanin and brown/black eumelanin (Westerhof et al, 1987), 
the ratio of which determines the skin phenotype of individuals including both 
the colour and tanning ability of the skin (Fitzpatrick, 1988). Differences in 
pigmentation between individuals arise not from differences in the number of 
melanocytes, which remains relatively constant, but rather from variations in 
the number, size, composition and distribution of melanosomes. Melanosomes 
are lysosomal-related organelles that contain acid-dependant hydrolyses and 
lysosome-associated membrane proteins (Schiaffino, 2010). Melanosomes 
originate from endosome precursors which go through a four stage maturation 
process; stage II are non-pigmented, stage III are partially pigmented immature 
organelles and stage IV are fully melanised mature melanosomes (Marks & 
Seabra, 2001). Important proteins for this process include the enzymes 
Tyrosinase, Tyrp1 and DCT, as well as the structural protein Pmel17, the main 
constituent of the internal matrix of the organelles (Berson et al, 2003), the 
membrane transporters P, MATP/SLC45A2 and SLC24A5 (Lamason et al, 
2005; Newton et al, 2001); and the G protein-coupled receptor OA1. The master 
regulator of pigmentation is the Mitf, which is evolutionary conserved, and is 
responsible for expression of the essential enzymes required for melanin 
synthesis including Tyrosinase, a copper-dependant rate-limiting enzyme, Tyrp1 
and DCT (Goding, 2000). Other important factors for the regulation of 
pigmentation include keratinocyte-derived factors such as SCF and α-MSH which 
signal through the c-Kit and MC1R cell membrane receptor respectively to induce 
activation of Mitf.  
The basal pigmentation capabilities of melanocytes per individual are mostly 
genetically determined. For example a single nucleotide polymorphism (SNP), 
that leads to the substitution of a conserved amino acid within the SLC24A5 gene 
accounts for almost 100% of skin colour differences between Europeans and 
Africans (Lamason et al, 2005), whereas SNPs within the MC1R gene, of which at 
least 30 allelic variants exist, are the main cause of differences in skin colour 
within the European community (Rana et al, 1999; Rees, 2003; Sturm et al, 
2003). Despite this melanocytes in the skin do also possess the ability to adapt 
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their pigmentation capabilities in response to a number of extracellular and 
external environmental stimuli. One of the main stimuli is UV radiation which 
induces a tanning response mediated through the MC1R protein (Garcia-Borron et 
al, 2005). The MC1R gene encodes a G-protein coupled receptor that is 
responsive to both α-MSH and ACTH while being antagonised by Agouti (Chhajlani 
& Wikberg, 1992; Cone et al, 1993; Furumura et al, 1996). Activation of MC1R 
stimulates the cAMP pathway, whereby adenylyl cyclase is activated leading to 
accumulation of cAMP which in turn activates PKA and CREB. Active CREB 
enhances the transcription of Mitf which ultimately leads to up-regulation of the 
machinery necessary for melanin synthesis and melanosome biogenesis. The 
importance of MC1R and its regulators is emphasised by the consequences of 
mutations in these genes. Inactivating mutations in the Agouti gene are 
responsible for the black fur of C57Bl/6 mice whereas SNPs in the human Agouti 
gene have been associated with dark hair and brown eyes (Kanetsky et al, 2002). 
Mutations in MC1R, R151C, R160W and D294H, which result in the inability of 
MC1R to bind its ligand or to activate adenylyl cyclase, are all associated with 
red hair, pale skin and freckling (Healy et al, 2001; Ringholm et al, 2004). UV 
radiation induces the tanning response through activation of p53 in keratinocytes 
(Cui et al, 2007; Liu et al, 2010). Induced p53 binds to the promoter of POMC 
driving its transcription. POMC is the precursor for both α-MSH and ACTH which 
are subsequently secreted by UV-induced keratinocytes; α-MSH and ACTH then 
bind to MC1R on neighbouring melanocytes triggering the Mitf-dependant 
induction of pigmentation (Cui et al, 2007; Liu et al, 2010; Song et al, 2009). 
DNA damage induced by UV radiation such as thymidine dimers are thought to be 
important in the initial activation of p53. Studies have shown that topical 
administration of small DNA fragments such as thymidine dimers induce 
tyrosinase up-regulation and increase pigmentation (Eller et al, 1994).        
1.4.2.2 Melanocyte stem cells in adult skin 
Fully differentiated melanocytes exist in the basal layer of the epidermis and in 
the bulb of the hair follicle. However there also exist a population of 
melanocyte stem cells in the adult that are located in the bulge region of the 
hair follicle just below the sebaceous gland along with the multi-potent 
epidermal stem cells which give rise to the keratinocytes (Moore & Lemischka, 
2006) (Figure 1.4). These melanocyte stem cells are responsible for restoring the 
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pool of differentiated melanocytes and maintaining pigmentation throughout the 
lifespan of the organism. The features that define a stem cell population include 
slow cycling, self-renewal, immaturity, and ability to generate progeny when 
appropriately stimulated (Nishimura et al, 2005). Analysis of the DCT-LacZ 
transgenic mouse model has helped to elucidate the location of the melanocyte 
stem cell population (Nisihimura et al, 2002). Inhibition of c-Kit postnatally in 
these mice results in lack of hair pigmentation; however subsequent hair cycles 
showed re-colouration of the hair presumably by a Kit-independent population of 
melanocytes. These were traced to a DCT+ population of melanocytes located in 
the bulge area of the hair follicle (Nishmura et al, 2002). Analysis of DCT+ 
melanocytes located in the bulge region showed that they had a significantly 
different transcription profile compared to the DCT+ melanocytes located in the 
bulb region. These cells expressed DCT and Pax3 but were virtually negative for 
markers of mature melanocytes such as Tyrosinase, Tyrp1, Mitf and MC1R 
(Osawa et al, 2005). The importance of the melanocyte stem cell population in 
adults for continued pigmentation is highlighted by animal models whereby 
genetic alterations in Bcl2 and Mitf cause a loss of DCT+ melanocyte cells 
located in the bulge region which is rapidly preceded by premature greying of 
the hair (Nishimura et al, 2005; Veis et al, 1993). 
 
Figure 1.4: Melanocyte populations within the hair follicle. (A) Cartoon representation of a hair 
follicle, showing melanocyte stem cells located in the bulge area and differentiated melanocytes at 
the base of the hair follicle in the bulb region. (B) Immunofluorescent microscopy showing the two 
populations of Trp2+ melanocytes cells in the bulge and bulb regions of the hair follicle.  
  
taken from Lin & Fisher 2007 taken from Rabbani 2011 
A.  B.  
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1.5 Melanoma 
Melanoma is an aggressive type of skin cancer whose cell of origin is the 
melanocyte. Melanoma is the 19th most common cancer worldwide, however in 
certain countries that are predominantly occupied by white Caucasians the 
incidence rate is much higher, for example in Australia melanoma is the 3rd most 
common type of cancer in both sexes (Ferlay et al, 2010). Alarmingly the 
incidence rate for melanoma has increased more rapidly over the past 30 years 
than for any of the other top ten cancers in both the UK and USA (Cancer 
Research UK; Howlader et al, 2012; Jemal et al, 2010). Although melanoma only 
accounts for a fraction of skin cancer cases, 5-10%, it is the most dangerous 
form, accounting for >80% of deaths from skin cancer. When melanoma is 
diagnosed early it can be cured by surgical resection, however once the 
condition becomes metastatic it is largely refractory to existing treatments with 
a median survival rate of 6 months and a 5 year survival rate of only 15% (Siegel 
et al, 2012).  
1.5.1 Genetics of melanoma 
The genetic alterations associated with the malignant transformation of 
melanocytes to melanoma are well established (Chin, 2003). The MAPK signalling 
pathway is important in the regulation of cellular proliferation and survival of 
melanocytes and as such is mutated causing hyper-activation in up to 90% of 
human melanomas (Cohen et al, 2002). The MAPK pathway is activated 
downstream of numerous receptor tyrosine kinases and G-protein coupled 
receptor (Wellbrock et al, 2004). In melanocytes this pathway is specifically 
activated in response to growth factors including SCF, FGF and HGF. The most 
common mutations of this pathway are found in B-Raf and N-Ras, and which are 
generally mutually exclusive owing to the fact that N-Ras is considered to act 
directly upstream of B-Raf and therefore the mutations are considered to be 
functionally equivalent. Mutations in B-Raf are seen in as many as 60% of human 
melanoma samples and cell lines (Davies et al, 2002), with the most common 
mutation being a valine to glutamic acid substitution at position 600, V600E. 
Activating point mutations in N-Ras have been seen in as many as 56% of 
congenital nevi, 33% of primary melanomas and 26% of metastatic samples 
(Demunter et al, 2001), with the most common mutation being a glutamine to 
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leucine substitution at position 61, Q61L. Both B-Raf and N-Ras mutations persist 
from early nevi to malignant disease, suggesting that MAPK signalling is 
important throughout melanoma development with particular emphasis on 
tumour maintenance. Mutant B-Raf (V600E) has been shown to be approximately 
480-fold more active than wild-type (Wan et al, 2004), resulting in constitutive 
ERK signalling that provides essential functions for the growth and maintenance 
of tumour growth (Gray-Schopfer et al, 2005). In addition to activation of ERK 
signalling, mutant B-Raf and N-Ras have been shown to activate other pathways 
important in tumour maintenance and progression. Mutant B-Raf is able to 
activate NF-κB, a known anti-apoptotic factor (Ikenoue et al, 2004) thus 
promoting cell survival. B-Raf has also been shown to regulate cell migration, 
with mutant B-Raf cells having increased levels of actin stress fibres (Pritchard 
et al, 2004), as well as up-regulation of MMP-2, which degrades the extracellular 
matrix, and β-integrin (Sumimoto et al, 2004). Mutant B-Raf also contributes 
towards angiogenesis by stimulating VEGF (Sharma et al, 2005), an important 
factor in promoting tumour growth by allowing the delivery of essential nutrients 
and oxygen to the tumour mass. More recently ERK signalling has also been 
implicated in altering the expression of Mitf, the master regulator of melanocyte 
function (Wellbrock et al, 2008; Primot et al, 2010).  
Although alterations in MAPK signalling represents the major oncogenic signal in 
melanoma the phosphoinositide-3-OH kinase (PI(3)K) pathway also plays a 
significant role. Mutations in PI(3)K occur in 3% of metastatic melanoma (Omholt 
et al, 2006) with overexpression of the downstream effector kinase PKB (also 
known as Akt) seen in up to 60% of melanomas (Stahl et al, 2004). The main 
inhibitor of the PI(3)K pathway is the lipid phosphatase PTEN, which is lost in 5-
20% of late stage melanomas (Wu et al, 2003) and in 30-40% of established 
melanoma cell lines (Guldberg et al, 1997; Teng et al, 1997). The PI(3)K pathway 
is activated in response to stimuli from receptor tyrosine kinases, and is 
important in regulating cell survival, proliferation, growth (Increase in cellular 
mass) and motility (Shaw & Cantley, 2006). The importance of this pathway is 
highlighted by three-dimensional in vitro melanoma cultures whereby both MAPK 
and PI(3)K signalling must be inhibited in order to suppress cell proliferation 
(Smalley et al, 2006). Finally another important pathway associated with 
melanoma tumour cell growth is Mitf, which has been shown to be expressed in 
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most human melanomas with its target genes being diagnostic markers of the 
disease (Levy et al, 2006). Furthermore continued expression of Mitf is essential 
for melanoma cell proliferation and survival (Levy et al, 2006), with loss of 
expression leading to cell cycle arrest and apoptosis. However high levels of 
expression promote cell cycle arrest and differentiation with a reduction of 
proliferation seen even in the presence of oncogenic B-Raf (Wellbrock & Marais, 
2005), therefore melanoma cell must maintain intermediate levels of Mitf 
expression in order to favour proliferation. In culture B-Raf and Mitf have been 
shown to co-operate thereby promoting immortalisation of primary melanocytes 
(Garraway et al, 2005).  
Many of the aforementioned oncogenes associated with melanoma are known to 
induce senescence, a barrier to tumourigenesis that is important in suppressing 
melanoma progression in vivo. In fact mutant B-Raf and N-Ras are frequently 
found in benign nevi, yet most nevi remain indolent for decades and only rarely 
progress to melanoma (Bauer et al, 2007; Pollock et al, 2003; Poynter et al, 
2006). This shows that both B-Raf and N-Ras mutations alone are not sufficient 
to promote malignant transformation, but that they more likely contribute to 
malignant melanoma only in conjunction with other mutations. The main gene 
implicated in oncogene-induced senescence in melanoma is the CDKN2A locus, 
which encodes two protein; p16Ink4a and p14Arf (humans) or p19Arf (mice) 
(Sharpless & Chin, 2003), that play key roles in the CDK4/6-pRB and ARF-p53 
pathways respectively. The importance of the CDKN2A locus is emphasised by 
the fact that loss of this locus is the most common mutation seen in familial 
melanoma (Hussussian et al, 1994). Furthermore p16Ink4a defects are found in 
dysplastic nevi but not benign nevi (Papp et al, 2003), with p16Ink4a loss also 
being seen in 15-28% of primary sporadic melanomas and almost all established 
melanoma cell lines (Fujimoto et al, 1999; Walker et al, 1998). Mutations in 
CDK4, the target of p16Ink4a, are also frequently seen in both sporadic and 
familial melanoma (Sharpless & Chin, 2003; Zuo et al, 1996). Notably mutant B-
Raf cannot transform human melanocytes in culture even when they are 
immortalised by TERT expression (Garraway et al, 2005); however mutant B-Raf 
is able to transform p16Inka-deficient mouse melanocytes (Wellbrock et al, 2004). 
This is further emphasised by mouse models of melanoma whereby p16Ink4a 
deficiency is required for N-Ras induced melanoma (Chin et al, 1999). 
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Collectively these underpin the importance of mutations affecting the CDK4-pRB 
pathway in overcoming senescence and driving malignant progression. 
1.5.2  Development and progression  
There are currently two models of melanoma development, one of which holds 
that melanoma originates from benign nevi whilst a second holds that it 
originates from isolated cutaneous melanocytes in normal skin. Only 25% of 
melanomas are associated with pre-existing nevi. These nevi have mutations in 
either B-Raf or N-Ras, with melanoma progression being dependant on 
acquirement of a secondary mutation (Bevona et al, 2003). The remaining 75% of 
melanomas arise in otherwise normal skin in the absence of pre-existing nevi 
(Bevona et al, 2003). This model is based on the idea that a melanocyte 
precursor cell in the skin, possibly a melanocyte stem cell, accumulates a 
number of mutations which drive malignancy. However, regardless of whether 
development starts from a nevus or directly from a cutaneous melanocyte, 
melanomas typically go through several defined stages of growth. Firstly cells 
proliferate in a radial-like fashion with contained of the cellular mass within the 
epidermis, this is termed the radial-growth phase (RGP). These lesions can then 
progress to a vertical-growth phase (VGP) characterised by cells breaking 
through the basement membrane and invading into the dermis, with distinct 
nodules or nests of cells. VGP cells have metastatic potential, from this point 
invading both the blood and lymphatic system leading first to local metastasis 
and eventually distant metastasis (Figure 1.5) (Clark et al, 1984; Cummins et al, 
2006; Miller & Mihm, 2006). However not all melanomas pass through each of 
these individual stages. Both RGP and VGP can develop directly from single 
melanocytes or nevi, and both can progress directly to metastatic melanoma 
(Cummins et al, 2006; Miller & Mihm, 2006). 
The cell of origin for melanoma is debatable; with arguments for both epidermal 
melanocytes and melanocyte stem cells. The nevus model for melanoma 
development supports the idea of the cell of origin being epidermal. This is 
supported by studies which reveal that melanocytes in culture can be 
transformed by the expression of oncogenes allowing them to acquire a 
malignant phenotype and invasive properties (Chudnovsky et al, 2005). 
Furthermore the tyrosinase promoter, which is not expressed in melanocyte 
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stem cells (Osawa et al, 2005), has been shown to induce melanoma when 
driving oncogenic proteins SV40E (Kelsall & Mintz, 1998) and N-Ras (Wong & 
Chin, 2000). Thus it is possible to generate melanoma from a cell expressing 
melanocyte proteins which are normally associated with fully differentiated 
melanocytes. However the extent to which these melanocytes are differentiated 
and their degree of plasticity is not fully understood. Conversely, the cell of 
origin has also been postulated to be a melanocyte stem cell located in the 
bulge region of the hair follicle, especially in the case of melanomas which 
develop in the absence of pre-existing nevi. This has already been shown in 
other skin tumour models whereby expression of an activated oncogene from a 
stem-cell specific promoter drives squamous cell carcinoma (Lapouge et al, 
2011; White et al, 2011). However regardless of the origin of melanoma it is 
clear that a subpopulation of tumour stem cells (TSCs) exist in melanoma. 
Studies on metastatic melanoma cell lines have revealed that the cultures are 
heterogeneous even when derived from a single cell clone (Grichnick et al, 
2006). The different cell populations within such cultures have distinct 
properties; the small cell phenotype which proliferate slowly but have the 
ability to expand the culture, and the large cell phenotype, which gives rise to 
melanised cells that appear to be terminally differentiated and are eventually 
lost from the culture (Grichnick et al, 2006). Other groups have also seen TSCs in 
melanoma cell cultures. These TSCs could be induced to differentiate into 
melanocytes, adipocytes, osteocytes and chondrocytes lineages (Fang et al, 
2005). Markers of these cells have been shown to be CD133, CD166 and nestin 
(Frank et al, 2005; Klein et al, 2007; Monzani et al, 2007), with cells isolated for 
these markers more tumorigenic in animal models (Fang et al, 2005; Monzani et 
al, 2007). 
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Figure 1.5: Molecular modelling of melanoma initiation and progression. This illustration 
depicts human melanoma progression and molecular alterations that can occur at different stages. 
Aberrant proliferation of normal melanocytes results in the formation of benign or dysplastic nevi. 
Radial growth phase (RGP) melanoma exhibits the ability to grow intra-epidermally, followed by 
invasion of the dermis in the vertical growth phase (VGP), and culminating with metastasis. Note 
that only about 25% of melanomas are known to arise from nevi, and progression can occur 
without going through all the stages depicted.  
 
1.5.3  Treatment 
Metastatic melanoma is an extremely aggressive disease that is largely 
refractory to current therapies including genotoxic agents, radiotherapy and 
immunotherapy. This is thought to be because of two reasons; firstly, the cell of 
origin for melanoma, melanocytes, originates from highly motile precursor cells, 
and secondly, melanocytes can absorb UV radiation and survive considerable 
genotoxic stress. This is demonstrated by the low levels of spontaneous 
apoptosis seen in melanoma tissue samples compared to other cancers, and by 
the relative resistance to drug-induced apoptosis seen in melanoma cells in 
culture (Soengas & Lowe, 2003). Recently melanocytes have been shown to 
possess higher levels of oxidative DNA damage than normal human skin 
fibroblasts (NHSFs), however despite this they also showed a reduced capability 
to repair this damage compared to NHSFs, suggesting a higher mutation 
frequency in melanocytes which could contribute towards malignant 
transformation (Wang et al, 2010). 
The only standard chemotherapeutic agents currently approved for the 
treatment of metastatic melanoma are interferon-α, high dose interleukin-2 and 
dacarbazine. However all show low response rates with little improvement on 
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patient survival times (Comis, 1976; Petrella et al, 2007; Tarhini et al, 2012). 
Given this novel therapies which target specific alterations associated with 
melanoma and to which melanoma cells are considered to be ‘addicted’ have 
recently started to emerge for the treatment of at least a subset of metastatic 
melanoma patients (Eggermont & Robert, 2011). As discussed previously one of 
the most altered pathways in melanoma is the MAPK signalling pathway, which is 
hyper-activated in up to 90% of melanomas by mutations in either N-Ras or B-Raf 
(Cohen et al, 2002). Both mutations in N-Ras and B-Raf persist from early nevi to 
malignant disease, and are essential for tumour growth and maintenance. As 
such knockdown of either N-Ras or B-Raf by siRNA has been shown to inhibit cell 
growth, invasion, and to induce apoptosis (Eskandarpour et al, 2005; Sumimoto 
et al, 2004). N-Ras is a small G-protein that is active when bound to GTP, and is 
therefore a less ‘druggable’ target than B-Raf which is a serine/threonine 
protein kinase. Despite this, Ras inhibitors have been generated; the farnesyl 
transferase inhibitor R115777 (tipifarnib) was shown to have anti-tumour effects 
in both human cell cultures and in vivo model of melanoma (End et al, 2001). 
However R115777 never reached clinical trials as a single-agent but has been 
trialled in combination with the multi-kinase inhibitor sorafenib, but this 
combination therapy did not show any significant improvement over sorafenib 
only treatment (Margolin et al, 2012).  While some non-selective kinase 
inhibitors such as sorafenib and Raf265 have showed some efficacy as single 
agents in both pre-clinical and clinical-phase trials neither has progressed 
successfully to patients (Maki et al, 2009; Panka et al, 2006; Su et al, 2012). The 
first selective B-Raf inhibitors to be developed were vemurafenib and 
dabrafenib. Both have shown very impressive single agent activity against 
melanoma in clinical trials (Chapman 2011 and Hauschild 2012), however both 
have also shown a significant appearance of squamous cell carcinomas in treated 
patients, with up to 18% affected (Chapman et al, 2011; Hauschild et al, 2012). 
Unfortunately, despite the initial reduction in metastatic tumour growth all 
patients became resistant to B-Raf inhibitor treatment, which has attributed to 
reactivation of the MAPK pathway and enhanced tumour growth through c-Raf 
(Hatzivassiliou et al, 2010; Heidorn et al, 2010; Johannessen et al, 2010; 
Nazarian et al, 2010; Robert et al, 2011). This has led to the conclusion that 
combination therapy with MEK inhibitors may be preferable, as all isoforms of 
both Ras and Raf signal through MEK. Phase I and II trials of combined treatment 
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with dabrafenib and trametinib (a selective MEK inhibitor) have shown increased 
progression free survival with a slight but statistically non-significant reduction 
in the appearance of squamous cell carcinoma (Flaherty et al, 2012).  
Other targets which are being investigated as possible treatments for melanoma 
include inhibitors of the PI(3)K pathway, both of PI(3)K itself and its downstream 
effectors Akt and mTOR (Lopez-Fauqued et al, 2010). Interestingly treatment 
with a dual PI(3)K/mTOR inhibitor promoted in vivo tumour growth and survival 
of sorafenib treated melanoma cells (Lopez-Fauqued et al, 2010). A phase I trial 
with sorafenib and an mTOR inhibitor showed significant toxicity and failed to 
achieve any clinical response (Davies et al, 2012). Other targets involve 
inhibitors of the CDK-pRb pathway, such as CDK inhibitors, which has shown to 
be important in malignant progression (Caporali et al, 2012; Jalili et al, 2012). 
Finally a new immunotherapy is emerging for the treatment of melanoma, with 
the use of Ipilimumab, a monoclonal antibody that blocks cytotoxic T-
lymphocyte-associated antigen-4 (CTLA-4), a negative regulator of T-cells (Hodi 
et al, 2012; Robert et al, 2011). Ipilimumab single agent therapy has recently 
been approved by the FDA for the treatment of late stage melanoma.  
1.5.4 Murine models of melanoma 
Owing to our better understanding of the genetics involved in driving the 
initiation and progression of human melanoma, more sophisticated models of 
melanoma in mice have been developed, which mimic the human condition more 
closely than ever before (Damsky & Bosenberg, 2010). Technical advances in 
mouse modelling techniques, especially inducible lox-Cre based recombination 
technology, has also played a key role in the development of these novel and 
useful models.  
1.5.4.1 B-Raf 
Activating point mutations in B-Raf are known to be important in driving 
melanoma, with up to 60% of human melanoma samples and cell lines containing 
mutant B-Raf (Davies et al, 2002). However B-Raf mutations are also common in 
benign nevi (Pollock et al, 2003; Poynter et al, 2006), and malignant 
transformation is dependent on other secondary mutations. This is demonstrated 
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by the observation that mutant B-Raf alone cannot transform human 
melanocytes in culture. There have been several mouse models of melanoma 
developed which use B-Raf (V600E) as the driving mutation (Dankort et al, 2009; 
Dhomen et al, 2009; Goel et al, 2009). All these models express B-Raf(V600E) in 
a melanocyte specific manner, resulting in skin hyperpigmentation and 
development of benign melanocytic nevi which express markers of senescence 
(Dhomen et al, 2009; Goel et al, 2009), and which in most cases failed to 
progress to melanoma. In the Dankort model all mice developed benign 
melanocytic nevi within 21-28 days after induction of B-Raf expression, however 
none of these progressed to melanoma over a 15-20 month period. In comparison 
two other models showed development of melanoma with B-Raf expression alone 
(Dhomen et al, 2009; Goel et al, 2009). In the Dhomen model 64% of mice 
developed malignant primary melanomas within 12 months, whereas the Goel 
model had only 10% penetrance of melanoma which occurred in mice that 
expressed the highest levels of B-Raf mRNA. Combination of B-Raf with loss of a 
tumour suppressor gene; including PTEN, CDKN2A and p53, increased penetrance 
of melanoma and decreased latency in all models. PTEN loss resulted in 100% 
penetrance of melanoma with a short latency of 25-50 days (Dankart et al, 
2009), p16Ink4a loss resulted in 80% penetrance with a median latency of 7 
months (Dhomen et al, 2009), CDKN2A loss resulted in 11-38% penetrance with a 
latency of 185 days and p53 loss resulted in 6-53% penetrance with a median 
latency of 107 days (Goel et al, 2009). However, only PTEN loss in combination 
with mutant B-Raf resulted in consistent metastatic disease, with metastatic 
growths seen in 100% of the lymph nodes and lungs (Dankart et al, 2009). Both 
CDKN2A and p53 loss also showed some metastasis to the lymph nodes and lungs, 
but this was only seen in a small subset of mice (Goel et al, 2009). This 
demonstrates that loss of PTEN appears to be more effective at inducing 
metastatic spread, which is consistent with other models of melanoma where 
oncogenesis is driven by the H-Ras oncogene in combination with PTEN loss 
(Nogueira et al, 2010). It is interesting to note that in the p16Ink4a model, mice 
still developed nevi prior to malignant conversion (Dhomen et al, 2009), while 
the nevi from B-Raf alone mice were histologically similar to both blue and 
epithelioid blue nevi in humans (Dhomen et al, 2009). 
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1.5.4.2 N-Ras 
Activating point mutations in N-Ras are also frequently seen in melanoma, with 
as many as 56% of congenital nevi, 33% of primary melanoma and 26% of 
metastatic samples expressing mutant N-Ras (Demunter et al, 2001). As with B-
Raf, N-Ras is also frequently seen in benign nevi (Bauer et al, 2007; Poynter et 
al, 2006) with malignant progression being dependent on the acquisition of 
additional mutations. There have been several mouse models of melanoma 
developed that use N-Ras(Q61K) as the driving mutation (Ackermann et al, 2005; 
Delmas et al, 2007; Ferguson et al, 2010; VanBrocklin et al, 2010). Most of these 
models express N-Ras(Q61K) in a melanocyte specific manner (Ackermann et al, 
2005; Delmas et al, 2007; Ferguson et al, 2010), with one model using a 
retrovirus containg N-Ras linked to Cre recombinase injected into mice 
(VanBrocklin et al, 2010). Melanocyte specific expression of mutant N-Ras caused 
hyperpigmentation of the skin (Ackermann et al, 2005; Delmas et al, 2007). In 
most of the models expression of N-Ras alone did not promote the formation of 
melanoma (Ferguson et al, 2010; VanBrocklin et al, 2010), with the exception of 
the Ackermann model were N-Ras alone caused melanoma with a penetrance of 
29% and median latency of 12 months. This difference may be due to different 
strain backgrounds, as the Ackermann mice are C57Bl/6 whereas others are FVB 
(Ferguson et al, 2010; VanBrocklin et al, 2010). Combination of N-Ras with loss 
of a tumour suppressor gene, including p53 and CDKN2A, activation of CDK4 or 
stabilisation of β-catenin, increased penetrance and decreased latency of 
melanoma. Both activating mutation of CDK4 (R24C) and loss of p53 resulted in 
100% penetrance with a median latency of 210 and 160 days respectively 
(Ferguson et al, 2010). Interestingly mutation of CDK4 was associated with the 
formation of benign nevi prior to malignant conversion whereas p53 loss was not 
(Ferguson et al, 2010). Stabilisation of β-catenin resulted in a penetrance of 85% 
with a median latency of 28 weeks (Delmas et al, 2007) whereas loss of CDKN2A 
resulted in 94% penetrance of melanoma by 6 months of age (Ackermann et al, 
2005). It is of note that CDKN2A loss was also associated with a high metastatic 
potential with 64% of tumour bearing mice having metastasis to the lymph nodes 
and 36% having metastasis to either the liver or lungs (Ackermann et al, 2005). 
Unlike the other models whereby the mice are genetically altered to express N-
Ras, the VanBrocklin model uses a retrovirus expressing N-Ras in combination 
Chapter 1  56 
 
with Cre recombinase. This is used for injection into mice which express a 
CDKN2A conditional allele driven from a melanocyte specific promoter, thereby 
allowing for loss of CDKN2A only in melanocytes infected with the virus. In this 
context no tumours arose from mice injected with N-Ras and Cre alone, while 
63% of mice bearing the CDKN2A allele injected with N-Ras and Cre developed a 
tumour at the site of injection with a mean latency of 47 days (VanBrocklin et 
al, 2010). It is of interest that VanBrocklin and colleagues also developed a 
retrovirus expressing a mutant K-Ras and Cre, however upon injection in 
combination with CDKN2A no tumours formed, demonstrating that mutant K-Ras 
does not induce melanoma.   
1.6 Project Aims 
Melanoma is an extremely aggressive type of skin cancer, which is largely 
refractory to standard therapies including genotoxins, radiotherapy and 
immunotherapy. Many of these agents will induce massive amounts of DNA 
damage and as such will strongly activate the DNA damage response network. 
Large components of this network are the DNA damage checkpoints which 
function to prevent cell cycling in the presence of DNA damage and DNA 
replicative stress. The ATR/Chk1 pathway is a key player in several of these 
checkpoints and is maintained in most cell types.  
The main aims of this thesis were to further understand the role that ATR/Chk1 
signalling may play in the initiation, maintenance and progression of melanoma 
using both in vitro and in vivo models, and to elucidate if targeting the Chk1 
kinase is a suitable therapeutic strategy for the treatment of melanoma. 
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2 Materials & Methods 
2.1 Materials 
2.1.1 General Reagents and Buffers 
Fisher Scientific 
Hydrochloric acid (HCl), Dimethyl sulfoxide (DMSO), Sodium dodecyl sulphate 
(SDS), Ammonium persulphate (APS), Isopropanol, Magnesium chloride, Sodium 
deoxycholate, Potassium chloride, EDTA, Glycerol, Sodium pyrophosphate 
Melford Laboratories Ltd 
Tris Base Ultrapure, Tris Hydrochloride Ultrapure, Agarose 
Sigma Aldrich 
Butanol, Methanol 
VWR 
Ethanol 
2.1.1.1 Buffers 
Buffer Composition 
PBS 170mM NaCl, 3.3mM KCl, 1.8mM Na2HPO4, 10.6mM 
H2PO4 
1x Semi Dry Blotting Buffer 48mM Tris-Cl pH9.2, 39mM Glycine, 1.3mM SDS- 
20% Methanol added just prior to use 
10 x Tris Buffered Saline Tween (TBS-T) 200mM Tris-Cl pH7.6, 1.37M Sodium Chloride, 1% 
Tween 20 
1 x SDS-PAGE Running Buffer 250mM Tris-Hcl, 1.92M Glycine, 0.01% SDS 
50 x TAE Buffer 2M Tris Acetate, 50mM EDTA 
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2.1.2 Animal Biology 
Amresco 
1M Calcium chloride (sterile) 
Axon Medchem 
CHIR-124 
Invitrogen (Gibco) 
Collagenase type I and IV, HBSS, Dissociation Buffer, Geneticin (G418) 
Leica Biosystems 
10% Neutral buffered formalin 
Melford Laboratories Ltd 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) 
Roche 
DNase 
Science Services Ltd 
16% Paraformaldehyde 
Sigma Aldrich 
Gluteraldehyde, Formaldehyde solution, Ferricyanide, Ferrocyanide, Phorbol 12-
myristate 13-acetate (TPA), 4-hydoxytamoxifen (4-OHT), Tamoxifen, Corn oil, 
Sunflower oil, Dacarbazine (DTIC) 
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2.1.3 Molecular Biology 
2.1.3.1 DNA 
Fermentas 
6x DNA loading dye, O’GeneRuler 100bp, O’GeneRuler 1kb, O’GeneRuler 1kb 
Plus 
Invitrogen 
Platinum® Pfx DNA polymerase, 10mM dNTP Mix 
Qiagen Ltd 
Qiaquick Gel Extraction kit, Qiaquick PCR purification kit, Qiagen QIAamp DNA 
Mini Kit 
Quanta Biosciences 
PerfeCTa® SYBR® Green FastMix 
Roche 
Expand High Fidelity PCR kit 
Sigma Aldrich 
Ethidium Bromide 
2.1.3.2 Protein 
Calciochem 
NP-40 
Fermentas  
High Range, Spectra™ Multicolor Broad Range Protein Ladder 
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GE Healthcare Life Sciences  
Full Range Rainbow Molecular Weight Markers, Amersham ECL™ Western Blotting 
Detection Reagents 
Invitrogen (Gibco) 
1M HEPES, NuPAGE LDS Sample Buffer  
Marvel 
Non-fat milk powder 
React Scientific 
Supported Nitrocellulose Membrane (30cm × 3 m) 0.45μm pore size 
Severn Biotech  
30% acrylamide solution (37.5:1), 40% acrylamide solution (125:1) 
Sigma Aldrich 
Tween 20, Benzamidine, Aprotinin, Leupeptin, Okadaic acid, EGTA, Sodium 
orthovanate, Sodium fluoride, β-glycerophosphate, Dithiothreitol, Triton-X-100, 
DTT, PMSF, Ponceau S solution, TEMED, BSA 
Thermo Fisher Scientific  
Bradford Assay Reagent, SuperSignal* West Femto Chemiluminescent Substrate 
2.1.4 Cell Biology 
2.1.4.1 Tissue Culture 
Fisher Scientific 
Mr Frosty cell freezing container 
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Invitrogen (Gibco) 
DMEM (high glucose, with pyruvate, no glutamine), DMEM: F12 (1:1), RPMI 1640, 
200mM, Glutamine, 2.5% Trypsin, OptiMEM, Lipofectamine 2000, Alamar Blue 
PAA 
Foetal Bovine serum (FBS) 
Sigma Aldrich 
Penicillin G, Streptomycin, Aphidicolin, Etoposide, Nocodazole, Temozolomide 
(TMZ) 
2.1.4.2 Flow Cytometry 
Biolegend 
Annexin V binding buffer 
Invitrogen 
Click-iT® EdU Imaging kit 
Qiagen Ltd 
RNase A 100mg/ml 
Sigma Aldrich 
Propidium Iodide (PI), Bromo-deoxyuridine (BrdU) 
2.1.4.3 Microscopy 
Dako 
DAB Envision+® kit, Hydrogen peroxidase blocking reagent 
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Sigma Aldrich 
Citrate Buffer pH6, DPX Mountant, Normal goat serum, Normal donkey serum 
Vector Labs 
Vectashield containing Dapi 
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2.2 Methods 
2.2.1 Generation of In vivo models 
2.2.1.1 Mice for Chapter 3: Chk1 requirement in embryonic development of 
murine melanocytes 
To examine the effect of Chk1 deletion on the survival and proliferation of 
neural-crest derived melanoblasts in utero Chk1 fl/fl mice were crossed with 
Tyr-Cre mice and DCT-LacZ mice to yield Chk1 fl/+, Tyr-Cre+, DCT-LacZ+ mice. 
These were then inter-crossed to produce pregnant females whose litters would 
contain Chk1 fl/fl, Chk1 fl/+ and Chk1 +/+ in the ratio of 1:2:1 respectively. 
These litters were harvested from the pregnant mother at appropriate days 
(E10.5 and E13.5). Chk1 fl/fl, Tyr-Cre+, DCT-LacZ+ embryos were the 
experimental mice with Chk1 fl//+, Tyr-Cre+, DCT-LacZ+ and Chk1+/+, Tyr-
Cre+, DCT-LacZ+ embryos as controls. The Chk1 flox mice were made by Stephen 
Elledges’s group at the Harvard Medical School, Boston (Liu et al, 2000). A chk1 
flox targeting vector was used which contained exon 2 of Chk1 flanked by LoxP 
sites. Exon 2 of Chk1 contains the translational initiation sequence and ATP-
binding site of the kinase. The Tyr-Cre mice were made by Lionel Larue’s group 
at the Institut Curie, Paris (Delmas 2003). The DCT-LacZ mice were made by Ian 
Jackson’s group at the MRC Human Genetics Unit, Edinburgh (MacKenzie 1997). 
2.2.1.2 Mice for Chapter 4: Chk1 requirement in melanoma initiation and 
progression in vivo 
To examine the effect of Chk1 deletion on the initiation and progression of 
melanoma in mice Chk1 fl/fl mice were crossed with mice containing oncogenic 
N-Ras targeted to the melanocyte lineage (Tyr-N-RasQ61K) and heterozygous 
knockout of the CDKN2A locus (loss of one allele of p16 and p19) combined with 
expression of p16Ink4a (which harbors a single point mutation to knockout p16 
protein only leaving p19 intact); this genotypically leaves the mice heterozygous 
for p19 and homozygous knockout for p16. These mice were then crossed with 
mice expressing Tyr-CreERT 2in order to facilitate inducible knockout of Chk1 in 
the Chk1 fl/fl mice. Cre expression was induced systemically with IP injection of 
4-OHT in mice at age 8 weeks. From birth mice were monitored at least once per 
week to note the presence of a primary tumor. From the time of the first 
appearance of a primary tumor animals were monitored multiple times a week 
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and weighed at least weekly. Tumor size was monitored using a skin caliper. 
Mice were monitored for signs of ruffling of coat, hunched appearance and loss 
of 20% body weight; if mice exhibited these symptoms they were culled using 
Schedule 1 methods. Equally if the primary tumor reached 1.5cm or became 
ulcerated the mice were culled using Schedule 1 methods. The Beermann 
melanoma mice expressing the Tyr-N-RasQ61Ktransgene on a CDKN2A deficient 
background were made by Friedrich Beermann’s group at the ISREC, Switzerland 
(Ackermann 2005). The p16Ink4a mice were made by Anton Berns’s group at the 
Netherlands Cancer Institute, Amsterdam (Krimpenfort 2001). The Tyr-CreERT2 
mice were made by Lionel Larue’s group at the Institut Curie, Paris (Yajima 
2006). 
2.2.2 Breeding Strategy and Colony Maintenance 
All mice were bred and maintained in the Beatson Institute for Cancer Research 
animal facility and in accordance with UK Home Office guidelines and 
regulations. All colonies were maintained on a mixed (minimum 75% C57Bl/6) 
genetic background. Animals were humanely culled using Schedule 1 techniques 
as stipulated in our project licence. 
2.2.3 Animal Genotyping 
For routine genotyping all animals were ear clipped at weaning and samples sent 
to Transnetyx genotyping service for analysis. Transnetyx analyses samples using 
real time PCR. For the genotyping of the Chk1 flox and wt alleles probes were 
designed which span the site of insertion for the first LoxP site before exon 2.  
2.2.4 Harvesting of Embryos and β-Galactosidase Assay 
Pregnant mice were sacrificed using Schedule 1 methods. Embryos were then 
harvested from the mother at appropriate days using aseptic techniques. The 
yolk sac was detached from the embryo and used for genotyping. Dissected 
embryos were put on ice in PBS until dissection was complete. Following 
dissection the PBS was aspirated off and cold fixative solution (0.25% 
Gluteraldehyde, Sigma) was added and incubated for 20-40mins at 4oC on a 
rocker (20mins for E9.5; 40mins for E14.5) followed by a wash in PBS for 15mins 
at 4oC. Aspirate PBS and add permeabilisation solution (2nM MgCl2, 0.01% Na-
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deoxycholate, 0.02% NP-40 in 100ml PBS), incubate for 30mins at room 
temperature (RT). Repeat with fresh permeabilisation solution for 2 further 
15min incubations (PBS washes were substituted for E10.5 where 
permeabilisation is not necessary). Aspirate and add staining solution (0.8g 
Ferricyanide, 1.0g Ferrocyanide, 1ml 1M MgCl2 in 500ml PBS, before staining add 
fresh 20ul NP-40, 1ml 1% Na-deoxycholate, 1ml 4% X-Gal in 100ml of staining 
solution) to the embryos. Incubate for 3-48hrs (depending on the size of the 
embryo) at RT on a rocker. Staining can also be done at 30oC to shorten the 
staining period. After staining embryos were post-fixed in 4% paraformaldehyde 
for 2-4hrs at 4oC and then rinsed in PBS overnight at 4oC. Embryos were then 
stored in N-formalin at 4oC. In some cases embryos were also embedded for 
sectioning however isopropanol should be substituted for xylene to prevent loss 
of staining.  
2.2.5 Melanocyte Isolation from mice 
All mice were sacrificed using Schedule 1 method. The backs of the mice were 
thoroughly shaved to remove most of the hair and cleaned with 70% ethanol 
before dissection. The back skin was then removed (approximately 2 cm2) and 
placed into a small petri dish containing ice-cold PBS for a few seconds. The skin 
was then cut up into pieces in a fresh petri dish containing 3ml of collagenase 
type I and 3ml of collagenase type IV (both at 5 mg/ml in PBS w/o Ca and Mg) 
and left to incubate at 37oC, 5% CO2 for 30-50mins. After incubation the 
epidermis was detached (keep) from the dermis (discard) with forceps (if this 
was difficult the pieces were just cut further). The content was transferred to a 
15ml tube with 10ml Wash Buffer (1 x HBSS (10ml of 10x), 1mM CaCl2 (100µl 1M), 
0.005% DNase (5 ml 1mg/ml)) and spun at 1100rpm for 5mins at RT. The pellet 
was re-suspended in 2ml Dissociation Buffer (Gibco) and placed in a small petri 
dish for incubation at 37C, 5% CO2 for 10mins. The content was then put through 
an 18g needle and then a 20g needle in order to further break up the tissue. The 
content was transferred to a 15ml tube with 10ml Wash Buffer and allowed to 
settle for 10mins. After 10mins the top layer consisting of grease and fur was 
removed and the remaining content was spun at 1100rpm for 5mins at RT. The 
pellet was re-suspended in PBS and the cells were counted. Cells were placed 
into a 6-well plate and put into a 37oC, 5% CO2 incubator, in DMEM: Ham F12 
(1:1) media supplemented with 10% FBS, 200nM TPA, 2mM Glutamine, 50U/ml 
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penicillin G and 50μg/ml Streptomycin. About 2 days after first putting the cells 
into culture, add G418 at 50 µg/ml and leave in the media for 3 days, then 
replace with fresh media for 4 days and repeat this cycle. This should selectively 
reduce the growth of fibroblasts. Use PBS-EDTA to carefully remove dying 
fibroblasts by adding a few mls and swilling around the plate for a few minutes. 
When the plate becomes confluent, trypsinise as normal, spin and re-suspend 
cells and use a very low dilution for the first few splits (i.e. just 1:2 or 1:3). 
Establishment of a pure population of melanocytes typically takes about 8 
weeks. 
2.2.6 Preparation and administration of substances into mice 
2.2.6.1 4-hydoxytamoxifen (4-OHT) 
4-OHT for IP injection into mice was prepared by dissolving 5mg of 4-OHT (Sigma 
H7904 active Z-isomer >98%) in 500µl 100% ethanol. This was subsequently 
diluted further in 4500µl of autoclaved sunflower oil (Sigma) to make a 1mg/ml 
solution. Mice received 100µl of this solution per day for 8 consecutive days, 
totalling 40mg/kg of 4-OHT. 
2.2.6.2 Tamoxifen 
Tamoxifen for IP injection into CD1 nude mice was prepared by dissolving 1g of 
tamoxifen (Sigma T5648) in 10ml 100% ethanol. This was subsequently diluted 
further in 40ml of corn oil (Sigma) to make a 20mg/ml solution. Mice received 
100ul of this solution per day for 8 consecutive days followed by 3x weekly 
treatments until endpoint reached.  
2.2.6.3 CHIR-124 
CHIR-124 for oral gavage into CD1 nude mice was prepared by dissolving 25mg of 
CHIR-124 (Axon Medchem 1636) in DMSO to make a 40mg/ml solution. This was 
subsequently diluted further in PBS to make a 0.4mg/ml solution. Mice received 
100ul of this solution twice daily for 6 consecutive days, totalling 20mg/kg. 
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2.2.6.4 Dacarbazine (DTIC) 
DTIC for IP injection into CD1 nude mice was prepared by dissolving 1g of DTIC 
(Sigma D2390) into DMSO to make an 80mg/ml solution. This was subsequently 
diluted further in corn oil (Sigma) to make a 0.8mg/ml solution. Mice received 
100ul of this solution twice daily for 3 consecutive days, totalling 20mg/kg. 
2.2.6.5 Cell suspension for allografts and xenografts 
Cells for subcutaneous and tail vein injection into CD1 nude mice were grown in 
the appropriate antibiotic free growth medium to ~70% confluency. Cells were 
trypsinised and counted using the Casy cell counter. Each mouse received the 
appropriate amount of cells in a volume of 100µl. The required amounts of cells 
were spun down for 5mins, the pellet washed in PBS and re-spun. The pellet was 
re-suspended in PBS for injection into the mice. 
2.2.7 Tissue fixation 
Tissue samples were harvested using aseptic techniques and fixed in 10% 
formaldehyde in PBS for 24 hours. They were paraffin embedded and tissue 
sections cut and fixed onto slides by the Histology Service at the Beatson 
Institute. Staining with Hematoxylin & Eosin (H&E), which marks the nucleus, 
cytoplasm and connective tissue in sections, was also carried out by Histology 
Service.  
2.2.8 Immunohistochemistry 
All immunohistochemistry (IHC) was performed on standard paraffin embedded 
sections of tissue fixed in 10% formaldehyde in PBS for 24hrs before processing. 
All sections were de-waxed in xylene (3x washes of 5mins each) before being 
rehydrated through decreasing concentrations of ethanol to distilled water (2x 
washes of 5mins each in 100% ethanol, 1x wash of 10mins in 95% ethanol and 1x 
wash of 10mins in 70% ethanol). Slides were then washed in excess dH20 (5mins) 
followed by 1x wash in PBS (5mins). Antigen retrieval was performed in citrate 
buffer (pH 6) by the water bath method (detailed below). Following antibody 
incubation (see below) and visualisation using DAB (3, 3’-diaminobenzidine) 
chromogen (except DCT which was visualised using a fluorescent method), slides 
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were counterstained with haematoxylin (1min) and Scots tap water (1-5mins), 
prior to being dehydrated in increasing concentrations of ethanol (1x 70% 
ethanol 5mins, 1x 95% ethanol 5mins, 1x 100% ethanol 5mins) washed in xylene 
(15mins) and mounted with DPX mountant (Sigma).  
2.2.8.1 Water bath antigen retrieval 
300ml of 10mM Citrate antigen retrieval buffer was put into a plastic slide 
chamber placed in a cold water bath and then heated to 99.9oC, prior to 
immersion of the slides. Slides were then place in the pre-heated solution for 20 
minutes. The slides were then removed from the water bath still immersed in 
the buffer and allowed to cool till the temperature fell below 35oC.  
2.2.8.2 γH2AX 
Following antigen retrieval slides were washed in excess dH20 and then 
endogenous peroxidase activity was blocked by incubating the slides in 3% 
hydrogen peroxide for 10 minutes. After endogenous peroxidase blocking, slides 
were blocked in 10% normal goat serum (NGS) for 30 minutes. Primary mouse 
anti-γH2AX antibody (Millipore, 1:100 in 10% NGS) was applied overnight at 4oC. 
After washing 3xPBS the secondary anti-mouse Envision +system (Dako) was used 
for 1hour at RT. After washing positivity was visualized using DAB for 10mins at 
RT and slides mounted as described in 2.2.8 
2.2.8.3 DCT (Tryp2) 
Following antigen retrieval slides were washed in excess dH20 and then blocked 
in 10% normal donkey serum (NDS) for 30 minutes. Primary goat anti-DCT (TRP2) 
antibody (Santa Cruz, 1:100 in 10% NDS) was applied overnight at 4oC. After 
washing 3xPBS the fluorescent secondary Alexa 555 anti-goat (Invitrogen, 1:500 
in 10% NDS) was used for 1hour at RT in the dark. After washing slides were 
mounted in Vectashield containing DAPI. 
2.2.9 DNA Preparation and PCR Genotyping 
Animal tissue and cells were genotyped by both PCR and rt-PCR analysis. DNA 
extraction was carried out using the Qiagen QIAamp DNA Mini Kit. Briefly animal 
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tissue was prepared in tissue lysis buffer ATL + proteinase K and incubated at 
56oC for 3hrs (tumour samples) to overnight (tail tips). Cultured cell pellets were 
re-suspended in 200µl PBS then prepared in lysis buffer AL + proteinase K and 
incubated at 56oC for 10mins. DNA was precipitated in ethanol, bound to a 
QIAamp mini spin column, washed and eluted into 200µl distilled water. DNA 
concentration was determined using a NanoVue spectrophotometer from GE 
Healthcare. 
2.2.9.1 PCR 
Standard PCR was carried out using either Platinum® Pfx (Invitrogen) or Expand 
High Fidelity (Roche) PCR kits. The PCR reactions were assembled in thin walled 
domed capped PCR tubes and typically consisted of 50-100ng of genomic DNA, 
1.5 ×PCR Buffer, 300μM each dNTP, 0.3μM forward and reverse primers and 1U 
of polymerase in a final volume of 50μl.  
Genotyping for the presence of the Chk1 flox and wild-type alleles using primer 
pair Chk1 581 (forward) and 1004 (reverse) was carried out using the Platinum® 
Pfx DNA polymerase kit. The PCR protocol consisted of initial denaturation at 
94oC for 2 minute, followed by 35 cycles of 94oC for 15 sec, annealing at 55oC for 
30 sec followed by 68oC for 30 sec. The PCR product was then cooled to 4oC until 
use. 
Primers; 
Chk1 581 forward: 5’ AGGACAAACGTGGAAACAGG 3’ 
Chk1 1004 reverse: 5’ TCCCTCCAAACCTTCAACAG 3’ 
Genotyping for the presence of Tyr-Cre on the X-chromosome of female mice 
using the primer pairs LL1433:LL1441 for Xwt and LL1403:LL1326 for Xtg was 
carried out using the Expand High Fidelity PCR kit. The PCR protocol for primer 
pair LL1433:LL1441 consisted of initial denaturation at 94oC for 2 minute, 
followed by 35 cycles of 94oC for 20 sec, annealing at 60oC for 30 sec followed by 
72oC for 60 sec. A final extension of 10 minutes at 72oC was carried out and the 
PCR product was then cooled to 4oC until use. The PCR protocol for primer pair 
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LL1403:LL1326 consisted of initial denaturation at 94oC for 2 minute, followed by 
35 cycles of 94oC for 20 sec, annealing at 64oC for 30 sec followed by 72oC for 50 
sec. A final extension of 10 minutes at 72oC was carried out and the PCR product 
was then cooled to 4oC until use. 
Primers; 
LL1433: 5’ TTCTGTTTGTGAATACCTGCAA 3’ 
LL1441: 5’ TTGAGGGACTTCTGGATATTGTAAG 3’ 
LL1403: 5’ GCCAGGACCAAGAAGTGAGA 3’ 
LL1326: 5’ CAGCAGACACCAAGGAAACA 3’ 
2.2.9.2 RT-PCR 
RT-PCR for recombination of the Chk1 flox and wild-type alleles was carried out 
using the PerfeCTa® SYBR® Green FastMix® (Quanta Biosciences). The PCR 
reactions were assembled in white walled 96 well qPCR plates. PCR reactions 
were carried out using 1ng, 4ng and 16ng of DNA per reaction. Reaction mixes 
consisted of template DNA, 2x reaction cocktail mix and 0.2µM forward and 
reverse primers in a final volume of 10µl. The PCR protocol consisted of initial 
denaturation at 95oC for 15 minute, followed by 40 cycles of 95oC for 20 sec, 
annealing at 60oC for 20 sec followed by 72oC for 20 sec. A final extension of 5 
minutes at 72oC was carried out followed by melt curve analysis whereby the 
reaction is heated from 65oC to 95oC in 0.5oC increments for 5 sec each. 
Primers; 
Chk1 821 forward: 5’ CTGGGATTTGGTGCAAACTT 3’ 
Chk1 1004 reverse: 5’ TCCCTCCAAACCTTCAACAG 3’ 
Arbp 652 forward: 5’ CATCTGAGACCTGCCAGTCA 3’ 
Arbp 858 reverse: 5’ TAGAGAGGTCGGGGGATCTT 3’ 
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2.2.9.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was used for the routine analysis of DNA from PCR. 
0.8% -2% agarose gels in 1×TAE buffer was boiled in the microwave, allowed to 
cool and poured into the casting tray. Prior to pouring Ethidium Bromide (final 
concentration 1μg/ml) was added to visualise the DNA. The DNA was mixed with 
6×DNA loading dye (Fermentas) and loaded into the gel along with DNA ladder 
for size estimation (O’GeneRuler 100bp, O’GeneRuler 1kb and O’GeneRuler 1kb 
Plus, Fermentas). The gel was typically run at between 8-10V/cm and the DNA 
visualised using a transilluminator or the Syngene Genius Bio imaging system 
with GeneSnap Software. 
2.2.9.4 DNA Sequencing 
DNA sequencing was carried out by the Molecular Technology Service at the 
Beatson Institute. DNA sequencing is carried out using the BigDye® Terminator 
v3.1 Cycle Sequencing Kit from Applied Biosystems, routinely using 
approximately 500ng of plasmid DNA as template and 20ng of sequencing primer. 
The resulting sequencing reactions are analysed using an Applied Biosystems 
3130xl (16 capillary) sequencer. The data was analysed using CLC Genomics 
Workbench 5. Prior to sequencing the DNA was ‘cleaned up’ using the following 
Qiagen kits following manufacturer’s instructions.  
Qiaquick Gel Extraction kit (Qiagen) – for routine purification of DNA from 
agarose gels. 
Qiaquick PCR purification kit (Qiagen) – for routine clean-up of PCR products.  
2.2.10 Tissue culture 
2.2.10.1 Culturing Human Melanoma cell lines 
Human melanoma cell lines Sk-Mel-2, Sk-Mel-5, Sk-Mel-28, Sk-Mel-37 and Sk-Mel-
39 were cultured in DMEM: F-12 (1:1) supplemented with 10% FBS, 2mM 
Glutamine, 50U/ml penicillin G and 50μg/ml Streptomycin. The cells were grown 
in a humidified incubator at 37oC. Cells were passaged by trypsinising and 
diluting 1:10-1:20 into fresh media every 4-5 days to maintain the cells in 
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exponential growth phase. Human melanoma cell lines A375MM, Sk-Mel-103 and 
Sk-Mel-147 were cultured in DMEM supplemented with 10% FBS, 2mM Glutamine, 
50U/ml penicillin G and 50μg/ml Streptomycin. The cells were grown in a 
humidified incubator at 37oC. Cells were passaged by trypsinising and diluting 
1:10-1:20 into fresh media every 4-5 days to maintain the cells in exponential 
growth phase. Human melanoma cell lines WM35, WM793 and MRI-H-221 were 
cultured in RPM1 supplemented with 10% FBS, 2mM Glutamine, 50U/ml penicillin 
G and 50μg/ml Streptomycin. The cells were grown in a humidified incubator at 
37oC. Cells were passaged by trypsinising and diluting 1:5-1:10 into fresh media 
every 4-5 days to maintain the cells in exponential growth phase. All Sk-Mel cell 
lines were kindly donated by the Sloan Kettering Memorial Centre New York and 
are from metastatic melanoma patients. MRI-H-221 was provided by ICC and is 
from a metastatic phase melanoma that has been shown to be haplo-insufficient 
for Chk1 (Papp 2007). WM35 and WM793 were kindly donated by the Wister 
Institute Philadelphia, WM35 is from a radial growth phase melanoma and 
WM793 is from a vertical growth phase melanoma. A375MM was provided by 
ATCC and is a highly metastatic variant of the A375 cell line. 
2.2.10.2 Culturing Mouse derived melanocytes 
Mouse melanocyte cell lines were derived from mice maintained in the Beatson 
animal facility (see 2.5) with the following genotypes: Chk1 fl/fl, Tyr-N-Ras+, 
p16Ink4a-/-, Arf+/-, Tyr-CreERT2; Chk1 fl/+, Tyr-N-Ras+, p16Ink4a-/-, Arf+/-, Tyr-
CreERT2; Chk1 +/+, Tyr-N-Ras+, p16Ink4a-/-, Arf+/-, Tyr-CreERT2. They were all 
cultured in DMEM: F-12 (1:1) supplemented with 10% FBS, 200nM TPA, 2mM 
Glutamine, 50U/ml penicillin G and 50μg/ml Streptomycin. The cells were grown 
in a humidified incubator at 37oC. Cells were passaged by trypsinising and 
diluting 1:3-1:5 into fresh media every 4-5 days to maintain the cells in 
exponential growth phase. The cells express and secrete melanin which colours 
the medium brown.  
2.2.10.3 Passaging Adherent Cells 
Once the cells had reached confluence an aliquot of the cells was transferred to 
a new flask to allow continued growth of the culture. The media was first 
aspirated from the cells and they were then washed with 10mls of pre-warmed 
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PBS. 1ml of pre-warmed 1% trypsin in PBS was added to the flask (the volume of 
trypsin depends on the size of the flask/dish, 1ml is sufficient for a T75 flask) 
and the trypsin solution was distributed evenly over the surface of the 
flask/dish. The flask was then returned to the incubator and monitored until the 
cells had detached form the plate. Once detached, 10mls of fresh pre-warmed 
media was added to the cells to inactivate the trypsin. An aliquot of this cell 
suspension was then added to a flask containing fresh media. The cells were 
then returned to the incubator to allow re-attachment of the cells. 
2.2.10.4 Cryogenetic Preservation of Cell lines 
For long term storage of cells, log phase healthy cells were trypsinised if 
necessary and then re-suspended in 90% FBS/10% DMSO and divided into 1ml 
aliquots in 1.5ml cryovials. Initial freezing was carried out in a Mr Frosty 
container (containing isopropanol) at -70oC to give a cooling rate of 1oC/minute. 
Once a temperature of -70oC was reached the cells were transferred to storage 
in liquid nitrogen vapour phase tanks at -180oC. To revive the cells the vials were 
retrieved and were quickly warmed up to 37oC by placing in a container of warm 
water. Once thawed the cells were added to pre-warmed media. The following 
day the cells were passaged or the media was changed depending on the 
confluence of the cells. 
2.2.10.5 Counting of Cells 
Cells were counted using the automated Casy® Cell Counter and Analyser System 
(Innovatis). The appropriate dilution of cells following trypsinisation was 
automatically counted by the machine set to exclude debris from the 
calculation. This also allows for easy determination of the viability of the 
culture. For growth curve analysis measurements were taken in triplicate. 
2.2.10.6 Transient transfection using Lipofectamine® 2000 
Lipofectamine® 2000 (Invitrogen) was used in order to introduce plasmid DNA 
into cells following the manufacturer’s instructions. Briefly the cells were set up 
the day before transfection to be 70-80% confluent. The cells were set up in 
antibiotic free medium. Separately an appropriate amount of plasmid and 
Lipofectamine® 2000 was diluted in OptiMEM®. For plasmid transfections the 
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ratio of Lipofectamine® 2000 to plasmid was typically 2.5μl:1μg. Following a 5 
minute incubation the diluted Lipofectamine® 2000 and plasmid was mixed and 
complexes were allowed to form for 20 minutes. The lipid – plasmid complexes 
were then applied to the cells and the dish rocked gently to ensure even 
coverage of the cells with the complexes. Cells were returned to the incubator 
and harvested at the appropriate time to check for expression.  
2.2.10.7 Irradiating cells 
As a method of inducing DNA damage cells were treated with γ-IR. Cells were 
irradiated with γ-IR using an Alcyon II Cobalt-60 Teletherapy Unit. Dose rates 
varied from 2-10 Gymin-1. Cells were irradiated directly in the media in the 
culture flask. Control cells were brought to the Co-60 source but were not 
exposed to the ionising radiation.  
2.2.11 Flow Cytometry 
2.2.11.1 Fixing Cells 
Cells were treated as required and pelleted at 250×g for 5 minutes in 15ml 
polystyrene tubes. The resulting pellet was then re-suspended in 200μl of ice 
cold PBS. While vortexing, 2mls of ice cold 70% Ethanol was added drop wise to 
fix the cells. This minimises the formation of clumps and ensures uniform fixing 
of the cells. Fixed cells were stored at 4oC overnight or at -20oC for a couple of 
hours to several weeks before further analysis. 
2.2.11.2 DNA content 
Cells were fixed as described and stored at -20oC for at least 30 minutes. The 
cells were pelleted and re-suspended in 1ml of PBS containing 10μg/ml 
Propidium Iodide and 250μg/ml RNase A. The cells were stored in the dark for 30 
minutes before analysis on the flow cytometer. 
2.2.11.3 S-phase 
To monitor DNA replication, cells were tested for their ability to incorporate 
either the synthetic thymidine analogue 5-bromo-2’-deoxyuridine (BrdU) or 5-
ethynyl-2’-deoxyuridine (EdU) into their DNA. Cells were treated as required and 
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then before being harvested 25μM BrdU or EdU was added for the appropriate 
time to the culture. Cells were then fixed as above and stored until use. 
For BrdU analysis the cells were centrifuged at 250×g and the ethanol was 
removed. The cells were re-suspended in 1ml of PBS and then 1ml of 4M HCl was 
added. The samples were incubated at RT for 15 minutes. The HCl treatment 
denatures the DNA and exposes the BrdU epitopes that are recognised by the 
anti-BrdU antibody. The cells were then washed once with PBS and once with 
PBT (0.5% BSA, 0.1% Tween 20 in PBS). The resulting pellet was re-suspended in 
200μl of PBT containing a 1:100 dilution of the anti-BrdU antibody (Dako for 
BrdU only analysis, Abcam for EdU/BrdU analysis) and incubated at RT for 30 
minutes. The cells were then washed with 1ml of PBT and re-suspended in 200μl 
of PBT containing a 1:100 dilution of the FITC conjugated anti-mouse antibody 
(for BrdU only analysis) or the Alexa 647 conjugated anti-sheep antibody (for 
EdU/BrdU analysis). The cells were incubated for 30 minutes in the dark and 
then washed with 1ml of PBT. The cell pellet was then re-suspended in 1ml of 
PBS containing 10μg/ml Propidium Iodide and 250μg/ml RNase A. The cells were 
stored in the dark for 30 minutes before analysis on the flow cytometer. Data 
was collected on a FACS Calibur flow cytometer and the data analysed using 
WinMDI software. 
 
For EdU analysis the cells were centrifuged at 250×g and the ethanol was 
removed. The cells were then washed once with PBS and once with PBT (0.5% 
BSA, 0.1% Tween 20 in PBS). The resulting pellet was re-suspended in EdU 
reaction buffer (Click-iT reaction buffer, CuSO4, Alexa Fluor 488 azide and 10x 
reaction buffer additive, Invitrogen) and incubated at RT for 30 minutes in the 
dark. The cells were then washed with 1ml of PBT and then either re-suspended 
in 1ml of PBS containing 10μg/ml Propidium Iodide and 250μg/ml RNase A or 
stained for BrdU (see above). The cells were stored in the dark for 30 minutes 
before analysis on the flow cytometer. Data was collected on a FACS Calibur 
flow cytometer and the data analysed using WinMDI software. 
 
2.2.11.4 Mitosis 
The number of mitotic cells was estimated by counting the number of cells that 
were positive for the mitosis specific marker, pS10 Histone H3, by flow 
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cytometry. Cells were treated as required, then fixed as above and stored until 
use. The cells were centrifuged at 250×g and the ethanol was removed. The cells 
were then re-suspended in 1ml of PBS containing 0.25% Triton-X-100 and 
incubated on ice for 15 minutes. The cells were then pelleted and re-suspended 
in 100μl of PBT (0.5% BSA, 0.1% Tween 20 in PBS) containing a 1:50 dilution of 
the anti-pS10 H3 antibody followed by 90 minute incubation at RT. The cells 
were washed once with PBT and then re-suspended in 100μl of PBT containing a 
1:100 dilution of the FITC conjugated anti-rabbit antibody. The cells were 
incubated for 30 minutes in the dark and then washed with 1ml of PBS. The cell 
pellet was then re-suspended in 1ml of PBS containing 10μg/ml Propidium Iodide 
and 250μg/ml RNase A. The cells were stored in the dark for 30 minutes before 
analysis on the flow cytometer. Data was collected on a FACS Calibur flow 
cytometer and the data analysed using WinMDI software. 
2.2.11.5 Apoptosis 
To monitor induction of apoptosis cells were tested for their Annexin V and 
Propidium Iodide staining. Cells were treated as required and then collected 
fresh by centrifugation at 250×g without fixing. The cells were then washed once 
with PBS and re-suspended in 50µl Annexin V binding buffer (BioLegend) 
containing 2.5µl FITC conjugated Annexin V. Cells were incubated for 15 minutes 
at RT in the dark. After the incubation period 250µl of Annexin V binding buffer 
containing 3µl of 1mg/ml Propidium Iodide was added. The cells were mixed 
gently, kept on ice and analysed as soon as possible on the flow cytometer.  
Data was collected on a FACS Calibur flow cytometer and the data analysed 
using WinMDI software. 
2.2.12 Protein Extraction 
Cells were treated or not as appropriate, pelleted at 250×g, then washed once 
with ice cold PBS. Unless cells were lysed immediately they were snap frozen on 
dry ice and stored at -70oC until use. Cell pellets were lysed in whole cell 
extract buffer (400mM Potassium Chloride, 20mM HEPES, 5mM EDTA, 10mM 
EGTA, 1mM DTT, 0.4% Triton-X-100, 10% Glycerol, 5μg/ml Leupeptin, 285μM 
PMSF, 1mM Benzamidine, 5μg/ml Aprotinin, 5mM Sodium Fluoride, 50ng/ml 
Okadaic Acid, 1mM Sodium Orthovanadate, 10mM β-glycerophosphate, 5mM 
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Sodium pyrophosphate) then incubated on ice for 20-30 minutes. The samples 
were then spun at 16,100 x g in a refrigerated microfuge for 15 minutes to pellet 
the cellular debris. The cleared lysate was then transferred to a fresh tube and 
an aliquot removed for quantitation. The remainder was snap frozen on dry ice 
and stored at -70oC until use. 
2.2.12.1 Protein Quantitation: Bradford Assay 
The Bradford Assay relies on the blue colour generated when Coomassie Brilliant 
Blue reagent binds to protein side chains. A standard curve of BSA was generated 
in a 1:10 dilution of the corresponding lysis buffer at the following 
concentrations: 2000μg/ml, 1000μg/ml, 750μg/ml, 500μg/ml, 250μg/ml, 
125μg/ml and 63μg/ml. The protein samples of unknown concentration were 
diluted 1:10 in dH2O. 10μl of each standard and 10μl of the diluted samples 
were placed in a cuvette. 1ml of working Bradford Assay reagent (50% Bradford 
Assay reagent: 50% dH2O) was then added to each cuvette. The absorbance at 
595nm of the standards and samples were then read using a Biophotometer. The 
concentration of protein in the unknown samples was determined by comparison 
with the standard curve. 
2.2.13 SDS-PAGE and Western Blotting 
SDS-PAGE was carried out in order to separate proteins so they could be 
analysed further by Western Blotting or to directly analyse protein by staining 
the gel. The mini vertical gel system from Atto was used. To cast the resolving 
gel a solution containing 6-15% acrylamide (acrylamide:bisacrylamide 
37.5:1),375mM Tris-HCl pH 8.8 and 0.1% SDS was made. To polymerise the gel 
ammonium persulphate and TEMED was added to a final concentration of 0.1% 
and 0.08% respectively. The gel mix was placed in the gel casting apparatus and 
over-laid with water-saturated butanol. Once set the stacking buffer (5% 
acrylamide (acrylamide:bisacrylamide 37.5:1), 125mM Tris-HCl pH 6.8, 0.1% SDS, 
0.1% ammonium persulphate and 0.1% TEMED) was layered on top and the combs 
were inserted to allow the loading of samples. Once set the gel apparatus was 
correctly assembled and 1 × SDS-PAGE Running Buffer was added to the upper 
and lower chambers of the tank. Samples to be analysed were added to 1x 
NuPAGE sample buffer (Invitrogen) and were boiled for 5 minutes to denature 
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the proteins. The samples were centrifuged briefly to remove debris and the 
samples were then loaded into the wells. Molecular weight markers were also 
run to estimate the size of the proteins to be analysed. The gels were then run 
at 180V at constant voltage until the dye front had just entered the running 
buffer. Western Blotting was carried out using the semi-dry blotting technique. 
Once the SDS-PAGE was run it was placed on top of 5 sheets of 3MM paper pre-
soaked in dry blot buffer and cut to the size of the gel. On top of this was placed 
the nitrocellulose membrane and then 5 more sheets of soaked 3MM paper. Air 
bubbles were removed by gently rolling with a marker pen. The ‘sandwich’ was 
placed on the transfer apparatus such that the gel was closest to the negative 
electrode. The proteins were transferred as standard at 20V, 200mA, 8W for 
1hour 20 minutes. Ponceau S stain (Applichem) was used to ensure even transfer 
of the proteins onto the membrane. Then the membrane was blocked in blocking 
buffer (5% Marvel (non-fat dried milk powder) solution in 1 × TBS-T) for 1 hour at 
RT with gentle agitation. The membrane was then incubated with the 
appropriate primary antibody. (See Table for the dilution of antibody used and 
what blocking buffer was used) The membrane was then washed three times for 
10 minutes each with 1 × TBS-T with gentle agitation. The membrane was then 
incubated with the secondary antibody coupled to horseradish peroxidase for 
1hour at RT. The appropriate secondary antibodies were diluted 1:5000 in 
blocking buffer. After this incubation the membrane was washed as before and 
the bound secondary antibody was detected using Enhanced Chemiluminescence 
and X-ray film. The film was developed in a Kodak X-Omat 3000RA automatic 
film processor. 
2.2.14 Microscopy 
2.2.14.1 Fluorescence 
After plating on glass coverslips Human melanoma cells were treated as required 
and then before being harvested 25μM EdU was added for 1hr. The cells were 
then fixed with 4% paraformaldehyde for 15 minutes at RT, washed in PBS + 3% 
BSA and then permeabilised with 0.5% triton X-100 for 20 minutes at RT. 
Following fixation the cells were then washed twice with PBS + 3% BSA. The 
resulting pellet was re-suspended in EdU reaction buffer (Click-iT reaction 
buffer, CuSO4, Alexa Fluor 488 azide and 10x reaction buffer additive, 
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Invitrogen) and incubated at RT for 30 minutes in the dark. The cells were then 
washed twice with 1ml of PBS + 3% BSA and then blocked with 3% BSA in PBS for 
10-30 minutes. Fixed cells were probed with anti-γH2AX antibody (Millipore) 
diluted 1:100 in PBS + 3% BSA for 1hr at RT. Following washing the cells were 
stained with Alexa 555 conjugated anti-rabbit antibody (Invitrogen) diluted 
1:500 in PBS + 3% BSA for 40 minutes at RT in the dark. Samples were then 
washed and mounted with Vectashield mounting medium containing DAPI (Vector 
labs). Fluorescent microscopic images were acquired with a 60x oil immersion 
lens on a Nikon A1R laser scanning confocal microscope. 
2.2.14.2 Alamar Blue Cytotoxicity Assay  
The cytotoxicity of the Chk1 inhibitor CHIR-124 and the chemotherapeutic 
agent’s dacarbazine (DTIC) and temozolomide (TMZ) on human melanoma cell 
lines was measured using the fluorimetric indicator, Alamar Blue (Invitrogen), 
which detects cellular metabolic activity.  The greater the level of metabolic 
activity, or corresponding cell viability, the more reduction of the Alamar Blue 
dye from a blue non-fluorescent product to a red-fluorescent product. Cells 
were plated in 96 well plate format at 2000-3500 cells per well in 100µl of 
media. Cells were treated as required and then incubated for 72 hrs at 37oC. 
After incubation 10µl Alamar Blue was added to the cells and incubated for a 
further 4hrs at 37oC. Absorbance was read at 570nm and 600nm using 
spectrophometer. Alamar Blue data was calculated as the percent difference in 
reduction between treated cells and control cells, which were calculated using 
the molar coefficients for both the oxidised and reduced forms of alarm blue at 
both 570nm and 600nm (see manufacturer’s instructions for details). The 
percent reduction is directly proportional to the percent cell viability. Dose 
response curves were plotted in GraphPad Prism and EC50 values were 
calculated using a non-linear regression with variable slope analysis. 
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2.2.15 List of primary antibodies 
Antigen (Ab Type) Supplier Dilution and incubation 
conditions 
Chk1 (Mouse monoclonal) 
 
Santa Cruz (G-4) 
Cat No: sc-8408 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
Actin (Mouse monoclonal) Sigma (AC-40) 
Cat No: A4700 
 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
pS345 Chk1 (Rabbit 
monoclonal) 
 
Cell Signalling (133D3) 
Cat No: 2348 
WB- 1:1000 in 5% BSA in 
TBS-T overnight at 4°C/ RT 
3hrs 
Chk2 (Goat polyclonal) Santa Cruz (N-17) 
Cat No: sc-8812 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
pT68 Chk2 (Rabbit 
monoclonal) 
Cell Signalling (C13C1) 
Cat No: 2197 
WB- 1:1000 in 5% BSA in 
TBS-T overnight at 4°C/ RT 
3hrs 
 
ATM (Rabbit polyclonal) Santa Cruz (H-248) 
Cat No: sc-7230 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
ATR (Goat polyclonal) Santa Cruz (N-19) 
Cat No: sc-1887 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
ATRIP (Rabbit polyclonal) Santa Cruz (H-300) 
Cat No: sc-33790 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
Mre11 (Mouse monoclonal) Novus Biologicals (12D7): 
Cat No: NB100-473 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
Nibrin (Nbs1) (Rabbit 
polyclonal) 
Santa Cruz (H-300) 
Cat No: sc-11431 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
Rad50 (Mouse monoclonal) Abcam (13B3/2C6) 
Cat No: ab89 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
Wee1 (Mouse monoclonal) Santa Cruz (B-11) 
Cat No: sc-5285 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
CDC25A (Mouse monoclonal) Santa Cruz (F-6) 
Cat No: sc-7389 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
pS216 CDC25C (Rabbit 
monoclonal) 
Cell Signalling (63F9) 
Cat No: 4901 
WB- 1:1000 in 5% BSA in 
TBS-T overnight at 4°C/ RT 
3hrs 
PARP (Rabbit polyclonal) Cell Signalling 
Cat No: 9542 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
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Cdk1 (cdc2) (Rabbit 
polyclonal) 
Cell Signalling 
Cat No: 9112 
WB- 1:1000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
pT15/Y15 Cdk1 (cdc2 p34) 
(Rabbit polyclonal) 
Santa Cruz  
Cat No: sc-12340-R 
WB- 1:1000 in 5% BSA in 
TBS-T overnight at 4°C/ RT 
3hrs 
α-tubulin (Mouse monoclonal) Sigma 
Cat No: T9026 
WB- 1:2000 in 5% Marvel in 
TBS-T overnight at 4
o
C/ RT 
3hrs 
BrdU (Mouse monoclonal) Dako (CloneBu20a) 
Cat No: M0744 
FACs- 1:100 in PBT for 
30mins RT 
BrdU (Sheep polyclonal) Abcam 
Cat No: ab1893 
FACs- 1:100 in PBT for 
30mins RT 
pS10 Histone H3 (Rabbit 
polyclonal) 
Santa Cruz 
Cat No: sc-8656-R 
FACs- 1:50 in PBT for 90mins 
RT  
Annexin-V FITC conjugated BioLegend 
Cat No: 640906 
FACs- 1:20 in Annexin-V 
binding buffer for 15mins RT 
EdU Alexa 488 conjugated Invitrogen 
Cat No: C35002 
FACs/IF- 7.5µl in 3ml EdU 
reaction buffer mix 
γH2AX (Mouse monoclonal) Millipore (Clone JBW301) 
Cat No: 05-636 
IHC- 1:100 in 10% normal 
goat serum overnight at 4
o
C 
IF- 1:100 in PBS + 3% BSA for 
1hr RT 
DCT (TRP2) (Goat polyclonal) Santa Cruz (D-18) 
Cat No: sc-10451 
IHC(F)- 1:100 in 10% normal 
donkey serum overnight at 
4
o
C 
 
2.2.16 List of secondary antibodies 
Antigen (Ab Type) Supplier Dilution and incubation 
conditions 
Anti-Mouse HRP conjugated Cell Signalling 
Cat No: 7076 
WB- 1:3000 in 5% Marvel in 
TBS-T for 1hr RT 
Anti-Rabbit HRP conjugated Cell Signalling 
Cat No: 7074 
WB- 1:3000 in 5% Marvel in 
TBS-T for 1hr RT 
Anti-Goat HRP conjugated Santa Cruz 
Cat No: sc-2020 
WB- 1:5000 in 5% Marvel in 
TBS-T for 1hr RT 
Anti-Mouse FITC conjugated Jackson Immuno Research  
Cat No: 515-095-003 
FACs: 1:100 in PBT for 30mins 
RT 
Anti-Rabbit FITC conjugated Jackson Immuno Research  
Cat No: 111-095-003 
FACs: 1:100 in PBT for 30mins 
RT 
Anti-Sheep Alexa 647 
conjugated 
Invitrogen 
Cat No: A21448 
FACs: 1:100 in PBT for 30mins 
RT 
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Anti-Mouse Alexa 555 
conjugated 
Invitrogen 
Cat No: A21427 
IF- 1:500 in PBS + 3% BSA for 
40mins RT 
Anti-Goat Alexa 555 
conjugated 
Invitrogen 
Cat No: A21432 
IHC(F)- 1:500 in 10% normal 
donkey serum for 1hr RT 
Anti-Mouse Envision+ system-
HRP labelled 
Dako 
Cat No: K4000 
IHC- apply enough to cover 
specimen on slide for 1hr RT 
84 
 
Chapter 3: Chk1 requirement in embryonic 
development of melanocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  85 
 
3 Chk1 requirement in embryonic development of 
melanocytes 
3.1 Introduction 
Murine melanocytes originate from a highly migratory group of embryonic cells 
called the neural crest, which gives rise to many cell types including osteocytes, 
chondrocytes and sensory neurons and are therefore truly multi-potent (Erickson 
& Reedy, 1998). The development of neural crest cell into mature melanocytes 
has been well studied showing that neural crest cells first develop into a bi-
potential glial-melanocyte lineage progenitor before becoming an un-pigmented 
precursor termed melanoblasts and finally maturing into a differentiated 
melanocyte (Dupin et al, 2000). Several genes have been identified to play 
crucial roles in melanocyte development including MITF (Lister et al, 1999; 
Hornyak et al, 2001), c-Kit (Wehrle-Haller & Weston 1995; Parcihy et al, 1999), 
WNT (Ikeya et al, 1997; Dorsky et al, 1998; Dunn et al, 2000), Snail/Slug, and 
Sox10 (Cano et al, 2000; Meulemans & Bronner-Fraser 2004). Melanocytes are 
the cell of origin for melanoma, an aggressive form of skin cancer and many of 
the genes involved in melanocyte development have also been implicated in the 
development of melanoma. Thus I examined the requirement of Chk1 in 
melanocyte development during embryogenesis.  
3.2 Developmental deletion of Chk1 leads to loss of 
pigmentation in adult mice 
Constitutive deletion of Chk1 is embryonic lethal (Liu et al, 2000) therefore in 
order to assess the consequences of Chk1 deletion in melanocytes I utilised a 
conditional knockout mouse model of Chk1 whereby exon 2 of the gene is 
flanked by LoxP sites (Figure 3.1). Upon recombination by Cre-recombinase exon 
2, which contains the translation initiation codon is deleted resulting in loss of 
Chk1 protein expression (Liu et al, 2000; Lam et al, 2004). To specifically 
knockout Chk1 in the melanocyte lineage I utilised a mouse model expressing 
Cre-recombinase under the control of the Tyrosinase (Tyr) promoter which is 
melanocyte specific and actively expressed at later times (E10.5) during 
embryonic development (Delmas et al, 2003). All mice were maintained on a 
C57Bl/6 background in order to maintain a pigmented phenotype. The Tyr-Cre 
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transgene is located on the X-chromosome, therefore in order to avoid problems 
associated with X-inactivation only male mice were initially used for the 
analysis. 
 
 
Figure 3.1: Conditional deletion of Chk1 in the melanocyte lineage. Conditional Chk1 flox 
mice, whereby Exon 2 (containing the translation initiation codon) of the Chk1 gene is flanked by 
LoxP sites, were crossed with mice expressing Cre-recombinase under the control of the 
Tyrosinase (Tyr) promoter allowing constitutive expression of Cre in the melanocyte lineage.  
 
Upon Chk1 deletion in adult C57Bl/6 mice all detectable pigmentation of the 
coat is lost converting a black coated mouse as seen in Chk1 +/+: Tyr-Cre (Figure 
3.2Ai) to a white coated mouse in Chk1 fl/fl: Tyr-Cre (Figure 3.2Aii). Mice which 
are wild-type for Chk1 in melanocytes are fully pigmented. This pigmentation is 
due to the presence of melanocyte cells which can be seen located at the base 
of their hair follicles (Figure 3.2Bi). These melanocytes are responsible for the 
synthesis of melanin which is transferred to the growing hair. However in Chk1 
deleted mice all detectable pigmentation of the coat is lost. Analysis of their 
hair follicles shows that these melanocyte cells are absent from the base of their 
hair follicles (Figure 3.2Bii). This demonstrates that loss of Chk1 specifically in 
the melanocyte lineage leads to the loss of melanocyte cells from the skin, 
resulting in the loss of melanin production and ultimately pigmentation. The 
phenotype observed upon Chk1 deletion is distinct from that observed in FVB 
albino mice (Figure 3.2Aiii). FVB albino mice possess the classical albino 
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mutation (c) which affects the expression of the tyrosinase gene (Montoliu et al, 
1996; Taketo et al 1991). Tyrosinase is the rate limiting enzyme in the melanin 
biosynthesis pathway. As such FVB albino mice retain melanocytes in their hair 
follicles (Figure 3.2Biii) but these cells lack expression of tyrosinase and thus 
melanin.   
Although most pigment cells are NC-derived including melanocytes of the skin, 
hair follicle, iris and choroid, pigment cells of the retinal pigmented epithelium 
(RPE) located in the eye are derived from the optic cup (Zhao et al, 1997). The 
expression of tyrosinase has been shown to be differentially regulated in the two 
pigment cell lineages with a specific enhancer-promoter combination allowing 
for expression to be specifically targeted to the NC-derived melanocytes 
(Camacho-Hubner & Beermann, 2001). The 6.1kb Tyr promoter used here 
contains 2.5kb of the region immediately upstream of exon 1 and 3.6kb of a 
region located 15kb upstream of exon 1. These regions encompass the two 
important elements for differential expression; the 270bp promoter fragment 
and the hs enhancer (Camacho-Hubner & Beermann, 2001; Delmas et al, 2003), 
which restricts the expression of the promoter to melanocytes of neural-crest 
origin and not to the RPE which is derived from the optic cup. As such we can 
see that in Chk1 deleted adult C57Bl/6 mice although coat pigmentation is lost 
they still retain pigment in the eye (Figure 3.3ii). This is presumably due to the 
continued expression of Chk1 within the RPE of these mice, although loss of NC-
derived melanocytes in the eye can still be seen (Figure 3.3v) in comparison to 
Chk1 +/+ mice which maintain this population of cells located posterior to the 
ciliary processes (Figure 3.3iv). This is in contrast to FVB albino mice which lack 
pigmentation in all structures of their eyes (Figure 3.3iii and vi).  Collectively 
this data shows that Chk1 expression in melanocytes during embryogenesis from 
E10.5 is essential for the formation or survival of this cell type. 
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Figure 3.2: Loss of pigmentation in adult mice upon Chk1 deletion. (A) Images of adult mice 
showing a black coated (i), a white coated (ii) and albino (iii) with the genotypes Chk1 +/+: Tyr-Cre 
on C57Bl/6, Chk1 fl/fl: Tyr-Cre on C57Bl/6 and Chk1 +/+: Tyr-Cre on FVB respectively. (B) 
Immunofluorescence microscopy of paraffin-embedded skin sections. Antibodies against DCT 
(red), a melanocyte specific marker, were used. Inserts show individual hair follicles in skin 
sections. Positive labelling for DCT was seen in Chk1 +/+ on both C57Bl/6 (i) and FVB (iii) in the 
hair follicle bulb. Chk1 fl/fl (ii) on C57Bl/6 were devoid of DCT expressing cells in the hair follicles.  
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Figure 3.3: Loss of Neural Crest (NC)-derived melanocyte in the eye Chk1 fl/fl: Tyr-Cre mice. 
(A) Images and corresponding H&E stained eye sections of adult mice. (ii and v) Chk1 fl/fl: Tyr-Cre 
on C57Bl/6 mice has black eyes due to the RPE (retinal pigment epithelium) but lack NC-derived 
melanocytes. (i and iv) Chk1 +/+: Tyr-Cre on C57Bl/6 mice has black eyes with NC-derived 
melanocytes present. (iii and vi) Albino mice have red non-pigmented eyes. H&E sections show 
ciliary processes (CP) and retina (R).    
 
3.3 Developmental deletion of Chk1 leads to loss of 
melanocyte precursor cells during embryogenesis 
The specific Tyr promoter used for the expression of Cre-recombinase becomes 
active at the early embryonic stage of E10.5, thus deletion of Chk1 is predicted 
to begin at this time during embryogenesis (Ferguson & Kidson 1997). In order to 
establish the time frame for melanocyte loss in utero I utilised a transgenic 
mouse model whereby the reporter gene LacZ is expressed in a melanocyte 
specific manner allowing visualisation of melanocytes by β-galactosidase 
cleavage of X-Gal (Figure 3.4A and B). The transgene is a recombinant construct 
in which the Escherichia coli β-galactosidase gene is driven by the mouse DCT 
promoter (Mackenzie et al, 1997). DCT is an enzyme involved in the biosynthesis 
of melanin and is first expressed in E9 melanoblasts and is still expressed later in 
adult melanocytes.  
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Figure 3.4: The LacZ reporter allele. (A) The LacZ transgene is under the control of the 
melanocyte specific DCT promoter which becomes expressed from embryonic day 9. (B) Image of 
wholemount β-galactosidase stained DCT-LacZ E9.5 embryo, taken from paper MacKenzie et al 
1997. 
 
To elucidate when Chk1 deletion is affecting melanocytes during embryogenesis 
whole-mount distribution of LacZ positive cells in Chk1 +/+: Tyr-Cre: DCT-LacZ 
and Chk1 fl/fl: Tyr-Cre: DCT-LacZ embryos at E10.5 through to E13.5 were 
compared (Figure 3.5). In early stage E10.5 (shortly after Cre-recombinase 
expression is activated) and E11.5 there was no obvious visual alteration in 
either the number or distribution pattern of melanocytes between Chk1 +/+ and 
Chk1 fl/fl embryos. In E10.5 embryos of both genotypes there is a high 
concentration of melanocytes in the brain, eye and neural tail tube with a 
smaller number visible in the head, shoulder, and dorsolateral trunk regions. In 
E11.5 embryos of both genotypes there are a greater number of melanocytes 
present in the head, shoulder and dorsolateral trunk regions than in E10.5; 
however the melanocytes are still concentrated in the brain, eye and neural tail 
tube. By E12.5 we can see that there is a visible reduction in the overall number 
of melanocytes in Chk1 fl/fl embryos compared to Chk1 +/+, but with no obvious 
effect on the distribution pattern and therefore presumably of the migratory 
potential. This reduction is particularly evident in the head, shoulder and 
dorsolateral trunk regions of the embryo. Strikingly by E13.5 we can see that all 
melanocytes are absent in Chk1 fl/fl embryos whereas Chk1 +/+ have a normal 
distribution of melanocytes with expansion throughout the whole embryo, 
uniformly across both dorsal and lateral surfaces of the trunk. 
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Figure 3.5: Loss of melanocytes between E12.5and E13.5 during embryogenesis upon Chk1 
deletion. Images of Wholemount β-galactosidase stained embryos from E10.5 to E13.5 for Chk1 
wildtype (Chk1 +/+: Tyr-Cre: DCT-LacZ) and Chk1 flox (Chk1 fl/fl: Tyr-Cre: DCT-LacZ) embryos. 
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Figure 3.6: Graph of melanocyte numbers between E12.5 and E13.5 during embryogenesis 
upon Chk1 deletion. Graphical representation of the average number of melanocytes quantified in 
the regions represented in Figure 3.5.  
 
Quantification of the number of melanocytes (Figure 3.6 and Table 3.1) in the 
head and dorsolateral trunk regions (as highlighted in Figure 3.5 and counted as 
one blue dot = one melanocyte) in E10.5 to E13.5 embryos confirmed that at 
early embryonic E10.5 (shortly after Cre-recombinase expression is activated) 
and E11.5 there is no significant difference between Chk1 deleted (Chk1 fl/fl) 
and Chk1 wild type (Chk1 +/+) embryos. However at later times in E12.5 
embryos where there is a visible reduction in the number of melanocytes in the 
Chk1 deleted embryos there is statistically a very high significant difference in 
both the head (p=0.00018) and dorsolateral trunk (p=0.00017) regions between 
Chk1 fl/fl and Chk1 +/+ embryos. By E13.5 when all visible melanocytes have 
disappeared from the Chk1 deleted embryo, there is an even higher statistical 
significant difference in both the head (p=2.132E-7) and dorsolateral trunk 
(p=4.26E-9) regions between Chk1 fl/fl and Chk1 +/+ embryos. This data shows 
that although deletion of the Chk1 gene presumably commences at E10.5 (when 
the Tyr promoter becomes active) no significant reduction in the number of 
melanocytes is seen until 48hrs later at E12.5. This may represent the timeframe 
for deletion of Chk1 to occur. In the model used it has been previously shown 
that Tyr-Cre is functional by E11.5, as shown by Cre-mediated expression of the 
LacZ reporter gene from the Rosa26 locus (Delmas et al, 2003; Soriano, 1999) 
whereby clear punctate staining was visible in E11.5 embryos. Thus Cre-
mediated recombination of the Chk1 gene should be complete by E11.5. 
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However in order for melanocytes to become functionally null for Chk1 any 
residual Chk1 protein present before recombination must be destroyed. The 
half-life of Chk1 in human cells has been shown to be fairly short; 3.4hrs in 
Hek293, 4.8hrs in A549 (Zhang et al, 2005) and 6h in Hela cells (Leung-Pineda et 
al, 2009) during unperturbed cycling with a reduction in the half-life seen in 
stressed cells. Therefore by late E11.5 melanocytes in Chk1 fl/fl embryos should 
express little or no Chk1. Within 24hrs of this, E12.5, the melanocyte number in 
both the head and dorsolateral trunk regions are significantly reduced (70% and 
50% respectively) with complete loss by 48hrs, E13.5. This shows that loss of 
melanocytes after Chk1 deletion is remarkably rapid, demonstrating that Chk1 
expression is highly essential for survival of melanocytes during embryogenesis. 
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  Head p-value Trunk p-value 
E10.5 Chk1 
+/+ 
86.5 ± 12.5 
(5) 
0.62861 70 ± 13 (5) 0.97330 
Chk1 
fl/fl 
96.5 ± 12.5 
(6) 
69.5 ± 2.5 
(6) 
E11.5 Chk1 
+/+ 
228 ± 26.89 
(9) 
0.75978 98 ± 4.58 (9) 0.57980 
Chk1 
fl/fl 
239.67 ± 
23.38 (7) 
91 ± 10.69 
(7) 
E12.5 Chk1 
+/+ 
182.75 ± 
14.53 (10)  
0.00018
***
 276 ± 16.15 
(10)  
0.00017
***
 
Chk1 
fl/fl 
49.75 ± 
7.36 (12)  
124.75 ± 
8.52 (12)  
E13.5 Chk1 
+/+ 
380.5 ± 
29.26 (11) 
2.132E-
7
***
 
693.25 ± 
27.69 (11) 
4.26E-9
***
 
Chk1 
fl/fl 
0 (8) 0 (8) 
Table 3.1: Quantification of melanocytes in wholemount embryos. Shown are the average 
number of melanocytes quantified, standard deviation and number of samples in brackets. P-
values are included with *** indicating highly significant values. The regions quantified are 
represented in Figure 5.  
 
3.4 Hemizygous deletion of Chk1 during development 
marginally affects melanocyte number with no 
detriment to pigmentation 
Although homozygous deletion of Chk1 in mice has been shown to be embryonic 
lethal (Liu et al, 2000), constitutively Chk1 hemizygous mice are viable. 
However tissue specific loss of one copy of Chk1 can result in cell cycle defects 
such as an increased number of S-phase cells, spontaneous DNA damage 
generation and premature mitotic entry (Lam et al, 2004). Recently a human 
Chk1 heterozygous cell line was generated using HCT116 cells. In this system 
Chk1 loss resulted in decreased proliferative potential accompanied by 
spontaneous cell death resulting in reduced cell survival (Wang et al, 2012). 
Therefore I analysed the effect of Chk1 heterozygosity on coat pigmentation in 
adult mice and melanocyte number in Chk1 fl/+ embryos whereby only one 
allele of Chk1 will be recombined upon Cre-recombinase treatment. 
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Comparison of Chk1+/+: Tyr-Cre and Chk1 fl/+: Tyr-Cre adult mice showed that 
loss of one copy of Chk1 had no visible effect on coat pigmentation (Figure 3.7Ai 
and ii respectively), with no subtle alterations such as loss of pigmentation at 
extremities. Wholemount distribution in E13.5 Chk1+/+: Tyr-Cre: DCT-LacZ and 
Chk1fl/+: Tyr-Cre: DCT-LacZ embryos (Figure 3.7Bi and ii respectively) showed 
that there was no obvious reduction in the overall melanocyte number or 
alterations in the pattern at this stage, whereas homozygous Chk1 deletion 
showed complete loss of melanocytes by E13.5. However careful quantification 
of the number of melanocytes in the head, dorsolateral trunk and abdominal 
regions (as highlighted in Figure 3.7B and counted as one blue dot= one 
melanocyte) revealed that there was a modest reduction in the number of 
melanocytes in all the areas analysed; 15%, 30% and 35% reduction in the 
dorsolateral trunk, head and abdominal regions respectively (Table 3.2). This 
difference is statistically significant in all regions; head p=0.0189, dorsolateral 
trunk p=0.006691 and abdomen p=0.000676. It is interesting to note that the 
statistical difference increases with distance of melanocytes from the original 
location in the brain and neural tube regions. 
 
Figure 3.7: Chk1 hemizygousity in the melanocyte lineage. (A-B) Images of adult black coated 
mice and wholemount β-galactosidase stained E13.5 embryos of the genotypes Chk1 +/+: Tyr-Cre: 
DCT-LacZ (Ai and Bi) and Chk1 fl/+: Tyr-Cre: DCT-LacZ (Aii and Bii).  
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 Chk1 fl/+ Chk1 +/+ p-value 
Head 276.5 ± 
57.8 (13) 
380 ± 29.2 
(11) 
0.01839
**
 
Abdomen 264.5 ± 
39.6 (13)  
403.25 ± 
17.2 (11) 
0.000676
***
 
Trunk 578.25 ± 
49.5 (13) 
693.25 ± 
27.7 (11) 
0.006691
***
 
Table 3.2: Quantification of melanocytes in wholemount E13.5 embryos. Shown are the 
average number of melanocytes quantified, standard deviation and number of samples in brackets. 
P-values are included with ** indicating significant and *** indicating highly significant values. The 
regions quantified are represented in Figure 6. 
  
3.5 Developmental deletion of Chk1 causes DNA damage 
in melanocyte precursor cells during embryogenesis 
The previously used model for specific deletion of Chk1 in melanocytes during 
embryogenesis showed that Chk1 loss initiated at E10.5 caused rapid loss of all 
melanocyte cells within the embryo, with complete loss established by E13.5 
(Figure 3.5) resulting in white non-pigmented adult mice (Figure 3.2Aii). In order 
to elucidate what is happening in the melanocytes upon Chk1 loss I analysed 
paraffin embedded sections of X-gal stained Chk1fl/fl: Tyr-Cre: DCT-LacZ and 
Chk1+/+: Tyr-Cre: DCT-LacZ E11.5 embryos. E11.5 embryos were used to 
establish any early phenotypes associated with Chk1 loss which could account for 
the loss of melanocytes from the embryo. At this embryonic stage melanocyte 
cells should be null for Chk1 but with no reduction seen in the melanocyte cell 
number, however within 24hrs a significant number of melanocytes (50-70%) are 
lost.  
Immunohistochemistry (IHC) analysis showed that in the Chk1fl/fl: Tyr-Cre: DCT-
LacZ embryo where Chk1 is deleted, melanocytes which are stained blue owing 
to the expression of LacZ are strongly positive for γH2AX, a marker of DNA 
damage (Figure 3.8A, red stars). However in the Chk1+/+: Tyr-Cre: DCT-LacZ 
embryo there was no positivity for γH2AX in melanocytes (Figure 3.8B), however 
there was γH2AX positive staining in other cell populations. This data suggests 
that upon deletion of Chk1 in melanocytes DNA damage is spontaneously 
generated, which suggests a possible mechanism for induction of cell death. 
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Previous studies have shown similar phenotypes in mammary cells, whereby 
specific deletion of Chk1 in proliferating mammary cells caused cell lethality by 
apoptosis as assessed by positivity for terminal transferase-based TUNEL 
assay(Lam et al, 2004). Heterozygous deletion of Chk1 in this model showed an 
increase in spontaneous DNA damage. In most cell types Chk1 loss appears to be 
lethal however in DT40 avian cells Chk1 loss does not affect viability however 
these cells show a reduction in their growth rate which is in part attributed to 
an increase in the levels of spontaneous apoptosis (Zachos et al, 2003). The role 
of DNA damage in the induction of apoptosis is well established (Norbury & 
Zhivotovsky, 2004) and is a key factor in maintaining genome integrity. 
 
 
Figure 3.8: DNA damage in Chk1 deleted embryos. (A-B) Immunohistochemistry (IHC) analysis 
of paraffin-embedded E11.5 embryos with the genotypes Chk1 fl/fl: Tyr-Cre: DCT-LacZ (A) and 
Chk1 +/+: Tyr-Cre: DCT-LacZ (B). Sections were stained for β-galactosidase (blue) to visualise 
melanocytes and then labelled with γH2AX (brown). In Chk1 deleted embryos melanocytes are 
positive for γH2AX (A, red arrows). 
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3.6 Developmental deletion of Chk1 in female mice 
shows variation in coat pigmentation 
The Tyr-Cre transgene in the model mouse used for the analysis of Chk1 deletion 
is located on the X-chromosome (Delmas et al, 2003). The sex chromosomes X 
and Y determine the sex in mammals with XY denoting a male and XX denoting a 
female. Therefore while all male progeny, which were used for the above 
analysis, are either positive, denoted as XTyr-CreY or negative, donated as XwtY for 
expression of Tyr-Cre; female progeny have the potential to be either 
homozygous positive, denoted as XTyr-CreXTyr-Cre  or hemizygous positive, denoted 
as XTyr-CreXwt for expression of Tyr-Cre. In order to compensate for gene dosage 
females undergo inactivation of one of their X-chromosomes in each cell of the 
body during early embryogenesis at about the 50-cell stage when the inner cell 
mass (which will form the embryo) differentiates from the primitive trophoblast 
(which will form the placenta) (Okamoto et al, 2004). This X-inactivation is 
random and can affect both the maternal and paternal derived X-chromosome; 
therefore female progeny of the hemizygous state have the potential to lose 
expression of Tyr-Cre in at least a sub-population of cells.  
 
In female progeny, which were previously genotyped by Transnetyx to be 
Chk1fl/fl: Tyr-Cre without any discrimination between homozygosity and 
hemizygosity for Tyr-Cre expression three distinct coat pigmentation phenotypes 
were observed. Some females were uniformly white in coat colour (Figure 3.9Ai) 
although they retained pigmentation in the eye. This phenotype was observed in 
all male progeny of the genotype Chk1fl/fl: Tyr-Cre. However there were also 
females which had a fully pigmented black coat (Figure 3.9Aii) with no 
observable difference from females with the genotype Chk1+/+: Tyr-Cre. In 
addition there were females which had a patchy/mosaic coat phenotype 
whereby the coat was mostly white in colour but with small areas of grey 
colouring (Figure 3.9Aiii). These patches of pigmentation were always localised 
around the head and hind areas (Figure 3.9Bi and ii respectively) of the animals. 
It is of potential interest to note that these areas are where the majority of 
melanocytes originate from in early embryos as can be seen in E9.5 embryos 
were strong blue staining (representing melanocytes) can be seen in the brain 
and neural tail tube (Figure 3.4B). 
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In order to determine if this phenotype could be due to selective inactivation of 
the X-chromosome carrying the Tyr-Cre transgene a PCR reaction was carried 
out which had been shown to be able to distinguish between homozygosity and 
heterozygosity of the XTyr-Cre gene in this model (Colombo et al, 2007). The Tyr-
Cre gene is inserted at a specific location within the X-chromosome which has 
been mapped. The PCR is able to precisely distinguish the genotype by using 
primer pairs which exist either within the transgene or in the X-chromosome 
either side of the insertion site (Figure 3.10A). In a wild-type X-chromosome 
(Xwt) an 1172bp product is generated using the specific primers LL1433 and 
LL1441, whereas in a transgenic X-chromosome (XTyr-Cre) a 364bp product is 
generated using specific primers LL1403 and LL1326. Presence of both bands 
represents a heterozygous (XTyr-CreXwt) female and presence of only the smaller 
band represents a homozygous (XTyr-CreXTyr-Cre) female. PCR analysis showed that 
all black coated females were heterozygous for the Tyr-Cre transgene, whereas 
all white and patchy coated females were homozygous for the Tyr-Cre transgene 
(Figure 3.10B). 
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Figure 3.9: Variations in coat pigmentation in Tyr-Cre positive females. (A) Images of female 
mice with the genotype Chk1 fl/fl: Tyr-Cre as assessed by transnetyx showing various coat 
phenotypes including white (i), black (ii) and patchy (iii). (B) Images of the patches of pigmentation 
seen in female mice with the above genotype as seen on the face (i) and hind (ii) regions of the 
animal. 
 
This data show that in heterozygous females up to 50% of the melanocytes 
express Tyr-Cre and therefore undergo recombination of the Chk1 gene during 
embryogenesis have a fully pigmented coat. This suggests that a potential loss of 
50% of the number of melanocytes, due to Chk1 loss, during embryogenesis has 
little or no impact on the coat pigmentation phenotype compared to controls. 
This is consistent with previous data showing that Chk1 fl/+: Tyr-Cre: DCT-LacZ 
male embryos, where up to 35% of melanocytes are lost in some regions of the 
embryo (Table 3.2), were still fully pigmented with a black coat as adults (Figure 
3.7Aii). This suggests that an excess of melanocytes are present during 
embryogenesis and only a percentage of these are needed for a normal coat 
colour phenotype or that there is compensation through increased proliferation. 
However there is also the possibility that the X-chromosome carrying the Tyr-Cre 
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transgene is selectively inactivated during X-inactivation essentially making the 
females wild-type. In context of the white and patchy coated females this data 
shows that in homozygous females 100% of the melanocytes should express the 
Tyr-Cre transgene during embryogenesis, no matter which X-chromosome is 
inactivated and therefore recombination and loss of the Chk1 gene should occur 
in all melanocytes.  In some females this results in complete loss of coat 
pigmentation (as seen in the males) however in some females this can result in 
retention of at least a small number of viable melanocytes giving rise to patches 
of pigmentation. This phenotype could arise due to loss of recombination 
efficiency in a small sub-set of cells, potentially by either inactivation of the 
expressed Cre-recombinase protein or loss of Cre-recombinase expression due to 
silencing of the Tyr promoter. However this phenomenon was only seen in the 
female mice with a frequency of 50% in Chk1 fl/fl: Tyr-Cre homozygous females 
and did not occur in the male mice. As any potential mechanism should also 
occur in the male mice this suggests that there must be a female-dependant 
mechanism in place for loss of Tyr-Cre expression in a sub-set of melanocyte 
cells. 
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Figure 3.10: Genotyping of Tyr-Cre positive females by PCR. (A) Scheme of PCR amplification 
corresponding to a hemizygous female (X
wt
/X
Tyr-Cre
). The line corresponds to genomic DNA with the 
blue box representing the inserted Tyr-Cre transgene in the X-chromosome. PCR products of sizes 
1172bp and 364bp screen for the presence of the X
wt
 and X
Tyr-Cre 
respectively. (B) PCR analysis of 
DNA from female mice with the genotype Chk1 fl/fl: Tyr-Cre as assessed by transnetyx. Analysed 
according to coat pigmentation phenotype (patchy, white or black) as seen in figure 3.9.  
 
3.7 Discussion 
The main aim if this chapter was to establish the requirement of Chk1 for the 
continued proliferation and survival of melanocyte precursor cells during 
embryogenesis. This could be of significance as many of the genes involved in 
melanocyte development have also been implicated in the development of 
melanoma, an aggressive and fatal form of skin cancer that originates from 
melanocytes. Chk1 has been shown to be important in the survival of many cell 
types including mammary tissue (Lam et al, 2004), T-cells (Zaugg et al, 2007) 
and the small intestine (Greenow et al, 2009), with constitutive Chk1 loss being 
embryonic lethal at the early blastocyst stage (E3) in mice (Liu et al, 2000). This 
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indicates that Chk1 is essential for cell survival even in the absence of 
exogenous DNA damage. Chk1 has also been shown to be important in tumour 
development. Chk1 deficiency inhibited the formation of mammary tumours in a 
p53 null background in mice; however hemizygousity for Chk1 in combination 
with p53 induced mammary tumour formation (Fishler et al, 2010). Chk1 loss 
inhibited the formation of chemical-induced skin tumours with Chk1 
hemizygousity having no effect on benign tumour formation but increasing the 
propensity for the conversion to carcinoma (Tho et al, 2012).  
 
Using a conditional Chk1 knockout mouse model (Liu et al, 2000) in combination 
with a melanocyte specific constitutively expressed Cre-recombinase (Delmas et 
al, 2003) I was able to show that Chk1 expression is essential for the continued 
survival of melanocytes during embryogenesis with loss of Chk1 resulting in adult 
mice which lack any pigmentation despite being on a C57Bl/6 strain background 
(Figure 3.2). Loss of Chk1, which happens at around E11.5 with Cre-recombinase 
expression turned on at 10.5, results in rapid loss of melanocyte cells from the 
embryo with complete absence of melanocytes seen by E13.5 (Figure 3.5). 
Mathematical modelling of melanocyte development has shown that the total 
number of melanocyte cell in an E11.5 embryo is 393.77±142.37 and in an E13.5 
embryo is 2873.86±419.51 (Aylaj et al, 2011). This constitutes a >700% increase 
in cell number over 48hrs, which represents extremely rapid proliferation of 
cells. Chk1 deletion was shown to cause spontaneous DNA damage (Figure 3.8), 
which suggests a possible mechanism for inducing cell death. Collectively this 
data shows that Chk1 loss is severely detrimental to melanocyte cells. The 
severity is possibly due to the rapid proliferation rate of these cells, as Chk1 is 
important during unperturbed cell cycle where it functions during S-phase in 
both the initiation of replication and stability of replication forks (Feijoo et al, 
2001; Paulsen & Cimprich, 2007; Petermann et al, 2006; Petermann et al, 2010). 
The data is also consistent with other data that has shown Chk1 loss causes cell 
death by apoptosis (Liu et al, 2000; Lam et al, 2004). 
  
However Chk1 hemizygosity in the melanocyte lineage was well tolerated with 
only a small but significant decrease in cell number observed and no obvious 
defect in the pigmentation phenotype of the adult mice (Figure 3.7). This is 
consistent with studies that have shown constitutive Chk1 hemizygous mice are 
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developmentally normal, fertile and lack an overt phenotype (Liu et al, 2000). 
Despite this, partial loss of Chk1 function has been shown to affect cell survival 
and tissue homeostasis in vivo. Chk1 hemizygosity induced specifically in the 
mammary tissue resulted in an increased proportion of S-phase cells, 
spontaneous DNA damage and premature entry to mitosis (Lam et al, 2004). 
Chk1 hemizygosity induced in the T-cell lineage led to developmental 
perturbation and cell loss (Zaugg et al, 2007). However Chk1 hemizygosity did 
not result in an obvious phenotype in the small intestine (Greenow et al, 2009). 
These data combined show that the consequences of partial loss of Chk1 
functions for cell proliferation and survival seem to vary according to cell and 
tissue type. 
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4 Chk1 requirement in melanoma initiation and 
progression in vivo 
4.1 Introduction 
Melanoma is the most aggressive type of skin cancer which predominantly 
affects Caucasians of north-western European descent. It is the 19th most 
common cancer worldwide with the most affected area being Australia, where it 
represents the 3rd most common type of cancer in both sexes (Ferlay et al, 
2010). In the UK and USA melanoma is the 5th and 6th most common cancer 
respectively (Cancer Research UK; American Cancer Society). Unlike other types 
of cancer incidence rates for melanoma have increased over the past 30 years. 
In both the UK and USA incidence rates have increased more rapidly than any of 
the other ten most common cancers (Cancer Research UK; Howlader et al, 2012; 
Jemal et al, 2010). Although melanoma only accounts for 5-10% of skin cancer 
cases it is the cause of >80% of deaths from skin cancer with the 5 year survival 
of metastatic melanoma being only 15% (Siegel et al, 2012).  
The cells of origin for melanoma are the pigment-producing melanocytes. The 
genetic alterations associated with the malignant transformation of melanocytes 
are well established (Chin et al, 2003). The MAPK signalling cascade is frequently 
mutated, with activating B-Raf mutations seen in as many as 60% of human 
melanoma samples and cell lines (Davies et al, 2002). Activating point mutations 
in N-Ras have been seen in as many as 56% of congenital nevi, 33% of primary 
melanomas and 26% of metastatic samples (Demunter et al, 2001). Mutations in 
B-Raf and N-Ras are mutually exclusive owing to the fact that N-Ras is directly 
upstream of B-Raf and therefore mutations in the two proteins act on the same 
pathway. The most common mutations seen in familial melanoma are loss of the 
tumour suppressor locus CDKN2A (also known as the INK4A locus) (Hussussian et 
al, 1994) which encodes for two proteins; p16Ink4a and p14Arf (human) or p19Arf 
(mouse), and mutation of CDK4 (Zuo et al, 1996). This implicates the importance 
of both the p16Ink4a- CDK4- RB and ARF-p53 pathways in the development of 
melanoma. In fact p16Ink4a loss is also seen in 15-28% of primary sporadic 
melanoma samples and in almost all established melanoma cell lines (Fujimoto 
et al, 1999; Walker et al, 1998). PTEN loss is also common in melanoma, 
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occurring in 5-15% of uncultured melanoma specimens and metastasis as well as 
in 30-40% of established melanoma cell lines (Guldberg et al, 1997; Teng et al, 
1997).  
4.2 Mouse model of melanoma: N-Ras and CDKN2A 
The melanoma model developed by Friedrich Beermann’s group (Ackermann et 
al, 2005) expresses an oncogenic form of human N-Ras with a point mutation in 
codon 61 (Q61K) from the melanocyte specific Tyrosinase promoter. This allows 
specific expression of the oncogene in the melanocyte lineage only. These mice 
were crossed onto a CDKN2A deficient background which has loss of both p16Ink4a 
and p19Arf (Serrano et al, 1996) (Figure 4.1A). In hereditary melanoma with 
germ line p16Ink4a mutations, 95% of patients have oncogenic N-RasQ61K 
(Eskandarpour et al, 2003) therefore this model closely mimics the genetics of 
the human condition. These mice exhibit hyper-pigmented skin, as most evident 
in the ears and paws and develop melanoma in the dermis and/or epidermis with 
a high incidence (>90%) and short latency (6 months), with frequent metastasis 
to the lymph nodes, liver and lungs (Ackermann et al, 2005). However upon 
experimental handling these mice also developed lymphoma with extremely high 
penetrance and were therefore not viable as a melanoma model in our hands; 
this is perhaps not surprising as the CDKN2A deficient mice alone have been 
shown to develop sarcomas and lymphomas with a high penetrance (69%) and 
short latency (29 weeks) (Serrano et al, 1996). Upon DMBA/UVB induced 
carcinogenesis tumourigenesis is increased to 90% penetrance with an average 
latency of 9 weeks in these mice (Serrano et al, 1996). Lymphoma development 
is thought to be a result of loss of p19Arf as genetic disruption of Arf alone has 
been shown to predispose mice to tumourigenesis (Kamijo et al, 1997) whereas 
disruption of p16Ink4a alone did not show a significant predisposition to 
spontaneous tumour formation (Krimpenfort et al, 2001).  
In order to circumvent the development of lymphoma the Beermann melanoma 
mice were crossed with mice developed by Anton Berns’s group that are 
deficient for p16Ink4a but retain one copy of Arf (Figure 4.1A). These mice have 
been shown to develop a wide spectrum of tumours including melanoma with an 
average latency of 12 months (Krimpenfort et al, 2001; Sharpless et al, 2001). In 
combination these mice are hyper pigmented (Figure 4.1Bi-ii, black arrow), 
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develop melanoma (Figure 4.1Biii-iv, white arrows) with an average tumour 
onset of 8 months and have metastasis to the lymph nodes and lung (Figure 
4.1Bv-vi, red arrow). 
 
 
Figure 4.1: Mouse model of melanoma: N-Ras and CDKN2A. A) Beerman melanoma with 
expression of oncogenic N-Ras from the melanocyte specific Tyrosinase promoter in combination 
with loss of the CDKN2A locus crossed with the p16
Ink4a
 model with a point mutation in Exon 2 
which affects the splicing of p16
Ink4a
 but not p19Arf. (B) Pictures and H&E sections of model mice 
with hyper-pigmented skin (i-ii), melanomas (i and iii white arrow, iv) and metastasis to the lung (v 
red arrow) and lymph nodes (vi).   
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4.3 Loss of Chk1 on tumour formation in nude mice 
In order to analyse the role of Chk1 in melanoma development the 
aforementioned melanoma mice bearing the p16Ink4a-deficient allele were 
crossed with a conditional knockout mouse model of Chk1 (as previously 
described in Chapter 3:2) in combination with a melanocyte specific inducible 
Cre-recombinase in which a Cre-recombinase: estrogen receptor fusion 
transgene is under the control of the tyrosinase promoter (Tyr-CreERT2) (Figure 
4.2). This allows for spatially and temporally controlled activation of Cre-
recombinase upon addition of 4-hydroxytamoxifen (4-OHT) (Yajima et al, 2006), 
and thus selective partial or complete deletion of Chk1 in melanocytes. 
 
Figure 4.2: Inducible deletion of Chk1 in the melanocyte lineage. Conditional Chk1 flox mice, 
whereby Exon 2 (containing the translation initiation site) of the Chk1 gene is flanked by LoxP sites, 
were crossed with mice expressing Cre-recombinase: estrogen receptor fusion transgene under 
the control of the Tyrosinase (Tyr) promoter allowing spatially and temporally controlled activation 
of Cre, and thus deletion of Chk1 in the melanocyte lineage.  
 
4.3.1 Melanocyte cell line generation and characterisation 
In order to further analyse the effects of Chk1 deletion on tumourigenesis 
melanocyte cell lines were generated from the aforementioned mouse model, 
which were subsequently used in allograft experiments in CD1 nudes. Melanocyte 
cell lines were established from the back skin of adult mice (>6 weeks old) and 
selected for in vitro growth (Figure 4.3, see Materials and methods 2.2.5 for full 
protocol). Establishment of viable cell lines takes about 8 weeks. Cell lines with 
the genotypes Chk1 fl/fl, Chk1 fl/+ and Chk1 +/+ were established.  
The Chk1 flox allele has the addition of two LoxP sites either side of exon 2 in 
the intervening introns that constitute a 78bp insert at each site. By using a 
primer pair that spans the first LoxP site (Forward 581: Reverse 1004) we can 
distinguish between the Chk1 flox allele, 501bp, and the Chk1 wild type allele, 
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423bp (Figure 4.4A). Screening by PCR showed that in both the Chk1 fl/fl and 
Chk1 fl/+ cell lines addition of 4-OHT [1µM] for five consecutive days resulted in 
very efficient loss of the Chk1 flox alleles (Figure 4.4B). This is further confirmed 
by WB analysis whereby in Chk1 fl/fl cells addition of 4-OHT [1µM] leads to rapid 
and complete loss of Chk1 protein within 5 days (Figure 4.5A). Chk1 loss is 
accompanied by cleavage of PARP, a marker of apoptosis. PARP is a nuclear 
protein that participates in DNA damage detection and repair, however during 
apoptosis the protein is cleaved by caspase-3 and caspase-7 (Duriez et al, 1997; 
Germain et al, 1999). This cleavage efficiently stops the ability of PARP to 
participate in DNA repair and contributes to the cell fate of apoptosis. 
Interestingly in Chk1 fl/+ cells addition of 4-OHT [1µM] also leads to significant 
loss of Chk1 protein within 5days of treatment, greater than a 50% reduction as 
expected (Figure 4.5B). Chk1 loss is also accompanied by cleavage of PARP as in 
the Chk1 fl/fl cell line. This effect is specific as addition of ethanol, the vehicle 
for 4-OHT, in both Chk1 fl/fl and Chk1 fl/+ cells had no effect on Chk1 protein 
levels or cleavage of PARP. Furthermore addition of 4-OHT in Chk1 +/+ cells also 
had no effect on Chk1 protein levels or cleavage of PARP (Figure 4.5C). 
 
 
Figure 4.3: Establishment of melanocyte cell lines. Melanocyte cell lines were generated from 
the excised back skin of transgenic melanoma mice expressing the conditional Chk1 flox allele and 
Tyr-CreER
T2
.  
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Figure 4.4: Screening of the Chk1 flox allele by PCR. (A) Scheme of PCR amplification. The line 
corresponds to genomic DNA with the blue boxes representing exons of the Chk1 gene. The Chk1 
flox allele contains a 78bp LoxP site inserted in the intron between exon 1 and 2. Primer pair 
Forward 581: Reverse 1004 generates PCR products of sizes 501bp and 423bp which screen for 
the presence of the Chk1 flox and Chk1 wt allele respectively. (B) PCR analysis of DNA from 
melanocyte cells of the genotypes Chk1 fl/fl, Chk1 fl/+ and Chk1 +/+ treated with [1µM] 4OHT or 
ethanol for 5 consecutive days.  
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Figure 4.5: Inducible Chk1 deletion in vitro. Western blot analysis of the levels of Chk1 and 
cleavage of PARP from melanocyte cells of the genotypes Chk1 fl/fl, Chk1 fl/+ and Chk1 +/+ 
treated with [1µM] 4OHT or ethanol for 5 consecutive days.  Antibodies against Chk1 and PARP 
were used. An equal quantity of protein was loaded as determined by Bradford Assay and 
confirmed by antibody against actin.  
 
4.3.2 Homozygous deletion of Chk1 leads to decreased tumour 
growth 
In order to assess the effect of complete Chk1 loss on melanoma tumour 
formation in vivo Chk1 fl/fl melanocyte cells were grown in culture until they 
were in a logarithmic phase of growth (70-80% confluent). Cells were then 
harvested and injected subcutaneously to the lower right flank of 6 week old 
female CD1 nudes at a concentration of 1 x 105 cells per mouse.  One week after 
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injection 20 mice were randomised into the following treatment groups: vehicle 
alone (10 mice) or daily dosing of tamoxifen at 2mg/ml for 8 consecutive days 
(10 mice) followed by 3x weekly dosing until endpoint reached (Figure 4.6).  
 
 
Figure 4.6: Treatment protocol for analysis of Chk1 loss in CD1 nude mice. Melanocyte cell 
lines of the genotypes Chk1 fl/fl and Chk1 fl/+ were injected into the lower right flank or tail vein of 
CD1 nude mice at 1x10
5
 cells per mice.  Seven days later mice were randomised into the treatment 
group’s vehicle alone or daily dosing of tamoxifen at 2mg/ml for 8 consecutive days followed by 3x 
weekly dosing until endpoint reached.   
 
PCR analysis of final tumour samples using primer pair, Forward 581: Reverse 
1004, showed that in all tamoxifen treated animals the Chk1 flox alleles were 
lost or significantly reduced. This results in final tumours which have either lost 
or have a significant reduction in their Chk1 expression, in contrast to all vehicle 
treated tumours which retained expression of the Chk1 flox alleles (Figure 4.7A). 
It should be noted that in some of the samples there is a band corresponding to 
the Chk1 wt allele, this is most likely due to contamination from stromal tissue 
which is derived from the nude mice. This was further confirmed by real time 
PCR analysis using primer pair, Forward 821: Reverse 1004, whereby the average 
recombination efficiency of the Chk1 gene in tamoxifen treated animals were 
69%, as compared to a control gene (Arbp), with the maximum being 80%. 
Whereas in vehicle treated animals the average recombination efficiency was 
negative compared to the control gene essentially meaning there was no 
recombination (Figure 4.7B).  This data shows that the Cre-LoxP recombination 
system is working fairly efficiently in the Chk1 fl/fl cell line allografts in vivo. 
Complete efficiency would be represented by a 100% recombination rate; 
therefore the system is either not completely functional or there has been some 
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repopulation of the tumours by Chk1 proficient cells which have escaped 
recombination. 
 
 
Figure 4.7: Screening for Chk1 deletion by PCR in final Chk1 fl/fl tumours of CD1 nudes. (A) 
PCR analysis of DNA from final tumour samples of CD1 nudes injected with melanocyte cells of the 
genotypes Chk1 fl/fl treated with tamoxifen or vehicle as outlined in figure 4.6. Chk1 flox allele is 
lost or reduced in final tumours of all tamoxifen treated animals. (B) Real-time PCR analysis of 
DNA from final tumour samples of CD1 nudes injected with melanocyte cells of the genotypes 
Chk1 fl/fl treated with tamoxifen or vehicle as outlined in figure 4.6. 
 
Analysis of the rate of tumour growth, as assessed by the increase in tumour 
volume over time as compared to the initial tumour volume (taken at 7 days post 
injection), showed that there is a very significant decrease in the tumour growth 
rate in the tamoxifen treated cohort compared to vehicle treated (Figure 4.8A). 
The reduction first becomes evident 31 days after the start of treatment. At 
time-points, 36, 38, 41 and 43 days after treatment there is a statistical 
significant reduction in the growth rate; p=0.039662, 0.015396, 0.032583 and 
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0.024268 respectively. 45 days after treatment this reduction in the growth rate 
becomes even more highly statistically significant; p=0.007695. Beyond this time 
point the tumour growth rate in tamoxifen treated animals does not increase 
much further, whereas in vehicle treated the growth rate increases 
exponentially.  This reduction in tumour growth rate is paralleled by an increase 
in the survival time of the tamoxifen treated animals.  Analysis by Kaplan Mier of 
the survival time in the tamoxifen and vehicle cohorts (Figure 4.8B) showed that 
there was a statistically significant increase in the survival potential of 
tamoxifen treated animals over vehicle (p=0.00174). The longest surviving 
vehicle treated animal was 52 days whereas the tamoxifen treated animal was 
88 days. 
This data demonstrates that Chk1 loss has a very significant effect on melanoma 
tumour formation in allograft models of melanoma development with a 
concurrent impact on survival. Chk1 has been shown to be important in tumour 
development in other models of cancer. Chk1 deficiency inhibits the formation 
of mammary tumours in a p53 null background in mice (Fishler et al, 2010) and 
inhibits the formation of chemical-induced skin tumours (Tho et al, 2012). 
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Figure 4.8: Effect of homozygous deletion of Chk1 on tumour formation and survival. (A) 
Analysis of the rate of tumour growth, as assessed by the increase in tumour volume over time as 
compared to the initial tumour volume in vehicle and tamoxifen treated cohorts. Statistically 
significant difference (*) as assessed by Student T-test at days 36, 38, 41, 43 and 45; p=0.039662, 
0.015396, 0.032583, 0.024268 and 0.00769536 respectively.  (B) Analysis of the survival time in 
vehicle and tamoxifen treated cohorts. Statistically significant difference as assessed by Kaplan 
Mier (Log rank test), p=0.0174; n=7 vehicle n=13 tamoxifen. 
   
4.3.3 Effect of heterozygous deletion of Chk1 on tumour 
formation and metastatic potential 
In order to assess the effect of loss of one copy of Chk1 on melanoma tumour 
formation in vivo Chk1 fl/+ transformed melanocyte cells were assessed as 
described above (2.3.2) for homozygous deletion of Chk1. PCR analysis of final 
tumour samples using primer pair, Forward 581: Reverse 1004, showed that in all 
ten tamoxifen treated animals the Chk1 flox allele was lost thereby resulting in 
final tumours being genetically hemizygous (Chk1 +/-) for Chk1 expression, in 
contrast to all ten vehicle treated tumours which retained expression of the 
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Chk1 flox allele (Figure 4.9A). This was further confirmed by real time PCR 
analysis using primer pair, Forward 821: Reverse 1004, whereby the average 
recombination efficiency of the Chk1 gene in tamoxifen treated animals was 43% 
as compared to a control gene (Arbp) whereas in vehicle treated animals the 
average recombination efficiency was negative compared to the control gene 
essentially meaning there was no recombination (Figure 4.9B).  This data shows 
that the Cre-LoxP recombination system is working efficiently in the Chk1 fl/+ 
cell line allografts in vivo. 
 
Figure 4.9: Screening for Chk1 deletion by PCR in final Chk1 fl/+ tumours of CD1 nudes. (A) 
PCR analysis of DNA from final tumour samples of CD1 nudes injected with melanocyte cells of the 
genotypes Chk1 fl/+ treated with tamoxifen or vehicle as outlined in figure 4.6. Chk1 flox allele is 
lost in final tumours of all tamoxifen treated animals. (B) Real-time PCR analysis of DNA from final 
tumour samples of CD1 nudes injected with melanocyte cells of the genotypes Chk1 fl/+ treated 
with tamoxifen or vehicle as outlined in Figure 4.6 
. 
Analysis of the rate of tumour growth, as assessed by the increase in tumour 
volume over time as compared to the initial tumour volume (taken at 7 days post 
injection), showed that there is an initial decrease in the tumour growth rate in 
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the tamoxifen treated cohort compared to vehicle treated however this 
reduction is not maintained indefinitely (Figure 4.10A). The reduction first 
becomes evident 14 days after the start of treatment. At time-points, 14 and 16 
days after treatment there is a statistical significant reduction in the growth 
rate; p=0.017889 and 0.01645 respectively. At later time-points 18, 21, 23 and 
25 days after treatment this reduction in the growth rate becomes highly 
statistically significant; p=0.002596, 0.007564, 0.001698 and 0.003952 
respectively. However at later time-points, 27, 30 and 32 days after treatment 
there is no longer a statistical significant difference in growth rate, p=0.203279, 
0.094093 and 0.48061 respectively with the curves converging. 
This data shows that loss of one copy of Chk1 initially decreases the rate of 
tumour growth/proliferation in vivo, however ultimately this reduction in growth 
rate is reversed and does not prevent the tumours from reaching endpoint. This 
may represent an ability of the tumour cells to adapt to the loss of one copy of 
Chk1.  Despite a high ulceration rate (5 out of 10 in vehicle cohort and 4 out of 
10 in tamoxifen cohort) the remaining animals in each group were all able to 
reach the designated tumour size endpoint of 15mm. This is further emphasised 
by Kaplan Mier analysis of survival in the tamoxifen and vehicle cohorts (Figure 
4.10Bi). Analysis of endpoint only animals showed that there was no statistically 
significant difference in the survival of tamoxifen treated animals over vehicle 
(p=0.6920) at any time-point, despite the initial reduction in the tumour growth 
rate. However this may be not be an accurate representation of the data as the 
average initial tumour volume at the commencement of treatment was 3 times 
larger in the tamoxifen treated cohort (31.01mm2) than that of the vehicle 
treated cohort (10.69mm2), due to inaccurate randomization of the animals prior 
to treatment . Analysis of the survival of animals whose initial tumour volume 
was between the ranges of 5mm2 to 20mm2 (Figure 4.10Bii) shows that there is 
an initial increase in the percentage of survival of tamoxifen treated animals 
between days 23-30 but that overall there is no statistically significant 
difference in the survival potential of tamoxifen treated animals over vehicle 
(p=0.4643) with the curves converging at 32 days post treatment. This data is 
consistent with the tumour growth analysis. Collectively these data show that 
the loss of one copy of Chk1 initially causes a decrease in the proliferation 
potential of melanocyte tumour cells; however this is a relatively transient 
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effect with the cells potentially able to adapt to the loss so that there is no 
longer an effect on tumour growth and ultimately no survival benefit. This 
adaptation is not a consequence of re-population of the tumour by cells which 
may have escaped Chk1 recombination as final tumour samples showed 
consistent loss of the Chk1 flox allele by PCR screening (Figure 4.9A). 
 
 
Figure 4.10: Effect of heterozygous deletion of Chk1 on tumour formation and survival. (A) 
Analysis of the rate of tumour growth, as assessed by the increase in tumour volume over time as 
compared to the initial tumour volume in vehicle and tamoxifen treated cohorts. Statistically 
significant difference (*) as assessed by Student T-test at days 14, 16, 18, 21, 23 and 25; 
p=0.017889, 0.01645, 0.002596, 0.007564, 0.001698 and 0.003952 respectively.  (B) Analysis of 
the survival time in vehicle and tamoxifen treated cohorts of all animals which reached endpoint (i, 
n=5 vehicle n=6 tamoxifen) and animals whose initial tumour volume was between the ranges of 
5mm
2
 to 20mm
2 
(ii, n=4 both) neither are significantly different.  
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The previous data shows that Chk1 heterozygosity has a transient effect on 
tumour growth in vivo. None of the subcutaneously grown tumours in either the 
vehicle or tamoxifen treated cohorts showed any metastasis. This result is 
probably a consequence of the fast nature of the CD1 nude mouse model and not 
necessarily an indication that Chk1 heterozygosity affects metastatic potential 
itself. In order to further assess the effect of loss of one copy of Chk1 on 
metastatic potential of melanoma cells in vivo Chk1 fl/+ transformed 
melanocyte cells were grown in culture until they were in a logarithmic phase of 
growth (70-80% confluent). Cells were then harvested and injected into the tail 
vein of 6 week old female CD1 nudes at a concentration of 1 x 105 cells per 
mouse. Mice were randomised and treated as previously described in 2.3.2. 
Analysis of the survival potential by Kaplan Mier (Figure 4.11A) showed that 
tamoxifen treated animals had a statistically significant increase in their survival 
time as compared to vehicle treated, p=0.0167. The longest surviving animal 
from the vehicle cohort was 24 days post treatment whereas in the tamoxifen 
cohort the longest surviving was 35 days post treatment. Endpoint was assessed 
by difficulty breathing, hunched appearance and/or >20% weight loss. 
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Figure 4.11: Effect of heterozygous deletion of Chk1 on metastasis formation and survival. 
(A) Analysis of the survival time in vehicle and tamoxifen treated cohorts of all animals which 
reached endpoint (i, n=5 vehicle n=8 tamoxifen), p=0.0167. (B) Pictures and H&E sections of 
metastases to the liver and lungs of vehicle (i) and tamoxifen (ii) treated animals. (C-D) Pictures 
and H&E sections of metastases to the lymph nodes and pancreas.  
 
At endpoint all mice in both cohorts had numerous metastases to both the lungs 
and liver (Figure 4.11Bi-ii). Metastasis was also seen in the pancreas of one 
tamoxifen treated mouse and in the lymph nodes of one vehicle treated mouse 
(Figure 4.11D and C respectively). Analysis of the final metastases size, burden 
and frequency in the liver of endpoint mice showed that there was no 
statistically significant difference between the vehicle cohort and tamoxifen 
cohort in any of the analysis (Figure 4.12A, B and C respectively). However, it is 
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interesting to note that the median values for metastases size and burden in the 
liver are significantly higher in the vehicle cohort as compared to the tamoxifen 
cohort; metastatic burden 162mm2 and 73mm2 respectively, metastases size 
23mm2 and 6mm2 respectively. Analysis of the final size and burden in the lungs 
of endpoint mice also showed that there was no statistically significant 
difference between the vehicle cohort and tamoxifen cohort in either analysis 
(Figure 4.13A and B respectively).  These data show that despite the increase in 
the survival time for the tamoxifen treated mice both cohorts are able to reach 
the specified endpoint with the same metastatic potential realised at endpoint. 
Therefore loss of one copy of Chk1 may delay but not completely suppress 
metastatic growth. Collectively these data show that the loss of one copy of 
Chk1 has a detrimental effect on the proliferation and/or survival potential of 
metastatic growths as demonstrated by the increase in survival time of the 
tamoxifen treated cohort. However this is only a transient effect with the cells 
able to adapt to the loss so that the final metastatic potential is the same in 
tamoxifen treated and vehicle treated animals. 
This data demonstrates that Chk1 hemizygousity has a slight effect on melanoma 
tumour formation in allograft models of melanoma development. The role of 
Chk1 hemizygousity in tumourigenesis is controversial with evidence to suggest 
that Chk1 hemizygousity could promote tumourigenesis by increasing genetic 
instability. In mammary tumour formation Chk1 hemizygousity in combination 
with p53 has been shown to induce tumour formation (Fishler et al, 2010). 
However in studies on chemical-induced carcinogenesis of the skin Chk1 
hemizygousity was shown to have no effect on benign tumour formation but 
increased the propensity for the conversion to carcinoma (Tho et al, 2012). Chk1 
hemizygous mice are viable. However loss of one copy of Chk1 does infer cell 
cycle defects such as an increased number of S-phase cells, spontaneous DNA 
damage generation and early mitotic entry, all phenotypes which could 
contribute to tumourigenesis (Lam et al, 2004). 
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Figure 4.12: Effect of heterozygous deletion of Chk1 on metastatic burden in liver. (A) 
Analysis of the size of individual metastases in the liver of vehicle and tamoxifen treated animals. 
(B) Analysis of the final metastatic burden per animal in the liver of vehicle and tamoxifen treated 
animals. (C) Analysis of the number of metastases per animal in the liver of vehicle and tamoxifen 
treated animals. No statistically significant difference with any analysis 
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Figure 4.13: Effect of heterozygous deletion of Chk1 on metastatic burden in lungs. (A) 
Analysis of the size of individual metastases in the liver of vehicle and tamoxifen treated animals. 
(B) Analysis of the final metastatic burden per animal in the liver of vehicle and tamoxifen treated 
animals. No statistically significant difference with either analysis. 
 
4.4 Discussion 
The aim of this chapter was to understand the role that Chk1 may play in the 
initiation, progression and maintenance of melanoma in vivo. This could be 
significant as melanoma is an extremely aggressive form of skin cancer which 
accounts for >80% of deaths from skin cancer. Melanomas display high levels of 
chromosomal instability (Bauer & Bastian, 2006) and large numbers of nuclear 
foci positive for γH2AX, a marker of DNA strand breaks (Gorgoulis et al, 2005; 
Warters et al, 2005). Activation of the DNA damage pathway has been observed 
in dysplastic nevi and in human skin xenografts (Gorgoulis et al, 2005). Chk1 is a 
key component of the DNA damage signalling pathway and is rarely mutated in 
cancer. Thus Chk1 activation is probably high in at least the earliest stages of 
melanoma development.  
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The role that ATR-Chk1 activation plays in malignant transformation and 
progression is not fully understood, with evidence for roles in both tumour 
progression and suppression. Studies have shown that the DNA damage response 
pathway is induced by active oncogenes and acts as a barrier to the progression 
of cancer beyond its early stages (Bartek et al, 2007). The ATR/Chk1 signalling 
module has been shown to be activated in an acute manner in response to 
activated oncogenes including Ras, Mos, Cdc6, Cyclin E, E2F1 and Stat5 in vitro 
and in Ras-driven mouse epithelial tumours in vivo, whereby it leads to the 
prevention of cancer progression by cellular senescence (Bartkova et al, 2005; 
Bartkova et al, 2006; Di Micco et al, 2006; Mallette et al, 2007). Thus active 
ATR/Chk1 signalling is suppressing malignant progression and is therefore 
protective.  
Other studies have shown that the ATR/Chk1 signalling module has a 
gatekeeping function which is essential to restrain oncogene-induced replicative 
stress and therefore for tumour maintenance (Campaner & Amati, 2012). In fact 
in myc-driven tumours it has been shown that Chk1 transcript and protein levels 
are indirectly induced and that these cells are sensitised to chemical inhibition 
of Chk1 which triggers a potent apoptotic response (Hoglund et al, 2011; Ferrao 
et al, 2012; Murga et al, 2011). In Ras-transformed cells ATR/Chk1 signalling is 
essential for limiting genomic instability; with siRNA knockdown of ATR causing 
increases in chromatid breaks, sister chromatid exchanges and γH2AX levels. In 
contrast to the synthetic lethal effects of ATR knockdown, haplo-insufficiency 
for ATR in combination with K-Ras elevated the incidence of lung 
adenocarcinoma, spindle cell sarcoma and thymic lymphomas in vivo (Gilad et 
al, 2010; Schoppy et al, 2012). Recently two point mutations in Chk1 have been 
identified that render Chk1 constitutively active. Expression of these mutant 
forms of Chk1 inhibits cancer cell proliferation (Wang et al, 2012).  
By using a genetically manipulated mouse model of melanoma which mimics the 
human condition in combination with a conditional knockout model of Chk1 I was 
able to show that complete loss of Chk1 causes a profound reduction in the 
proliferation potential of melanoma tumour formation in in vivo models of 
melanoma development with a concurrent increase in the survival time of these 
mice (Figure 4.8). This data shows that Chk1 is essential for the maintenance 
and progression of melanoma in vivo. This result is similar to previous studies 
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which have also shown that loss of Chk1 inhibits tumour formation in both 
mammary tumour models on a p53 null background (Fishler et al, 2010) and 
chemically-induced skin tumour models (Tho et al, 2012). I was also able to show 
that while complete Chk1 loss has a pronounced negative effect on melanoma 
tumour formation hemizygousity for Chk1 also exerts a more modest but 
nevertheless measureable effect on melanoma tumour formation and survival in 
vivo (Figure 4.10). In addition Chk1 hemizygousity does appear to have a 
detrimental effect on the proliferation and/or survival potential of melanoma 
metastatic growths as demonstrated by the increase in survival time (Figure 
4.11). However the final metastatic potential in the liver and lungs is not 
permanently suppressed but only delayed (Figure 4.12 and 4.13 respectively). 
This data shows that reduction in Chk1 levels modestly effects the primary 
tumour formation of melanoma in vivo, and also has a negative effect on the 
proliferation and/or survival of metastatic growths.  
This is in contrast to previous data from my lab which showed that in chemical-
induced skin carcinogenesis Chk1 hemizygousity had no effect on benign tumour 
formation but promoted benign-malignant conversion (Tho et al, 2012). However 
the role of Chk1 hemizygousity in tumourigenesis is controversial and seems to 
be tissue specific. In mammary tumour formation Chk1 hemizygousity in 
combination with p53 loss has been shown to induce tumour formation (Fisher 
2010). Chk1 hemizygous cells have been shown to have spontaneous DNA damage 
(Lam et al, 2004) and to increase the conversions of benign skin papilloma to 
carcinoma in vivo (Tho et al, 2012). These data indicate that Chk1 hemizygous 
cells are more genetically unstable than Chk1 proficient cells. This may put a 
high selective pressure, potentially through increased levels of cell death or 
replicative failure, on metastatic growths which could account for the delay 
seen in the metastatic growth of melanoma cells in vivo.
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5 DNA damage signalling in human melanoma cell 
lines 
5.1 Introduction 
In order to prevent the accumulation of mutations during cell division cells have 
developed complex mechanisms, known as the DNA damage responses. Key 
among these mechanisms is cell cycle checkpoints which are activated in 
response to DNA damaging agents and replication stress. They function by 
delaying cell cycle progression thus allowing cells to repair DNA damage or deal 
with replication problems. Consequently they are important in maintaining 
genome stability and defects in these pathways have been implicated in genetic 
instability and malignant progression (Rai et al, 2007; Smith et al, 2011). Key 
players in activation of the DNA damage checkpoint responses are the protein 
kinases Chk1 and Chk2 which are activated by the upstream protein kinases ATR 
and ATM respectively in response to a variety of DNA damaging agents including 
IR, UV, ROS and many chemical genotoxins (Bartek & Lucas, 2003; Sancar et al, 
2004). Although Chk2 has been shown to be mutated in many cancers (Hangaishi 
et al, 2002; Ingvarsson et al, 2002; Papp et al, 2007; Wu et al, 2001) Chk1 
expression and function is consistently conserved in cancer cells. Therefore I 
examined the proficiency of checkpoint activation in a panel of melanoma cell 
lines.  
5.2 Mutational status of a panel of human malignant 
melanoma cell lines 
In order to analyse the cell cycle checkpoint proficiency in melanoma cell lines, 
and to establish whether any variations may be attributed to specific oncogenic 
mutations, I examined a panel of eleven human melanoma cell lines. Cell lines 
were selected based on their oncogene status (B-Raf or N-Ras) and their tumour 
suppressor status (CDK2NA, PTEN and p53) (See Table 5.1). Melanoma is known 
to be a progressive condition whereby the cancer cells typically go through 
several phases of growth: radial, followed by vertical and finally metastatic 
growth to both local and distant sites; therefore I also selected one radial 
growth phase (WM35) and one vertical growth phase (WM793) cell line in order 
to have a comparison with the other metastatic cell lines. Finally I also included 
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one cell line which has recently been shown to be haplo-insufficient for Chk1, 
MRI-H-221 (Papp et al, 2007), in order to analyse whether one copy of Chk1 is 
sufficient for checkpoint proficiency. 
Cell Line Oncogene  
(B-Raf/N-Ras) 
CDKN2A 
status 
PTEN 
status 
Other known 
mutations 
A375MM B-Raf V600E WT - - 
WM35 B-Raf V600E Mutant - - 
WM793 B-Raf V600E - - Cdk4 mutation 
Sk-Mel-5 B-Raf V600E WT Mutant - 
Sk-Mel-28 B-Raf V600E WT Mutant p53 (L145R) 
Cdk4 (R24C) 
Sk-Mel-37 B-Raf V600E WT Mutant (loss 
of exon2) 
p53 (R175H), 
Cdk4 (R24H) 
Sk-Mel-39 B-Raf V600E WT Mutant 
(1352InsA) 
p53, Cdk4 
(K22Q) 
Sk-Mel-2 N-Ras Q61R - - - 
Sk-Mel-103 N-Ras Q61R Null - - 
Sk-Mel-147 N-Ras Q61R Mutant - - 
MRI-H-221 - - - Chk1 haplo-
insufficient 
Table 5.1: Panel of Melanoma cell lines with oncogene and tumour suppressor status. 
 
5.3 Analysis of G2/M checkpoint proficiency and Chk1 
activation following irradiation-induced DNA damage 
The G2/M checkpoint is activated when dividing cells have acquired DNA damage 
during S or G2 phase of the cell cycle in order to prevent them from entering 
mitosis. The cells subsequently block in the G2 phase of the cell cycle until the 
damage is either repaired or they are targeted for cell death (apoptosis). The 
checkpoint is assayed using a flow cytometry technique whereby the DNA 
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content is measured via propidium iodide (PI) staining. This gives a cell cycle 
profile as seen in Figure 5.1Ai whereby the G1 (2N DNA content) and the G2/M 
phases (4N DNA content) can be visualised as two distinct peaks with S-phase 
cells in-between. Phosphorylated histone H3 (pH3) is used as a marker of mitotic 
cells. Checkpoint proficient cells will display an accumulation in the G2/M peak 
but with negativity for pH3 after irradiation treatment (IR) which generates DNA 
DSBs. The cells are also treated with Nocodozole (Noc), a spindle poison, which 
blocks the cells in mitosis and acts as a positive control for the accumulation of 
pH3-positive mitotic cells in undamaged cultures. 
 
In the B-Raf oncogene containing cell lines we can see that WM35, Sk-Mel-5 and 
Sk-Mel-39 (Figure 5.1B, D and G respectively) all display a functional G2/M 
checkpoint. This is demonstrated by their accumulation in the G2/M peak  as 
assayed by PI accompanied by diminished pH3 staining (Figure 5.1Biii, Diii and 
Giii respectively), indicating the cells are blocked in G2 and not progressing to 
mitosis as seen in the Noc only treated (Figure 5.1Bii, Dii and Gii respectively).  
However in the B-Raf oncogene containing cell lines A375MM, WM793, Sk-Mel-28 
and Sk-Mel-37 (Figure 5.1A, C, E and F respectively) we can see that there is 
variation in G2/M checkpoint proficiency with the cells not fully blocking in G2 
after IR. This can be seen by the positive pH3 staining observed (Figure 5.1Aiii, 
Ciii, Eiii and Fiii respectively) after IR treatment indicating cells are not blocking 
in G2 but are still able to progress into mitosis in the presence of DNA damage. 
When the pH3 accumulation in the IR samples are compared as a percentage of 
the Noc only treated samples (taken as 100%) for each cell line (Figure 5.1H) we 
can see that A375MM, WM793 and Sk-Mel-37 have a decreased ability to block in 
G2 after IR with 40-60% of cells positive for pH3 staining (indicated by the black 
stars in Figure 5.1H). This shows that in the presence of DNA damage a 
significant proportion of cells can still progress into mitosis. However Sk-Mel-28 
has a completely defective G2/M checkpoint (indicated by the red star in Figure 
5.1H) showing that the pH3 positivity and thus mitotic progression is not 
inhibited at all by the presence of DNA damage. 
 
In the N-Ras oncogene containing cell lines we can see that Sk-Mel-2, Sk-Mel-103 
and Sk-Mel-147 (Figure 5.2A, B and C respectively) all display a functional G2/M 
checkpoint. This is demonstrated by their accumulation in the G2/M peak  as 
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assayed by PI accompanied by diminished pH3 staining (Figure 5.2Aiii, Biii and 
Ciii respectively), indicating the cells are blocked in G2 and not progressing to 
mitosis as seen in the Noc only treated (Figure 5.2Aii, Bii and Cii respectively).  
This can be further seen when the pH3 accumulation in the IR samples are 
compared as a percentage of the Noc only treated samples (taken as 100%) for 
each cell line (Figure 5.2E) we can see that there is a small amount of pH3 
staining (as indicated by the white stars in Figure 5.2E) which is less than that 
seen in the untreated samples for each cell line. This represents an effective 
block to progression into mitosis in the presence of DNA damage. 
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Figure5.1: Characterisation of G2/M checkpoint proficiency in B-Raf mutant melanoma cell 
lines. (A-G) G2/M Checkpoint Assay. Cells were treated for 16hrs with Nocodazole (Noc) with or 
without 10Gy γIR. The number of mitotic cells (pH3 positive) after 16hrs was assessed by flow 
cytometry. Dot plots and DNA histograms are shown. (H) Quantification of the number of mitotic 
cells taken as a percentage of Noc only treated for each cell line. White stars represent G2/M 
checkpoint proficient cell lines, red star represents a G2/M defective cell line and black stars 
represent cell lines with intermediate G2/M checkpoint proficiency.  
 
Collectively this data demonstrates that there is a significant variation in the 
G2/M checkpoint proficiency in melanoma cell lines (4 out of 11 have a weak or 
defective G2 arrest). Based on this small analysis we can see that the loss of this 
checkpoint only occurs in B-Raf mutant cell lines and not in N-Ras mutant cell 
lines however this is only a small collection of cell lines and may not be 
representative of melanoma as a whole. We can also note that the checkpoint is 
functional in the early radial growth phase cell line (WM35, Figure 5.1B) but is 
partially defective in the more advanced vertical growth phase cell line (WM793, 
Figure 5.1C). This may represent a possible mechanism for increased genetic 
instability and subsequently transition to more aggressive forms of melanoma. 
Loss of checkpoint function as a mechanism for malignant transition is already 
well documented (Kaufmann et al, 2001; Mukherjee et al, 2010; Nuciforo et al, 
2007). Loss or mutation of p53 is a common marker of cancer cells and is thought 
to be present in up to 50% of all cancers, although this is a less common 
occurrence in melanoma.  One consequence of the mutation or loss of p53 
signalling is the loss of the G1/S checkpoint (Bartek & Lucas, 2001; Ryan et al, 
2001). The G1/S checkpoint is activated when dividing cells have acquired DNA 
damage during G1 or M phase of the cell cycle in order to prevent them from 
entering the DNA replication phase of the cell cycle. It is interesting to note that 
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only four of the melanoma cell lines appear to have a functional G1/S 
checkpoint after IR treatment as assessed by the substantial G1 peak seen in 
these cell lines; WM35, WM793, Sk-Mel-5, Sk-Mel-37 and Sk-Mel-147 (Figure 
5.1Biii, Ciii, Diii, Fiii and 5.2Ciii respectively). 
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Figure 5.2: Characterisation of G2/M checkpoint proficiency in N-Ras mutant melanoma cell 
lines. (A-D) G2/ M Checkpoint Assay. Cells were treated for 16hrs with Nocodazole (Noc) with or 
without 10Gy γIR. The number of mitotic cells (pH3 positive) after 16hrs was assessed by flow 
cytometry. Dot plots and DNA histograms are shown. (E) Quantification of the number of mitotic 
cells taken as a percentage of Noc only treated for each cell line. White stars represent G2/M 
checkpoint proficient cell lines. 
 
In the Chk1 haplo-insufficient melanoma cell line we can see that there is a 
functional G2/M checkpoint (Figure 5.2D). The cells accumulate in G2/M as 
assayed by PI accompanied by a lack of pH3 staining (Figure 5.2Diii), indicating 
the cells are blocked in G2 and not progressing to mitosis in the presence of DNA 
damage. This is further quantified by the pH3 accumulation in the IR samples as 
compared as a percentage of the Noc only treated samples (taken as 100%) 
(Figure 5.2E). We can see that there is a small amount of pH3 staining (as 
indicated by the white star in Figure 5.2E) which is less than that seen in the 
untreated sample. This represents a lack of progression into mitosis in the 
presence of DNA damage. This data demonstrates that one functional allele for 
Chk1 is sufficient for Chk1 activity in the G2/M checkpoint, at least in this 
particular cell line.  
 
Analysis of Chk1 activation in the G2/M checkpoint proficient cell lines by WB 
(Figure 5.3A-G) shows a consistent pattern of activating phosphorylation of Chk1 
on S345 after IR treatment. Chk1 is phosphorylated on S345 within 10mins-1hr 
after treatment which is then maintained in all cells lines for 6hrs and up to 
16hrs in some cells lines (Sk-Mel-39 and MRI-H-221). Chk2 activation in the G2/M 
proficient cell lines shows a more varied pattern. In cell lines WM35, Sk-Mel-5, 
Sk-Mel-2 and MRI-H-221 (Figure 5.3A, B, D and G respectively) there is a 
consistent pattern of activating phosphorylation on T68 after IR treatment. Chk2 
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is phosphorylated on T68 within 10mins treatment which is then maintained for 
16hrs. However in cell lines Sk-Mel-39 (Figure 5.3C) and Sk-Mel-103 (Figure 5.3E) 
there is no detectable induction of pChk2 in either the untreated or IR treated 
samples at any time point. In cell line Sk-Mel-147 (Figure 5.3F) there are very 
low basal levels of pChk2 with a small increase seen 10mins after treatment but 
which is subsequently reduced by 1hr and lost by 6hrs after IR treatment. 
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Figure 5.3: Activation of Chk1 and Chk2 signalling post γIR treatment in melanoma cell lines 
with efficient G2/M checkpoint activation. (A-G) Western blot analysis of activating 
phosphorylation on Chk1 and Chk2. Cells were harvested 10mins, 1hr, 6hr and 16hr post 10Gy 
γIR. Antibodies against pChk1 S345 and pChk2 T68 were used. An equal quantity of protein was 
loaded as determined by Bradford Assay and confirmed by antibody against actin.  
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Chk1 activation was analysed in the cell lines which demonstrated a variation in 
their G2/M checkpoint function by WB (Figure 5.4A-D). These cell lines show 
variations in their activation patterns of Chk1. A375MM cells (Figure 5.4A) show 
an increase in the pChk1 S345 levels 10mins after IR treatment, which is 
maintained for 6hrs post treatment. This pattern of activation is as expected and 
was seen in the G2/M proficient cell lines. This suggests there may be a problem 
with signalling downstream of Chk1 in this cell line. In cell lines WM793 (Figure 
5.4B) and Sk-Mel-37 (Figure 5.4D) there is a sharp increase in pChk1 levels 
however this is only seen at one time point for each cell line, after 6hrs IR 
treatment in WM793 cells and after 1hr IR treatment in Sk-Mel-37 cells and is not 
maintained at any other times. This pattern suggests that Chk1 activation may 
be turned off rapidly (potentially by phosphatases) or that the upstream 
activating signal is short-lived. In cell line Sk-Mel-28 (Figure 5.4C) there is a 
small increase in pChk1 levels after 10mins treatment which is then maintained 
for 6hrs; this is the expected pattern of activation however the basal levels of 
activated Chk1 in the untreated samples are very high. This suggests that 
potentially the pathway is always on and perhaps the cells are no longer 
responsive to the DNA damage signal.  Chk2 activation in these cell lines is also 
variable. In cell lines A375MM (Figure 5.4A) and Sk-Mel-28 (Figure 5.4C) which 
have the expected pattern of Chk1 activation also show increases in pChk2 levels 
that are similar to the G2/M proficient cell lines. Chk2 is phosphorylated on T68 
after 10mins IR treatment and is maintained for 6hrs post treatment. This clearly 
shows that these cell lines have functional pathway signalling upstream of Chk1 
and Chk2 however the signal maybe lost at some point downstream so that they 
have diminished G2/M checkpoint proficiency. WM793 cells (Figure 5.4B) show a 
sharp increase in pChk2 levels after 10mins however the signal is not maintained 
with loss of the signal by 1hr. This is consistent with the pChk1 levels in these 
cells which also showed a short sharp increase. This data suggests that WM793 
cells may have problems with activation of upstream signalling of Chk1 and 
Chk2. 
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Figure 5.4: Activation of Chk1 and Chk2 signalling post γIR treatment in melanoma cell lines 
with deficient and intermediate G2/M checkpoint proficiency. (A-D) Western blot analysis of 
activating phosphorylation on Chk1 and Chk2. Cells were harvested 10mins, 1hr, 6hr and 16hr post 
10Gy γIR. Antibodies against pChk1 S345 and pChk2 T68 were used. An equal quantity of protein 
was loaded as determined by Bradford Assay and confirmed by antibody against actin. 
 
5.4 Analysis of S/M checkpoint proficiency and Chk1 
activation following replication stress 
The S/M checkpoint is activated when dividing cells encounter problems during 
DNA replication which cause stalling of replication forks. The checkpoint is 
activated in order to prevent collapse of these replication forks and ultimately 
prevent cells from entering mitosis in the presence of DNA which is not fully 
replicated.  The cells will block in S phase of the cell cycle until the DNA is 
properly replicated or they are targeted for cell death (apoptosis). The 
checkpoint is assayed using a flow cytometry technique whereby the DNA 
content is analysed via PI staining giving a cell cycle profile where the G1 (2N 
DNA content) and the G2/M phases (4N DNA content) are visualised as two 
distinct peaks with a bridge in-between representing the S-phase cells. The DNA 
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content of these cells is gradually changing from 2N to 4N. Phosphorylated 
histone H3 (pH3) is used as a marker of mitotic cells. Checkpoint proficient cells 
will display a blockage at early S-phase with failure to progress to G/M and 
negativity for pH3 after aphidicolin treatment (Aph) which inhibits DNA 
polymerase causing stalling of active replication forks. The cells are also treated 
with Nocodozole (Noc), a spindle poison, which blocks the cells in mitosis and 
acts as a positive control for accumulation of pH3-positive mitotic cells in the 
absence of DNA synthesis inhibition. 
 
All the melanoma cell lines tested (Figure 5.5A-G and Figure 5.6A-D) displayed a 
functional S/M checkpoint upon inhibition of DNA replication. Treatment with 
Aph caused all cells to block in early to late S-phase, as assayed by PI staining 
accompanied by severely diminished pH3 staining (Figure 5.5Aiii-Giii and Figure 
5.6Aiii-Diii). When the pH3 accumulation in the Aph treated samples are 
compared as a percentage for each individual cell line to the Noc only treated 
samples (taken as 100%) (Figure 5.5H and Figure 5.6E) we can see that the pH3 
positivity is equal to or below the level seen in the untreated samples for each 
cell line.  
 
This data demonstrates that the S/M checkpoint is always functional in 
melanoma cell lines. Based on this small analysis we can suggest that although 
loss or impairment of checkpoint functions; both G1/S by p53 mutation, as seen 
in cell lines Sk-Mel-28 and Sk-Mel-39 which both harbour a known p53 mutation 
and have lost an apparent G1/S checkpoint after IR treatment, and G2/M as seen 
above, can contribute to malignant transformation, the S/M checkpoint is 
possibly essential for tumour cell growth and proliferation and as such is always 
retained. However this hypothesis is only based on a small number of cell lines 
and may not be true for a larger scale of melanoma cell lines. This data also 
demonstrates that one functional allele for Chk1 is sufficient for full S/M 
checkpoint proficiency. 
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Figure 5.5: Characterisation of S/M checkpoint proficiency in B-Raf mutant melanoma cell 
lines. (A-G) S-M Checkpoint Assay. Cells were treated for 16hrs with Nocodazole (Noc) with or 
without [20µM] Aphidicolin. The number of mitotic cells (pH3 positive) after 16hrs was assessed by 
flow cytometry. Dot plots and DNA histograms are shown. (H) Quantification of the number of 
mitotic cells taken as a percentage of Noc only treated for each cell line.  
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Figure 5.6: Characterisation of S/M checkpoint proficiency in N-Ras mutant melanoma cell 
lines. (A-D) S-M Checkpoint Assay. Cells were treated for 16hrs with Nocodazole (Noc) with or 
without [20µM] Aphidicolin. The number of mitotic cells (pH3 positive) after 16hrs was assessed by 
flow cytometry. Dot plots and DNA histograms are shown. (E) Quantification of the number of 
mitotic cells taken as a percentage of Noc only treated for each cell line. 
 
Analysis of Chk1 activation by WB after Aph treatment shows a consistent 
pattern of activating phosphorylation on S345 (Figure 5.7A-K). Chk1 is 
phosphorylated on S345 within 10mins of treatment in most cell lines and at the 
latest by 1hr in cell lines WM793 and SK-Mel-147 (Figure 5.7C and J 
respectively). There is a peak of pChk1 S345 after 1hr to 6hr treatment with 
maintenance of this activating phosphorylation until 16hrs after Aph treatment 
in all cell lines except Sk-Mel-103 (Figure 5.7I) which is back to basal levels by 
this time point.  Chk2 activation shows a more varied pattern of activating 
phosphorylation on T68. In cell lines Sk-Mel-39 and Sk-Mel-103 (Figure 5.7G and I 
respectively) there are no detectable levels of pChk2 T68 in either the untreated 
or treated samples at any time point. In cell lines A375MM, WM793 and MRI-H-
221 (Figure 5.7A, C and K respectively) there is no significant increase in pChk2 
levels beyond the basal levels of activation seen in the untreated samples.  In 
cell lines WM35, Sk-Mel-5,  Sk-Mel-28, Sk-Mel-2 and Sk-Mel-147 (Figure 5.7B, D, 
E, H and J respectively)  there is activation of Chk2 at one or more time points 
for each cell line after Aph treatment, however these vary between cell line. 
Finally in cell line SK-Mel-37 (Figure 5.7F) there is activation of pChk2 above 
basal levels 16hrs after Aph treatment. These data demonstrate that Chk1 is 
activated after DNA replication stress in all cell lines whereas activation of Chk2 
is cell line-dependent. This may reflect variations in the ability of each cell line 
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to repair damage caused by replication fork stalling. Cell lines which activate 
Chk2 as well as Chk1 may be less efficient at stabilising stalled forks and 
potentially DNA DSBs could be generated as well as ssDNA, through fork collapse 
or other mechanisms. 
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Figure 5.7: Activation of Chk1 and Chk2 signalling post Aphidicolin treatment in melanoma 
cell lines. (A-K) Western blot analysis of activating phosphorylation on Chk1 and Chk2. Cells were 
harvested 10mins, 1hr, 6hr and 16hr post [20µM] Aphidicolin treatment. Antibodies against pChk1 
S345 and pChk2 T68 were used. An equal quantity of protein was loaded as determined by 
Bradford Assay and confirmed by antibody against actin.  
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5.5 Analysis of MRN complex in malignant melanoma cell 
lines 
In order to assess whether the variations in G2/M and S/M checkpoint function 
and Chk1/Chk2 signalling patterns observed before could be due to differences 
in the protein expression levels of components of the DNA damage response 
pathways in each cell line, I analysed several important proteins involved in the 
processing and execution of this pathway. The core components of the DNA 
damage checkpoint response pathway can be classified into three main groups; 
sensors, signal transducers and effectors. Sensor proteins are the first class to be 
activated upon DNA damage and these proteins are involved in the initial sensing 
and processing of the DNA damage signal (D’Amours & Jackson, 2002). A key 
player in the initial sensing and processing of DNA DSBs is the MRN complex; 
consisting of three components Mre11, Rad50 and Nbs1.  
Protein lysates of human melanoma cell lines were analysed by WB for their 
basal levels of the MRN complex members (Figure 5.8). Unexpectedly both Mre11 
and Nbs1 were undetectable in two of the cell lines (Sk-Mel-39 and Sk-Mel-103) 
with a corresponding reduction in the Rad50 levels. The levels of Mre11, Nbs1 
and Rad50 are also greatly reduced in cell line Sk-Mel-147.  These data could 
suggest that these cell lines could potentially have a defective response to DNA 
DSBs. This would be consistent with their lack of active Chk2. Phosphorylated 
Chk2 on T68 is a direct read-out of active ATM which is activated in conjunction 
with the MRN complex.  In cell lines Sk-Mel-39 and Sk-Mel-103 we have 
previously seen that these cell lines lack detectable levels of pChk2 T68 after 
irradiation (Figure 5.3C and E respectively).  This could now be attributed to 
their lack of Mre11 and Nbs1 complex members and thus their inability to 
activate ATM. In cell lines Sk-Mel-147 we have seen previously that they have 
very low levels of basal pChk2 in untreated samples and are only able to activate 
pChk2 for a very short time after IR (Figure 5.3F). Again this could now be 
attributed to their apparent low levels of the MRN complex members with 
respect to other melanoma cell lines. However it should be noted that all these 
cell lines are still able to activate Chk1 after IR and possess a functional G2/M 
checkpoint. All other cell lines show presence of all three complex members to 
varying degrees however it should be noted that Nbs1 appears to exist in two 
isoforms with different apparent molecular mass. A lower molecular mass Nbs1 
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appears in cell lines A375MM, Sk-Mel-5 and Sk-Mel-37 and is also present in the 
human colon cancer cell line HCT-116. In the remaining cell lines there is a 
higher molecular mass Nbs1. This is possibly due to post-translational 
modifications of Nbs1or alternatively it could represent differences splicing. In 
fact Nbs1 is known to have several DNA damage inducible phosphorylation sites 
(Seno & Dynlacht, 2004). 
 
Figure 5.8: Levels of MRN complex components in melanoma cells. Western blot analysis of 
the components of the MRN complex which senses DNA DSBs. Antibodies against Mre11, Rad50 
and Nbs1 were used. An equal quantity of protein was loaded as determined by Bradford Assay 
and confirmed by antibody against actin. 
 
The second class of proteins in the DNA damage response checkpoint pathway 
are the signal transducers. These proteins are able to convert the signal from 
the sensor proteins and activate downstream effector kinases. Main players in 
this response are the ATM and ATR serine/threonine protein kinases which are 
activated in response to DNA DSBs and ssDNA respectively, and the ATR partner 
protein, ATRIP. Protein lysates of human melanoma cell lines were analysed by 
WB for their basal levels of ATM, ATR and ATRIP (Figure 5.9). The ATM kinase is 
present in most cell lines but appears to be absent or at reduced levels in cell 
lines Sk-Mel-39, Sk-Mel-103 and Sk-Mel-147 which have all been aforementioned 
to lack or have very low levels of MRN complex expression. The ATR kinase is 
present in all cell lines to varying degrees however at lower levels than in the 
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human colon cancer cell line HCT-116. The ATR binding protein ATRIP is present 
in all cell lines at similar levels. 
 
Figure 5.9: Ataxia telangiectasia mutated (ATM), Ataxia telangiectasia and Rad3 related 
(ATR) and ATR-interacting protein (ATRIP) expression in melanoma cells. Western blot 
analysis of the levels of expression of kinases ATM and ATR which are activated  in response to 
DNA DSBs and ssDNA respectively, and the essential ATR adaptor protein ATRIP. Antibodies 
against ATM, ATR and ATRIP were used. An equal quantity of protein was loaded as determined 
by Bradford Assay and confirmed by antibody against actin.  
 
The third class of proteins in the DNA damage response checkpoint pathway are 
the effector kinases that are directly responsible for checkpoint activation. The 
main effectors are the Chk1 and Chk2 protein kinases which are activated 
primarily by ATR and ATM respectively.  Downstream targets of Chk1 include 
activation of the Wee1 kinase (which subsequently imposes inhibitory 
phosphorylation on CDK1) and inhibition of CDC25C phosphatases (O’Connell et 
al, 1997; Peng et al, 1997; Rhind et al, 1997; Sanchez et al, 1997). Downstream 
targets of Chk2 include activation of p53 and inhibition of CDC25A phosphatases 
(Mailand et al, 2000). The overall effect of Chk1/2 activation is to block 
progression from one phase of the cell cycle to the next by inhibiting CDK/Cyclin 
complexes.  
 
Protein lysates of human melanoma cell lines were analysed by WB for their 
basal levels of Chk1, Chk2, Wee1, Cdk1 and CDC25A (Figure 5.10).  The Chk1 
protein kinase is present in all the cell lines however it is expressed substantially 
less in all the melanoma cell lines compared to human colon cancer HCT 116 
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cells. Chk1 protein levels are the lowest in cell line MRI-H-221 which is to be 
expected as this cell line only has one functional allele of Chk1.  Wee1 kinase, a 
downstream target of Chk1, appears to be absent in Sk-Mel-103 cells, however 
these cells have both a functional S/M and G2/M checkpoint therefore this loss 
does not seem to affect signalling downstream of Chk1. This could be due to 
CDC25C, another target of Chk1, over-riding the loss of Wee1 signalling in these 
cells.  In A375MM cells the Wee1 levels are very low. These cells have displayed 
a partially defective G2/M checkpoint in response to IR (Figure 5.1A) despite 
having increased pChk1 levels (Figure 5.4A). This phenotype could perhaps be 
accounted for by the low levels of Wee1. In all other cell lines there is a similar 
basal level of Wee1.  The CDK1 kinase, a downstream target of Wee1, is 
expressed in all cell lines. The Chk2 protein kinase appears to be absent in cell 
line Sk-Mel-28 and Sk-Mel-39 and at low levels in cell lines WM35 and MRI-H-221. 
However the antibody is not very clear therefore it is hard to make any 
definitive conclusions.  It should be noted that Chk2 is clearly present in cell line 
Sk-Mel-103 and Sk-Mel-147  all of which have displayed absent or very low basal 
levels of pChk2 T68 after IR treatment (Figure 5.3E and F respectively), 
therefore this absence is not due to the loss of Chk2 itself but the loss of 
signalling to Chk2.  The CDC25A serine/threonine phosphatase, a downstream 
target of Chk2, is expressed in all the cell lines at very similar levels. 
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Figure 5.10: Levels of the essential effector kinase Chk1 and Chk2 in melanoma cells. 
Western blot analysis of the expression of kinases Chk1 and Chk2, which are activated by ATR 
and ATM respectively, and downstream targets of checkpoint signalling. Antibodies against Chk1, 
Chk2, Wee1, Cdk1 and Cdc25A were used. An equal quantity of protein was loaded as determined 
by Bradford Assay and confirmed by antibody against actin.  
 
These data demonstrate that there are variations in the levels of certain 
proteins involved in the DNA damage checkpoint response pathway in melanoma 
cells, however there does not appear to be any obvious consistent differences in 
the A375MM, WM793, Sk-Mel-37 and SK-Mel-28 cell lines compared to the others 
which would account for their lack of a fully functional G2/M checkpoint. This 
suggests that the mechanism responsible for the loss of function may be 
different in each affected cell line. However it is interesting to note that several 
proteins; ATR, Chk1 and CDK1 are lower in their basal expression levels in the 
melanoma cells compared to HCT 116 cells, this may be an example of cell type-
specific difference.  
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5.6 The requirement of MRN complex for Chk1 activation 
after IR 
The MRN complex is responsible for the initial sensing and processing of DNA 
DSBs, and also the recruitment and activation of Chk2 via ATM (Uziel et al, 
2003). However due to its role in strand resection, a process initiated by the 
nuclease activity of Mre11 to generate tracks of ssDNA, it has also been 
implicated in activation of ATR and Chk1 after DNA DSBs (Chen et al, 2008; Lewis 
et al, 2004). In my previous data I have shown that indeed the MRN complex is 
required for activation of ATM and thus Chk2.  Melanoma cell line Sk-Mel-103 
lacks both the Mre11 and Nbs1 components with a corresponding reduction in 
the Rad50 levels (Figure 5.8). This cell line also lacks any detectable levels of 
pChk2 T68, a read out of active ATM, in both untreated and IR treated samples 
(Figure 5.3E) despite possessing Chk2 (Figure 5.10). In comparison all Mre11 
proficient cell lines (A375MM, WM35, WM793, Sk-Mel-2, Sk-Mel-5, Sk-Mel-28, Sk-
Mel-37, Sk-Mel-147 and MRI-H-221) (Figure 5.8) are able to phosphorylate Chk2 
after IR induced DNA damage (Figure 5.3 and 5.4). There is even a suggestion of 
a linear reduction in the activation of the pathway whereby cell line Sk-Mel-147, 
which has very low levels of both Mre11 and Nbs1 compared to the other cell 
lines, also displays a concurrent reduction in the activation levels of pChk2 after 
IR (Figure 5.3F) However despite that fact Sk-Mel-103 cells are unable to 
activate Chk2 they do not appear to have any problems activating Chk1 after IR 
(Figure 5.3E).   
 
In order to assess if the restriction of functional MRN complex in these cells 
would alter the activation of Chk1, I transiently transfected wild type human 
Mre11 into both Sk-Mel-103 and Sk-Mel-39 cells and analysed the phosphorylation 
of Chk1 on S345 after both IR and Aph treatment. Transfection efficiency in both 
cell lines was 20-25% after 24hrs. Protein lysates of Sk-Mel-39 and Sk-Mel-103 
cells which had been transfected with either a control plasmid or a plasmid 
expressing wild type Mre11 (donated from Stephen Jackson’s lab with permission 
granted from Yossi Shiloh) for 24hrs then treated with either IR or Aph and 
analysed by WB. In both Sk-Mel-39 and Sk-Mel-103 cells Mre11 protein was 
successfully expressed after transfection (Figure 5.11A and B respectively). In 
Sk-Mel-39 cells it could be observed that after IR treatment in the presence of 
Chapter 5  153 
 
Mre11 the levels of active pChk1 S345 are increased at each time point 
compared to controls. After quantification with compensation for differences in 
loading (as assessed by the actin protein levels) we can see that there was a 
significant increase in the activation of Chk1 after IR in the presence of Mre11 
with the highest increase at 6hrs post IR treatment (>1 = increase in 
experimental group, 1=no change between control and experimental group, <1= 
decrease in experimental group). No significant difference was seen in the 
activation of Chk1 after Aph compared to controls (Figure 5.12A). In Sk-Mel-103 
cells a similar phenotype can also be observed in that after IR in the presence of 
Mre11 the levels of active pChk1 S345 are increased compared to the control 
cells (Figure 5.11B), however quantification shows that this increase is only 
significant at the later time point of 6hrs post IR with no real increase compared 
to controls observed at either 10mins or 1hr post IR (Figure 5.12B). 
 
Figure 5.11: Chk1 and Chk2 phosphorylation after γIR or Aphidicolin following transient 
transfection of Mre11 into Mre11-deficient melanoma cell lines. (A-B) Western blot analysis of 
activating phosphorylation of Chk1 and Chk2 in Sk-Mel-39 and Sk-Mel-103 cell lines respectively. 
Cells were transiently transfected with either control plasmid or plasmid expressing Mre11 for 
24hrs, then harvested 10mins, 1hr and 6hr post 10Gy γIR or [20µM] aphidicolin treatment. 
Antibodies against Mre11, pChk1 S345, pChk2 T68 and Rad50 were used. An equal quantity of 
protein was loaded as determined by Bradford Assay and confirmed by antibody against actin.  
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Figure 5.12: Western blot quantification of pChk1 (S345) levels. (A-B) Quantification of pChk1 
(S345) levels in Mre11 transfected cells compared to control cells after 10Gy γIR and [20µM] 
aphidicolin treatment in Sk-Mel-39 and Sk-Mel-103 cell lines respectively. Protein levels were 
corrected for loading by actin. 1= no difference between pChk1 levels in Mre11 transfected cells 
compared to control cells. >1= increase in pChk1 levels in Mre11 transfected cells compared to 
control cells. 
 
These data demonstrate that although in both cell lines Sk-Mel-39 and Sk-Mel-
103 a functional MRN complex is required for activation of ATM/Chk2 it is not 
absolutely required for activation of ATR/Chk1 after irradiation. However the 
presence of functional Mre11 is sufficient to increase the activation of Chk1 
after IR especially at later time points. This suggests that the initial activation of 
Chk1 after IR treatment does not require strand resection of the DSB but that at 
later time points strand resection is required in order to maintain the activation 
of Chk1. This demonstrates that there may be two distinct waves of activation of 
Chk1 after DNA DSBs with two distinct mechanisms; one of which is reliant on 
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processing of the DNA strand by the MRN complex. In fact a recent study has 
shown that CtIP, a key factor in DNA resection, was dispensable for the initial 
activation of Chk1 following DNA damage with both camptothecin and IR, with 
rapid activation of Chk1 seen before any detectable end resection. In contrast it 
was shown that DNA end resection was critically required for sustained 
ATR/Chk1 activity in both the intra-S and G2-phase checkpoints (Kousholt et al, 
2012) 
 
5.7 Discussion 
The main aim of this chapter was to understand whether melanoma cells have 
any common phenotypic defects in their DNA damage responses and whether 
these can be attributed to specific oncogenic mutations. This could be important 
as studies have shown that melanomas display high levels of chromosomal 
instability (Bauer & Bastian, 2006) and display large numbers of nuclear foci 
positive for γH2AX (a marker of DNA damage) (Gorgoulis et al, 2005; Warters et 
al, 2005). Such defects could potentially account for their ability to proliferate 
in the presence of high levels of chromosomal instability and perhaps underlie a 
mechanism for the continued accrual of genetic alterations. DNA damage 
response pathways play key roles in maintaining genome integrity in cells during 
cellular division. In fact studies have shown that DNA damage response 
activation in early benign legions can act as a strong tumour suppression 
mechanism (Bartkova et al, 2005; Bartkova et al, 2006; Di Micco et al, 2006) 
preventing malignant transformation.  
 
When examining the G2/M checkpoint after IR-induced DNA DSBs and the S/M 
checkpoint after blockage of DNA replication by Aph in a panel of melanoma cell 
lines, I was able to observe that while the S/M checkpoint function was 
maintained in all cell lines there is a significant variation in the G2/M checkpoint 
proficiency of melanoma cell lines (4 out of 11 display variations). This data 
suggests that while the G2/M checkpoint is dispensable for cell survival the S/M 
checkpoint may not be. In fact studies have shown that DNA damage induced 
checkpoint function can be disrupted in cells without affecting survival (Wilsker 
et al, 2008), whereas complete loss of Chk1 is not conducive with cell survival as 
shown by embryonic lethality in Chk1 null mice (Lam et al, 2004). In fact the 
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only cell line able to survive without Chk1 is the DT40 avian cell line (Zachos et 
al, 2003).  The data also suggests that this variation in G2/M checkpoint 
proficiency may be associated with mutations in the B-Raf oncogene but not 
mutations in the N-Ras oncogene. 
 
Recent studies have also shown that B-Raf oncogenic melanoma cell lines display 
significant attenuation of G2/M checkpoint function with an average of 38% of 
G2 cells evading the checkpoint in a panel of 16 cells lines, however they also 
showed that N-Ras oncogenic cell lines displayed a more mild but still significant 
attenuation of the G2/M checkpoint with an average of 21% of G2 cells evading 
the checkpoint (Kaufmann et al, 2008).  Other studies have also shown that Ras 
oncogenes are able to attenuate G2/M checkpoint function (Agapova et al, 2004; 
Knauf et al, 2006), possibly by enhancing the expression of cyclin B1 and CDK1 
the key CDK/cyclin complex involved in promoting the onset of mitosis (Santana 
et al, 2002). The G2/M and S/M checkpoints are regulated through the activity 
of the protein kinase Chk1 which acts by positively regulating Wee1, the 
inhibitor of CDK1. Wee1 functions by adding inhibitory phosphorylation to CDK1 
(T14/ Y15) thereby preventing activation of the CDK1/cyclin B1 complex. Chk1 
also acts by negatively regulating CDC25C, the activator of CDK1. CDC25C 
functions by removing the inhibitory phosphorylation from CDK1.  
 
In order to elucidate how cells are able to maintain an efficient S/M checkpoint 
in the face of variable G2/M checkpoint proficiency when both act through a 
common effector, Chk1, I analysed the activation pattern of Chk1 after IR and 
Aph treatment. As expected after Aph treatment all cell lines activated Chk1 
strongly (as assessed by phosphorylation on S345) with maintenance of the signal 
for up to 16hrs post treatment (Figure 5.7A-K). After IR treatment all the G2/M 
checkpoint proficient cell lines activated Chk1 strongly with maintenance of the 
signal for up to 16hrs post treatment (Figure 5.3A-G). Cell lines with variable 
G2/M checkpoint proficiency displayed variations in their Chk1 activation 
patterns. In cell lines WM793 and Sk-Mel-37 (Figure 5.4B and D respectively) it 
was observed that there is a sharp increase in pChk1 levels however this is only 
seen at one time point for each cell line, after 6hrs IR treatment in WM793 cells 
and after 1hr IR treatment in Sk-Mel-37 cells and is not maintained at any other 
times. This pattern suggests that the upstream signal for Chk1 activation after 
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DNA DSBs may be short lived or that Chk1 itself is ‘turned off’ rapidly. This could 
possibly be through the action of phosphatases, both PP1 and PP2A phosphatases 
have been shown to inactivate Chk1 following DNA damage (Elzen & O’Connell, 
2004; Leung-Pineda et al, 2006). This suggests a potential mechanism for the 
loss of signalling after IR-induced damage compared to DNA replicative stress as, 
replicative stress directly activates ATR/Chk1 by generation of ssDNA tracts 
whereas DSBs require resection by the MRN complex before ATR/Chk1 can be 
activated. In cell lines A357MM and Sk-Mel-28 (Figure 5.4A and C) there is an 
increase in pChk1 S345 levels 10mins after IR treatment which is maintained for 
6hrs post treatment. This pattern of activation is similar to that seen in the 
G2/M proficient cell lines. This pattern suggests that the upstream activation of 
Chk1 is efficient however the signal is not appropriately transmitted downstream 
of Chk1. The targets of Chk1 in the S/M and G2/M checkpoint are thought to be 
the same therefore how cells are able to distinguish between the two signals in 
order to maintain a functional S/M checkpoint with variable G2/M checkpoint 
proficiency is unclear. One possibility is that cells may be able to distinguish 
between the two signals due to the cell cycle phase at which the signal is 
initiated. In S-phase cells the levels of cyclin B are quite low whereas in G2-
phase cells the levels of cyclin B are high. The key way in which Chk1 activity 
works to regulate mitotic entry is to regulate the CDK1/cyclin B1 complex. 
Therefore Chk1 activity may need to be higher in G2 phase cells in order to 
prevent mitotic entry than in S-phase cells. Together this data shows that partial 
or complete loss of G2/M checkpoint function but not S/M checkpoint function 
can be seen in a sub-set of melanoma cells and may present a functional 
mechanism in melanoma for the accumulation of genetic instability and 
malignant progression.  A recent study of genome wide susceptibility loci in 
melanoma showed mutations in ATM as a common event (Barrett et al, 2011). 
Loss of checkpoint function as a contributory factor in malignant transition is an 
already well documented phenotype. Loss or mutation of p53 is a common event 
in cancer cells and is thought to occur in up to 50% of all cancers, although this 
is a less common occurrence in melanoma.  One consequence of the mutation or 
loss of p53 signalling is the loss of the G1/S checkpoint. 
 
When examining the importance of MRN complex signalling in activation of 
ATR/Chk1 after IR-induced DNA DSBs I was able to observe that cell lines which 
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possessed Mre11, Nbs1 and Rad50 were able to phosphorylate both Chk2 and 
Chk1 after IR. In contrast cell lines which lacked the Mre11 and Nbs1 
components of the MRN complex were still able to phosphorylate Chk1 but had 
lost their ability to activate Chk2 (Sk-Mel-39 and Sk-Mel-103, Figure 5.3C and E 
respectively). This loss of Chk2 activation is consistent with studies which have 
shown that the MRN complex is essential for activation of ATM/Chk2 (Takemura 
et al, 2006). However the situation with Chk1 is less clear. In my experiments I 
have shown that Chk1 activation is still able to occur after IR despite that lack of 
the MRN complex, this is in direct opposition to studies which have shown that 
Mre11 nuclease activity is critical for efficient ATR/Chk1 signalling via 
generation of RPA-coated ssDNA that is needed for ATR recruitment and 
activation (Jazayeri et al, 2005; Limbo et al, 2011). However by adding back 
Mre11 by transient transfection into these cell lines (Sk-Mel-39 and Sk-Mel-103, 
Figure 5.11A and B respectively) I was able to show that the addition of Mre11 
and presumed activation of the MRN complex was able to enhance the activation 
of Chk1 after IR, especially at later time points (6hrs). This is consistent with 
other recent studies that have shown that although the initial activation of Chk1 
is not dependant on MRN complex signalling it does play a role in the 
maintenance of Chk1 activation after IR-induced DNA damage (Buis et al, 2008; 
Kousholt et al, 2012; Sartori et al, 2007). It is interesting to note that mutations 
in Mre11 are the hallmark of the radiosensitive ataxia-telangiectasia-like 
disorder (Delia et al, 2004) and are commonly associated with mismatch-repair 
deficient cancers such as colon, breast and haematological (Giannini et al, 
2002). Mre11 mutant cancers show supressed responses to replicative stress 
coupled with disruption of replication forks (Wen et al, 2008), possibly 
demonstrating a connection between MRN complex signalling and Chk1 
signalling, which has been shown to be important during S-phase of unperturbed 
cells and in the maintenance of stalled replication forks during perturbed S-
phase. Furthermore recent studies have highlighted the importance of MRN 
complex signalling and Chk1. The Mre11 nuclease has been shown to be critical 
for the sensitivity of cells to Chk1 inhibition, with Mre11-deficient ATLD1 cells 
being highly resistant to Chk1 inhibition. It was shown that Mre11 is required for 
the appearance of both ssDNA and DNA DSBs following Chk1 inhibition, with 
inhibition or lack of Mre11 protein preventing the appearance of these DNA 
lesions following treatment with a Chk1 inhibitor (Thompson et al, 2012). 
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6 Chk1 Inhibition as a therapeutic strategy 
6.1 Introduction 
The treatment of cancer is beginning to focus on more personalised therapies 
targeting specific genetic alterations present in tumours, for instance 
Vemurafenib and Dabrafenib, two B-Raf (V600E) inhibitors currently being 
trialled in the treatment of melanoma (Hauschild et al, 2012; Ravnan & Matalka, 
2012). However the standard treatment strategy for most cancers still focuses on 
the use of genotoxic agents (which cause severe DNA damage) such as radiation 
therapy and chemotherapeutics which will activate cellular DNA damage 
responses. As a result, in recent years much interest has focused on whether 
manipulating these responses could be useful for therapy (Basu et al, 2012). In 
particular Chk1 has appeared as a potential target for drug development as it is 
known to be a key effector in multiple cell cycle checkpoint responses triggered 
by both DNA damage and replication stress. Initially Chk1 inhibitors were trialled 
in combination with standard genotoxic agents to determine whether there was 
a synergistic effect on cell killing (Dent et al, 2011; Hotte et al, 2006; Ma et al, 
2012; Xu et al, 2011; Zhang et al, 2009) and more recently in combination with 
other inhibitors which target important cell cycle proteins such as Wee1 (Aarts 
et al, 2012; Carrassa et al, 2012). However more recent studies have also shown 
that Chk1 inhibitors may have potential as single agents in some cancer types 
(Brooks et al, 2012; Davies et al, 2011a; Ferrao et al, 2012). Therefore I 
examined the effect of a specific allosteric inhibitor of Chk1 (CHIR-124) on a 
sub-set of metastatic melanoma cell lines from the previously mentioned panel 
(Table 6.1) to determine the potential benefit as a single agent treatment in 
melanoma.  
 
6.2 The Chk1 inhibitor CHIR-124 
CHIR-124 is a quinolone-based small molecule that is structurally unrelated to 
other known inhibitors of Chk1. CHIR-124 was generated by the Chiron 
Corporation and has been shown to be a potent and selective inhibitor of Chk1 
with an IC50 of 0.32nM compared to 697nM for Chk2 (Ni et al, 2006). It has also 
been shown to have 500-fold, 5000-fold and 1500-fold selectively of Chk1 over 
cdk2/cyclin A, cdk4/cyclin D and cdk1/cyclin B complexes respectively. Its basic 
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structure is a ABIQ (4-(aminoalkylamino)-3-benzimidazole-quinolin-one) scaffold 
(Figure 6.1A) which binds to the hinge region of the ATP binding pocket of Chk1 
forming hydrogen bonds with the Glu85 and Cys87 residues. Its specificity over 
other related kinases is determined by the charge-charge interactions between 
the tertiary amine of the inhibitor and residues Glu91 and Glu134 (Figure 6.1B).  
In studies CHIR-124 has been shown to synergise with a number of known 
cytotoxic agents including with topoisomerase inhibitors in MDA-MB-435 breast 
cancer cells (Tse et al, 2007) and increasing radio-sensitivity in HCT 116 cells 
especially in a p53 null background (Tao et al, 2009). In more recent studies 
CHIR-124 has been shown to increase the sensitivity to cell death induced by 
histone deacetylase inhibitors, which is associated with extensive mitotic 
disruption (Lee J et al, 2011), and to enhance the sensitivity to gemcitabine in a 
multicellular tumour spheroid model of pancreatic cancer (Dufau et al, 2012). 
 
Figure 6.1: CHIR-124 structural interactions. (A) Chemical structure of CHIR-124. (B) X-ray co-
crystal structure of CHIR-124 bound to Chk1.  
 
6.3 CHIR-124 inhibits the G2/M checkpoint function of 
Chk1 in melanoma cells 
The G2/M checkpoint is assayed using a flow cytometry techniques described 
previously in Chapter 3.3. Checkpoint proficient cells will display an 
accumulation in the G2/M peak but with diminished pH3 staining after 
irradiation treatment (IR). The cells are also treated with Nocodozole (Noc), a 
spindle poison, which blocks the cells in mitosis and acts as a positive control for 
the accumulation of pH3-positive mitotic cells in undamaged cultures.  
In the Sk-Mel-2 melanoma cell line we can see that after treatment with CHIR-
124 [500nM] for 8hrs prior to IR the cells were subsequently unable to arrest in 
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G2-phase, compared to the IR + Noc treated alone, and progressed into mitosis 
as assessed by pH3 staining. This indicates that inhibition of Chk1 by CHIR-124 is 
able to over-ride the DNA damage-induced G2/M checkpoint (Figure 6.2A). 
Quantification of the pH3 accumulation in the CHIR-124+ IR+ Noc and IR+ Noc 
samples are compared as a percentage of the Noc only treated (taken as 100%) 
(Figure 6.2B) also demonstrates that in the presence of CHIR-124 the cells are no 
longer able to block in G2 efficiently and continue cycling into mitosis (as 
indicated by black star in Figure 6.2B).  It should be noted that treatment with 
CHIR-124 itself does not decrease the accumulation of the cells into mitosis as 
seen in the control whereby cells are treated with CHIR-124 [500nM] 8hrs prior 
to Noc only treatment. 
  
Downstream targets of Chk1 include activation of the Wee1 kinase, which 
imposes inhibitory phosphorylation on CDK1, and inhibition of CDC25C 
phosphatases, which reverse this modification (O’Connell et al, 1997; Peng et al, 
1997; Rhind et al, 1997; Sanchez et al, 1997). Analysis of signalling downstream 
of Chk1 by WB (Figure 6.2C) shows that treatment with CHIR-124 supresses both 
the inhibitory phosphorylation of CDK1 and the activating phosphorylation of 
CDC25C (S216) both alone and after IR treatment. It is interesting to note that 
CHIR-124 treatment leads to induction of Chk1 phosphorylation at S345 to a 
greater extent even than IR treatment. This data shows that CHIR-124 
effectively inhibits Chk1 signalling in melanoma cell lines. 
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Figure 6.2: CHIR-124 inhibition of G2/M checkpoint function in Sk-Mel-2 melanoma cell line. 
(A) G2/M checkpoint assay. Cells were treated for 8hrs with [1µM] CHIR-124, and then treated with 
Noc with or without 10Gy γIR. The number of mitotic cells (pH3 positive) after 24hrs was assessed 
by flow cytometry. Dot plots and DNA histograms are shown. (B) Quantification of the number of 
mitotic cells taken as a percentage of Noc only treated, n=1. White star represents G2/M 
checkpoint activation. Black star represents inhibition of checkpoint in the presence of CHIR-124. 
(C) Western blot analysis of Chk1 activation and downstream signalling. Antibodies against pChk1 
S345, pCdk1 T14/Y15 and pCdc25C S216 were used. An equal quantity of protein was loaded as 
determined by Bradford Assay and confirmed by antibody against actin.  
 
6.4 Chk1 Inhibition causes apoptotic cell death 
Cellular death by apoptosis is assayed using a flow cytometry technique whereby 
living cells are double labelled for Annexin V and PI. Annexin V is used as a probe 
to detect expression of phosphatidylserine (PS) on the surface of cells, an event 
which occurs during programmed cell death. PI stains DNA; in live cells with an 
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intact membrane PI is unable to enter and bind to the DNA, however in 
apoptotic cells where the cell membrane integrity is compromised PI can bind to 
exposed DNA. Cells are analysed for staining with both markers, whereby 
staining with Annexin V represents early apoptosis and double Annexin V: PI 
staining represents late apoptosis.  
 
In a set of metastatic melanoma cell lines we can see that after continual 
treatment with 1µM CHIR-124 cells become firstly Annexin V positive (24hrs) and 
then progress to Annexin V: PI positive (48hrs) in a time dependent manner 
(Figure 6.3A, B, C, D, F and G respectively) This phenotype is exacerbated with 
10µM CHIR-124 treatment. In the Sk-Mel-39 cell line there is no detectable level 
of Annexin V positivity with the cells becoming single PI positive after both 24hrs 
and 48hrs with both 1µM and 10µM CHIR-124 treatment. This phenotype is also 
seen in the staurosporine (Sts) treated Sk-Mel-5, Sk-Mel-28 and Sk-Mel-39 cells 
(Figure 6.3C, D and E respectively) and may represent a cell type-specific 
variation in the mechanism of cell death. When we quantify the percentage of 
double positive cells (Figure 6.3H) we can see that in most cells lines there is a 
small increase of 5-20% after 24hrs of treatment which increases further to 25%-
60% after 48hrs with 1µM CHIR-124 treatment. This is exacerbated by 10µM CHIR-
124 treatment, with the percentage of double positive cells ranging from 25-90% 
after 24hrs of treatment which increases further to 80%-100% after 48hrs. The 
phenotype is slightly different in the Sk-Mel-5 cell line where with both 1µM and 
10µM treatment there is no increase in double positive cells between 24hrs and 
48hrs.  
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Figure 6.3: Characterisation of Annexin-V and PI staining in CHIR-124 treated metastatic 
melanoma cells. (A-G) Melanoma cells lines A375MM, Sk-Mel-2, Sk-Mel-5, Sk-Mel-28, Sk-Mel-39, 
Sk-Mel-103 and Sk-Mel-147 respectively were treated with [1µM] and [10µM] CHIR-124. Cells 
were harvested after 24hrs and 48hrs and analysed for Annexin-V and PI labelling. Cells were 
treated with [1µM] staurosporine (Sts) for 16hrs as a positive control. Dot plots are shown, n=1. (H) 
Quantification of the number of double positive Annexin-V: PI labelled cells after CHIR-124 
treatment in each cell line. 
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This data shows that metastatic melanoma cell lines are highly sensitive to 
inhibition of Chk1 with CHIR-124 resulting in a high percentage of cell death 
after 48hrs treatment. Cell death is attributable to apoptosis as indicated by 
positive staining for Annexin V, except in cell line Sk-Mel-39 where cells become 
single PI positive therefore losing their membrane integrity without translocation 
of PS to the outer membrane.  
 
To further confirm that cell death upon Chk1 inhibition occurs by apoptosis, 
protein extracts of cell lines were analysed by WB for cleavage of PARP. PARP is 
a nuclear protein that participates in DNA damage detection and repair, 
however during apoptosis the protein is cleaved by caspase-3 and caspase-7 
(Duriez et al, 1997; Germain et al, 1999). This cleavage efficiently stops the 
ability of PARP to participate in DNA repair and contributes to the cell fate of 
apoptosis. Analysis of PARP cleavage shows that in cell lines A375MM and Sk-Mel-
2 there is clear cleavage of PARP after treatment with 1µM CHIR-124 (Figure 
6.4A and B respectively). In A375MM cells the cleavage is detectable at 6hrs 
post-treatment whereas in Sk-Mel-2 cells the cleavage is already detectable at 
3hrs post-treatment with a further increase seen at 6hrs. In cell lines Sk-Mel-5 
and Sk-Mel-28 there may be a small detectable level of PARP cleavage at 6hrs 
post treatment with 1µM CHIR-124 (Figure 6.4C and D respectively). In all other 
cells lines which became Annexin V: PI positive within 48hrs of treatment with 
1µM CHIR-124 there is no detectable cleavage of PARP with 1µM CHIR-124 at 
either 3hrs or 6hrs post treatment. This may be a cell type specific response 
with cleavage of PARP happening at later time points in these cells. However if a 
higher concentration of CHIR-124 is used, 10µM we can see that all cell lines 
which become Annexin V: PI positive have cleavage of PARP at both 3hrs and 
6hrs post- treatment with a time dependant increase (Figure 6.4A-D, F and G). In 
cell line SK-Mel-39 which does not become Annexin V positive after either Sts or 
CHIR-124 treatment we can see that there is also no cleavage of PARP seen with 
either drug at any concentration. This suggests that the cell line SK-Mel-39 does 
not undergo apoptosis but instead may die by necrosis. Collectively this data 
shows that most metastatic melanoma cell lines are highly sensitive to Chk1 
inhibition alone and undergo apoptotic cell death as seen by cleavage of PARP at 
early time points (3-6hrs) followed by Annexin V and PI positivity at later time 
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points (24-48hrs), however the data also shows that there are variations in the 
response with some cell lines showing cleavage of PARP sooner than others and a 
range of  25%-60% double Annexin V: PI positivity after 48hrs treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Western blot analysis of PARP cleavage and Chk1 activation in CHIR-124 treated 
metastatic melanoma cells. (A-G) Melanoma cells lines A375MM, Sk-Mel-2, Sk-Mel-5, Sk-Mel-
28, Sk-Mel-39, Sk-Mel-103 and Sk-Mel-147 respectively were treated with [1µM] and [10µM] CHIR-
124 for 3hrs and 6hrs. Cells were treated with [1µM] staurosporine (Sts) for 3hrs as a positive 
control. Antibodies against PARP (full length and cleaved forms) and pChk1 (S345) were used. An 
equal quantity of protein was loaded as determined by Bradford Assay and confirmed by antibody 
against actin.  
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6.5 Chk1 inhibition causes generation of DNA damage 
specifically in S-phase cells with blockage of cells in 
S-phase 
During S-phase of the cell cycle DNA replication occurs thus allowing the specific 
labelling of S-phase cells using nucleoside analogs which become incorporated 
into the DNA. Examples include 5-bromo-2’-deoxyuridine (BrdU) and 5-ethynyl-
2’-deoxyuridine (EdU) which are both synthetic analogs of thymidine.  BrdU can 
be visualised using anti-BrdU antibodies whereas EdU can be visualised using a 
click-reaction (Figure 6.5), whereby a copper (I) catalysed reaction occurs 
between an azide and an alkyne. The alkyne is contained within the EdU 
molecule which reacts with an azide conjugated to a detection reagent to form 
a stable triazole ring.  
 
Figure 6.5: Incorporation and detection of EdU. (EdU) is incorporated into the DNA as a 
thymidine analog. EdU is visualised using a copper (I) catalysed click-reaction which occurs 
between a fluorescently conjugated azide and incorporated EdU.  
 
In order to analyse if treatment with CHIR-124 causes the generation of DNA 
damage before inducing apoptosis I treated cell lines A375MM and Sk-Mel-2, 
which were the most sensitive to CHIR-124 in terms of their cleavage of PARP, 
with EdU in combination with 1µM CHIR-124 for 1hr and analysed cells by IF. The 
appearance of DNA damage, as marked by γH2AX following treatment with 1µM 
CHIR-124 was only seen in EdU+ (S-phase) cells in both A375MM (Figure 6.6A) and 
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Sk-Mel-2 (Figure 6.7A) cells, whereas treatment with etoposide, an anti-cancer 
DNA damaging agent, induced DNA damage in all cells regardless of their EdU 
status. When the intensity of the γH2AX signal was quantified in both EdU+ and 
EdU- cell populations we can see that the intensity of the γH2AX signal is not 
only specific to EdU+ cells after CHIR-124 treatment but also that the intensity is 
half of that seen in the etoposide treated cells (which show no selectivity for 
EdU+/ EdU-) in both A375MM (Figure 6.6B) and Sk-Mel-2 (Figure 6.7B) cells. This 
suggests that less DNA damage is generated with CHIR-124 treatment than with 
etoposide, at least with this relatively short time frame. In the EdU- cells 
treated with CHIR-124 the γH2AX signal is equivalent to that of untreated cells 
(both EdU+ and EdU- cell populations). 
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Figure 6.6: Characterisation of DNA damage induction with CHIR-124. (A) 
Immunofluorescence (IF) microscopy of A375MM cells. Cells were grown on glass coverslips then 
treated simultaneously with EdU to label proliferating cells and [1µM] CHIR-124 for 1hr. Cells were 
treated with [5µM] etoposide as a positive control. Cells were labelled for EdU and γH2AX and 
mounted in vectashield containing dapi. Cells were examined by confocal fluorescence 
microscopy. (B) Quantification of the intensity of γH2AX labelling in both EdU positive (S-phase 
cells) and EdU negative cells. IF images were quantified using arbitrary units for fluorescence 
intensity. 
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Figure 6.7: Characterisation of DNA damage induction with CHIR-124. (A) 
Immunofluorescence (IF) microscopy of Sk-Mel-2 cells. Cells were grown on glass coverslips then 
treated simultaneously with EdU to label proliferating cells and [1µM] CHIR-124 for 1hr. Cells were 
treated with [5µM] etoposide as a positive control. Cells were labelled for EdU and γH2AX and 
mounted in vectashield containing dapi. Cells were examined by confocal fluorescence 
microscopy. (B) Quantification of the intensity of γH2AX labelling in both EdU positive (S-phase 
cells) and EdU negative cells. IF images were quantified using arbitrary units for fluorescence 
intensity. 
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Due to the observation that CHIR-124 specifically generated DNA damage in S-
phase cells we analysed the cell cycle profile of these cells using flow 
cytometry.  BrdU incorporation after a 1hr pulse is used as a marker of S-phase 
cells giving an arc of positive cells ranging between the negative G1 and G2/M 
populations. To assess how Chk1 inhibition is affecting the cell cycle 
distribution, BrdU positive cells were gated into early S-phase and late S-phase 
populations.  
  
At low concentrations of CHIR-124 (100nM) treated for 24hrs there is an initial 
increase in the percentage of cells in late S-phase (6%) with no change in the 
early S-phase population. This is possibly due to the slowing of cells through S-
phase in the presence of Chk1 inhibition, causing a small number of cells to 
persist in S-phase for longer than normal. However with increasing 
concentrations of CHIR-124 (200nM to 1µM) we can observe that there is a dose-
dependent increase in the percentage of cells in early S-phase with a concurrent 
decrease in late S-phase cells. This suggests that in the presence of CHIR-124 the 
cells are still able to initiate DNA replication however inhibition of Chk1 
prevents them from progressing normally resulting in a build of cells in early S-
phase (Figure 6.8). 
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Figure 6.8: Analysis of S-phase progression during CHIR-124 treatment. (A-B) Assessment of 
BrdU incorporation as a marker of S-phase cells in A375MM and Sk-Mel-2 cell lines respectively. 
Cells were treated with a range of concentrations of CHIR-124 from 100nM to 1µM for 24hrs. 
During the last hour of treatment cells were treated with BrdU to label S-phase cells. Early and late 
S-phase populations are marked as dark blue and pink respectively. Dot plots and DNA histograms 
are shown. (C) Quantification of the percentage of total cells which incorporated BrdU.  
 
This observation is suggestive of the distinct role that Chk1 plays during an 
unperturbed cell cycle in comparison to its role during a perturbed cell cycle. 
This data suggests that upon Chk1 inhibition in unperturbed cells there is a 
blockage of cells in early S-phase. Studies have shown that Chk1 is important in 
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replication initiation and replication fork stability during an unperturbed cell 
cycle (Feijoo et al, 2001; Paulsen & Cimprich, 2007; Petermann & Caldecott, 
2006; Petermann et al, 2006; Petermann et al, 2010). Thus inhibition of Chk1 in 
this situation may cause collapse of replication forks resulting in the S-phase 
blockage seen. During a perturbed cell cycle where DNA replication is inhibited 
with Aphidicolin which causes acute stalling of replication forks directly, there is 
activation of the S/M checkpoint. The S/M checkpoint is mediated via activation 
of Chk1 in order to prevent collapse of these replication forks and ultimately 
prevent cells from entering mitosis in the presence of DNA which is not fully 
replicated.  The cells will block in S phase of the cell cycle until the DNA is 
properly replicated or they are targeted for cell death (apoptosis). This S-phase 
blockage is phenotypically similar but functionally distinct to that seen with 
Chk1 inhibition. 
6.6 Chk1 inhibition causes replication fork collapse 
Replication forks are dynamic structures which are formed during DNA 
replication whereby the DNA double helix is unwound by helicases to form two 
single strands of DNA which act as templates for DNA synthesis (Chagin et al, 
2010). Chk1 has been shown be important during S-phase of unperturbed cell 
cycles, where it has functions in both the initiation of replication and stability of 
replication forks (Feijoo et al, 2001; Paulsen & Cimprich, 2007; Petermann & 
Caldecott, 2006; Petermann et al, 2006; Petermann et al, 2010).  Therefore I 
assessed replication fork stability in the presence of CHIR-124 in cell lines 
A375MM and Sk-Mel-2 to determine if the inhibition of Chk1 in these cells is 
affecting DNA synthesis, and whether this could be the source of DNA damage in 
Chk1 inhibited cells. Replication fork stability was assessed using a double EdU/ 
BrdU pulse assay and flow cytometry. In control cells (Figure 6.9A-B) we can see 
that incubation with EdU for 1hr or BrdU for 1hr can be selectively detected 
using different fluorophores. In double EdU/BrdU incubated cells, were cells 
were incubated with EdU for 1hr and then BrdU for a subsequent 1hr, we can 
detect four distinct populations of cells. Double negative cells in green represent 
cells which were not in S-phase during the total incubation time. Single EdU 
positive cells in dark blue represent cells which were in S-phase with active 
replication forks during the first incubation but had finished or collapsed before 
the second incubation. Single BrdU positive cells in pink represent cells which 
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had entered S-phase during the second incubation. Double EdU/BrdU positive 
cells in light blue represents cells which were in S-phase with active replication 
forks during both incubation periods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Dual pulse-labelling of proliferating melanoma cells. A375MM cells were treated 
with either EdU or BrdU for 1hr, or sequentially with EdU for 1hr followed by BrdU for 1hr to label 
proliferating S-phase cells. EdU labelled cells are visualised using a click-it reaction. BrdU labelled 
cells are visualised using an antibody which does not cross react with EdU. EdU and BrdU 
incorporation was assessed by flow cytometry. Dark blue represents EdU positive cells, pink 
represent BrdU positive cells and light blue represents double EdU and BrdU positive cells. Dot 
plots are shown; single dot plots (A) show EdU and BrdU labelling on separate plots, double dot 
plots (B) show EdU and BrdU labelling on the same plot.  
 
In order to analyse the effect of Chk1 inhibition on the stability of replication 
forks cells were pre-labelled with EdU for 1hr in order to label active replication 
forks, EdU was then removed and the cells were incubated with 20µM aphidicolin 
alone or in combination with 1µM CHIR-124 for 1-4hrs. Cells were then 
subsequently released from aphidicolin arrest and pulse-labelled with BrdU for 
1hr (Figure 6.10A). Aphidicolin is a reversible inhibitor of DNA polymerase which 
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stalls active replication forks. In this assay double labelling identifies replication 
forks which were active prior to the addition of aphidicolin and which remained 
capable of resuming replication after the period of arrest. Single EdU and BrdU 
labelling identifies replication forks which were active prior to the addition of 
aphidicolin but that subsequently collapsed during the period of arrest and 
replication forks which became active during the period of arrest with 
aphidicolin respectively.  
 
In both A375MM and Sk-Mel-2 cell lines there is a relative increase in the EdU+ 
population in the presence of CHIR-124 compared to aphidicolin treated alone 
for 4hrs (Figure 6.10B). In A375MM cells this increase in the EdU+ population is 
evident at all time-points treated with CHIR-124 (1-4hrs) however in cell line Sk-
Mel-2 it is not visible until later time-points (3-4hrs). There is a concurrent 
decrease in the double EdU+/BrdU+ populations and BrdU+ populations. 
Quantification of the percentages of each population shows that in A375MM cells 
there is a time-dependant increase/ decrease in the respective populations; the 
EdU+ population increases from 28% to 65% (2.3-fold increase), the EdU+/BrdU+ 
population decreases from 40% to 17% (2.4-fold decrease) and the BrdU+ 
population decreases from 3% to 1.9% (1.6-fold decrease)(Figure 6.10Ci).  
Quantification of the percentages of each population in Sk-Mel-2 cells also show 
there is a time-dependant increase/ decrease in respective populations; the 
EdU+ population increases from 18% to 35% (1.9-fold increase), the EdU+/BrdU+ 
population decreases from 40% to 23% (1.7-fold decrease) and the BrdU+ 
population decreases from 4% to 1% (4-fold decrease) (Figure 6.10Cii). 
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Figure 6.10: Loss of replication fork viability in CHIR-124 treated cells during replication 
arrest. (A) Experimental protocol (see text for details). Cells were pre-labelled with EdU, then 
pulse-labelled with BrdU following 1-4hrs treatment with Aphidicolin with or without CHIR-124. (B) 
Double pulse labelling. A375MM and Sk-Mel-2 treated cells were assessed for EdU and BrdU 
incorporation by flow cytometry after treatment with aphidicolin to arrest replication with or without 
CHIR-124. Dot plots are shown where green represents no incorporation; dark blue represents 
EdU positive cells, pink represent BrdU positive cells and light blue represents double EdU and 
BrdU positive cells. (C) Quantification of the number of EdU+, BrdU+ and EdU/BrdU+ cells in the 
presence of aphidicolin plus CHIR-124 over 1-4hrs.  
 
This data shows that the effect of Chk1 inhibition on EdU+/BrdU+ labelling, 
which represents replication forks which were active prior to the addition of 
aphidicolin and which resumed replication after the period of arrest, is 
decreased compared to aphidicolin arrested cells. In contrast EdU+ labelling, 
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which represents replication forks that were previously active but became 
incapable of resuming replication, is increased. These observations suggest that 
active Chk1 is required to maintain the viability of stalled replication forks in 
these melanoma cell lines. Replication fork collapse may represent a mechanism 
by which DNA damage is generated as a consequence of Chk1 inhibition. This is 
consistent with recent studies which have revealed that the activities of Chk1 
are required during normal S-phase to avoid deleterious DNA breakage (Beck et 
al, 2010; Lam et al, 2004; Syljuasen et al, 2005), and that inhibition of Chk1 or 
siRNA knockdown of Chk1 causes rapid destabilisation of the genome associated 
with massive amounts of DNA DSBs (Syljuasen et al, 2005). It has also recently 
been shown that loss of Chk1 leads to increased CDK activity resulting in loss of 
control of replication co-ordination (Beck et al, 2010). 
 .  
6.7 Chk1 inhibition exhibits single agent toxicity against 
melanoma cell lines in vitro and xenografts in vivo 
In recent years the treatment of advanced melanoma has begun to focus on 
targeted therapies, for instance Vemurafenib and Dabrafenib are two B-Raf 
(V600E) inhibitors currently being trialled in the treatment of melanoma 
(Hauschild et al, 2012; Ravnan & Matalka, 2012). However the standard single 
agent chemotherapeutic treatment of advanced melanoma is still focused on the 
use of dacarbazine (DTIC), a DNA alkylating agent. DTIC was the first FDA 
approved chemotherapeutic agent for the treatment of metastatic melanoma in 
1975. DTIC has an overall response rate of 15-25% with median response 
durations of 5–6 months, but less than 5% of complete response (Comis et al, 
1976; Hill et al, 1979). The related agent, temozolomide (TMZ), an orally 
available analog of DTIC, has also demonstrated efficacy in the treatment of 
advanced melanoma with overall response rate of 14% (Bleehen et al, 1995; 
Middleton et al, 2000; Newlands et al, 1992). However advanced melanoma still 
remains one of the most treatment-refractory cancers. 
  
Owing to my previous observations in which Chk1 inhibition in human melanoma 
cell lines lead to DNA damage, replication fork collapse and apoptosis, I tested 
the in vitro efficacy of CHIR-124 as a single agent treatment for killing 
metastatic melanoma cell lines. In order to evaluate the cytotoxic effect, cells 
were seeded in a 96-well plate format. After 24hrs cells were treated with CHIR-
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124, DTIC or TMZ for 72hrs; CHIR-124 treatment 0 -100µM, DTIC/TMZ treatment 
0-1mM in a 12-step 1:3 dilution range in triplicate. After 72hrs incubation alamar 
blue was added to the cells for 1-4hrs. Alamar blue is a cell viability indicator 
which contains resazurin, a non-fluorescent compound. Within metabolically 
active cells resazurin is reduced to resorufin, a red-fluorescent compound which 
can be quantified by absorbance at 570nm and 600nm (Figure 6.11). The amount 
of fluorescence produced is proportional to the number of living cells in each 
well.  Dose-response curves were generated to calculate the half maximal 
effective concentration (EC50) of each agent which gives a measure of drug 
potency. Cells treated with vehicle alone were used as a positive control (red 
colour) whereas empty wells were used as a negative control (blue colour), as 
can be seen in the bottom two rows respectively of the example plate shown in 
figure 6.11. 
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Figure 6.11: Analysis of cell viability by Alamar Blue. Experimental protocol. Cells were 
cultivated in 96 well plates (2000 cells/well) and treated with drug compounds for 72hrs. Addition of 
alamar blue (1:10 dilution) assessed the number of metabolically active cells by a reduction 
reaction which produces the red fluorescent compound resorufin. Pink= reducing environment, 
Blue= non-reducing environment, where amount of reduction is proportional to the number of viable 
cells in each well.  
 
Dose-response curves for each individual cell line show that in all metastatic 
melanoma cell lines tested A375MM, Sk-Mel-2, SK-Mel-5, Sk-Mel-28, Sk-Mel-39, 
Sk-Mel-103 and Sk-Mel-147 (Figure 6.12A-G respectively) CHIR-124 is more toxic 
as a single agent than either DTIC or TMZ alone, as can be seen by the red curve 
in each graph which is shifted to the left in respect of both the blue (TMZ) and 
green (DTIC) curves. In addition the dose-response curves for DTIC and TMZ are 
similar to each other in each respective cell lines showing that the potency of 
DTIC and TMZ in each cell line is similar. However they differ from one cell line 
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to the other showing cell line specific variations in sensitivity. Although CHIR-124 
is more potent as a single agent than either DTIC or TMZ when dose-response 
curves for CHIR-124 treatment were plotted on the same axis it was observed 
that there was a large range of sensitivity to CHIR-124. Two distinct groups of 
cell lines are apparent with CHIR-124 showing less potency in cell lines Sk-Mel-5, 
Sk-Mel-28 and Sk-Mel-39 (Figure 6.13 green, blue and purple lines respectively) 
than cell lines A375MM, Sk-Mel-2, Sk-Mel-103 and Sk-Mel-147 (Figure 6.13 red, 
orange, pink and grey lines respectively) which appeared more sensitive to the 
cytotoxic effects of CHIR-124. Interestingly the most sensitive cell lines are all 
N-Ras mutant (except A375MM) whereas the less sensitive cell lines are all B-Raf 
mutant.  EC50 values were calculated using a non-linear regression dose response 
curve with variable slope analysis in graph-pad prism software. Melanoma cell 
lines have a large variation in their calculated EC50 values ranging from the low 
nano-molar range (71.6 ± 11.9 nM) in Sk-Mel-147 cells to micro-molar range 
(19.186 ±3.326 µM) in Sk-Mel-28 cells (Table 6.1). 
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Figure 6.12: Drug-dose response curves for Dacarbazine, Temozolomide and CHIR-124 in 
metastatic melanoma cell lines. (A-G) Cell viability for cell lines A375MM, Sk-Mel-2, Sk-Mel-5, 
Sk-Mel-28, Sk-Mel-39, Sk-Mel-103 and Sk-Mel-147 respectively were assessed over a range of 
drug concentrations for DTIC (max 1mM), TMZ (max 1mM) and CHIR-124 (max 100µM). Dose-
response curves were generated using absorbance measurements taken at 570nm and 600nm. 
Graphpad prism software was used to plot survival curves on a logarithmic scale. 
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Figure 6.13: Drug-dose response curves for CHIR-124 treatment in metastatic melanoma cell 
lines. Cell viability for cell lines A375MM, Sk-Mel-2, Sk-Mel-5, Sk-Mel-28, Sk-Mel-39, Sk-Mel-103 
and Sk-Mel-147 respectively were assessed over a range of concentrations for CHIR-124 (max 
100µM). Dose-response curves were generated using absorbance measurements taken at 570nm 
and 600nm. Graphpad prism software was used to plot survival curves on a logarithmic scale and 
to calculate EC50 values. 
 
 
 CHIR-124 
EC50 (nM) 
A375MM 341 ± 71.8 
Sk-Mel-2 653 ± 71.5 
Sk-Mel-5 12971 ± ? 
Sk-Mel-28 19186 ± 3326 
Sk-Mel-39 7406 ± 1495 
Sk-Mel-103 189 ± 27.7 
Sk-Mel-147 71.6 ± 11.9 
Table 6.1: Table 6.1: EC50 values for CHIR-124 in metastatic melanoma cell line 
   
 
  
The previous data demonstrates that Chk1 inhibition by CHIR-124 has anti-
proliferative activity in vitro in a number of metastatic melanoma cell lines, 
associated with an apoptotic cell death. To evaluate if CHIR-124 has potential as 
a single agent treatment in advanced melanoma, with toxicity greater than that 
of standard chemotherapeutic approaches I utilised a tumour xenograft model of 
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melanoma.  In order to assess in vivo potential melanoma cells (A375MM) were 
grown in culture until they were in a logarithmic phase of growth (70-80% 
confluent). Cells were then harvested and injected subcutaneously to the lower 
right flank of 6 week old female CD1 nudes at a concentration of 1 x 106 cells 
per mouse. Five days after injection 32 mice were randomised into the following 
treatment groups: vehicle alone (14 mice), twice daily dosing of CHIR-124 at 
20mg/kg for 6 consecutive days (9 mice) or twice daily dosing of DTIC at 
20mg/kg for 3 consecutive days (9 mice).  The vehicle group was further divided 
into oral gavage (6 mice) and IP (8 mice) which were the control groups for 
CHIR-124 and DTIC treatment respectively.  
 
The rate of increase in tumour growth was analysed over time for each cohort 
with correction for the initial tumour size. Analysis of tumour growth in the 
treated cohorts (DTIC and CHIR-124) showed that both treatments slowed the 
rate of growth of the subcutaneous tumours as compared to their respective 
vehicle treated controls (Figure 6.14A and B). However this slowing of the 
growth rate was not statistically significant in either case; p=0.510128 and 
p=0.13249 for CHIR-124 vs. vehicle and DTIC vs. vehicle respectively. The trend 
in the reduction of tumour growth is quite convincing therefore the lack of 
statistical significance as calculated by the Mann-Whitney test is possibly due to 
the small sample size. Only 32 mice in total were used during the experiment 
with a significant number failing to establish a tumour at all (9/32). Furthermore 
analysis of tumour growth rate of the DTIC treated cohort compared to the CHIR-
124 treated cohort (Figure 6.15) showed that CHIR-124 slowed the rate of 
tumour growth compared to DTIC treatment which is a conventional 
chemotherapeutic treatment for melanoma, however again this was also not 
statistically significant, p=0.133632. 
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Figure 6.14: Chk1 inhibition and Dacarbazine treatment on tumour formation in A375MM 
cells in vivo. (A) Analysis of the rate of tumour growth, as assessed by the increase in tumour 
volume over time as compared to the initial tumour volume in vehicle and CHIR-124 treated 
cohorts; n=4 vehicle cohort, n=7 CHIR-124 cohort. (B) Analysis of the rate of tumour growth, as 
assessed by the increase in tumour volume over time as compared to the initial tumour volume in 
vehicle and DTIC treated cohorts; n=5 vehicle cohort, n=7 DTIC cohort. 
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Figure 6.15: Chk1 inhibition and Dacarbazine treatment on tumour formation in A375MM 
cells in vivo. Analysis of the rate of tumour growth, as assessed by the increase in tumour volume 
over time as compared to the initial tumour volume in CHIR-124  and DTIC treated cohorts; n=7 for 
both cohorts.  
 
This data shows that Chk1 inhibition by the specific allosteric inhibitor CHIR-124 
may exhibit potential as a single agent treatment in advanced melanoma, in 
particular in N-Ras mutant melanoma where it appears to be more toxic. This is 
of interest as most new current targeted therapies for melanoma are targeted to 
B-Raf mutant melanoma, for instance Vemurafenib and Dabrafenib with only one 
N-Ras inhibitor (R115777) in Phase II trials (Eggermont & Robert, 2011).  
However CHIR-124 still showed efficacy in B-Raf mutant cell lines. This is 
consistent with recent papers which have shown other Chk1 inhibitors to have 
efficacy as single agents in cancer cells (Brooks et al, 2012; Davies et al, 2011a; 
Ferrao et al, 2012). In Myc-driven lymphomas Chk1 inhibition showed single 
agent efficacy associated with high levels of endogenous replicative stress 
(Ferrao et al, 2012) with collapse of DNA replication followed by apoptosis 
(Davies et al, 2011a). In melanoma two novel inhibitors of Chk1 have been shown 
to display single agent potency, whereby they saw premature entry of late S-
phase cells into an aberrant mitosis (Brooks et al, 2012). 
 
6.8 Discussion 
The main aim of this chapter was to discover if Chk1 inhibition by the specific 
allosteric inhibitor CHIR-124 exhibits any potential as a therapeutic agent for the 
treatment of advanced metastatic melanoma. This could be of particular 
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importance as advanced metastatic melanoma has a very low survival rate, with 
a median survival of stage IV melanoma being 6-9 months with only a 15% 5-year 
survival rate (Siegel et al, 2012). Overall improvements in survival in the last 20 
years have been minimal (Pollack et al, 2011) with advanced melanoma 
remaining one of the most treatment refractory malignancies. Despite recent 
advancements with selective B-Raf inhibitors which showed an overall survival 
increase after 6 months treatment compared to DTIC, 84% vs. 64%, (Chapman et 
al, 2011) advanced melanoma is still considered incurable.  
Due to the well-established role of Chk1 in the DDR pathway in both the S/M and 
G2/M checkpoints, as well as the vital role shown during maintenance of S-phase 
in unperturbed cell cycling, many Chk1 inhibitors have been developed for 
cancer therapy. In preclinical trials inhibitors of Chk1 showed efficacy in 
combination trials, whereby they enhanced the anti-tumour activity of a number 
of anti-cancer agents including gemcitabine, irinotecan, topotecan, cisplatin, IR 
and docetaxel with several progressing to clinical phase I and II trials. Although 
initial trials focused on Chk1 inhibitors in combination therapy more recently 
Chk1 inhibitors have been shown to have single agent efficacy in some cancers, 
including PF-477736 in lymphoma (Ferrao et al, 2012), Chk1-A in leukaemia 
(Davies et al, 2011a) and most interestingly AR323 and AR678 in melanoma 
(Brooks et al, 2012). 
Evaluation of the functional ability of CHIR-124 showed that CHIR-124 was 
indeed able to over-ride the G2-M checkpoint (Figure 6.2A and B) which would 
normally be induced by Chk1 after IR treatment, and that downstream targets of 
Chk1 associated with induction of the checkpoint such as CDC25C and CDK1 are 
successfully supressed in the presence of CHIR-124 both alone and after IR 
treatment (Figure 6.2C). Thus as CHIR-124 was successfully shown to inhibit 
phenotypes associated with active Chk1, evaluation of the anti-survival effects 
of CHIR-124 on a panel of metastatic melanoma cell lines was undertaken. 
Analysis showed that CHIR-124 was able to induce cell death in all melanoma 
cell lines tested, with between 25-60% of cells double Annexin: PI positive within 
48hrs of treatment (Figure 6.3H). In most, although not all, cases cell death 
induced was characterised by an apoptotic phenotype, including cleavage of 
PARP (Figure 6.4) and Annexin V staining (Figure 6.3A-G). This data suggests that 
cell death induced by Chk1 inhibition is apoptotic, which is concurrent with 
other studies which looked at Chk1 inhibition as a single agent (Brooks et al, 
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2012; Davies et al, 2011a; Ferrao et al, 2012). These studies also saw that Chk1 
inhibition caused cell death by caspase-dependant apoptosis in their respective 
systems.  Genetic analysis shows that cell line Sk-Mel-28 carries a mutant p53 
(L145R) and cell lines Sk-Mel-103 and Sk-Mel-147 are null/mutant for the CDK2NA 
locus respectively (Table 5.1). The CDK2NA locus is a common site for mutations 
in melanoma (Ibrahim & Haluska, 2009) and encodes both the p16 and ARF 
proteins. ARF is a negative inhibitor of the p53 inhibitor MDM2 (Sherr, 2006) 
therefore cell lines Sk-Mel-103 and Sk-Mel-147 have a deregulated p53 pathway. 
This suggests that the apoptotic cell death induced by Chk1 inhibition in these 
cell lines is independent of the p53 pathway. Although p53 is well known to be a 
key initiator of apoptosis recent studies have shown that in p53 deficient cell 
lines, HCT 116 (p53-/-) and Hep3B,  apoptotic cell death can be induced in a 
TRAIL/DR5 –dependant manner (Cheng et al, 2012; Yeh et al, 2012). In HCT 116 
(p53-/-) cells this was shown to be dependent on the up regulation of TRIAL/DR5 
by JNK signalling (Cheng et al, 2012). However Sk-Mel-39 which also carries a 
mutant p53 fails to initiate cell death by apoptosis upon Chk1 inhibition with no 
cleavage of PARP or Annexin V staining after treatment (Figure 6.4E and Figure 
6.3E respectively). This may be a result of the p53 status of this cell line 
however it could also represent a cell line specific phenotype as Sk-Mel-39 cells 
also fail to induce apoptosis after staurosporine treatment despite staurosporine 
being shown to induce both caspase -dependant and –independent apoptosis in 
melanoma cell lines (Zhang et al, 2004). 
  
Inhibition of Chk1 by CHIR-124 during an unperturbed cell cycle caused the 
generation of DNA damage specifically in S-phase cells (Figure 6.6 and 6.7), with 
a concurrent blockage of cells in early S-phase (Figure 6.8). This data suggests 
that Chk1 inhibition does not affect entry to S-phase, but once there normal DNA 
replication is inhibited and DNA damage is generated. Studies have shown that 
Chk1 is important during unperturbed S-phase where active Chk1 is required to 
avoid deleterious DNA breakage in the absence of exogenous DNA damaging 
agents (Lam et al, 2004; Maya-Mendoza et al, 2007; Petermann & Caldecott, 
2006). A possible mechanism for this indicates that DNA damage occurs as a 
consequence of the deregulation of the ATR-CHK1-CDC25-CDK pathway with 
uncontrolled CDK activity being implicated (Beck et al, 2010; Sorenson et al, 
2004; Toledo et al, 2011). This has been demonstrated by studies whereby the 
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deleterious effects of Chk1 inhibition or siRNA knockdown, such as accumulation 
of ssDNA  and DNA DSBs, can be blocked by depleting CDC25C (Beck et al, 2010). 
Other studies have shown that siRNA knockdown of Wee1 also rapidly induces 
DNA damage in S-phase cells, similar to Chk1 inhibition (Beck et al, 2010). As the 
target of Chk1, Wee1 and CDC25C is the CDK1, it has been postulated that 
uncontrolled CDK1 activity is responsible for the generation of DNA damage. 
Furthermore depletion of ATR leads to DNA damage and deregulation of CDC25 
in the absence of exogenous DNA damaging agents (Sorenson et al, 2004), with 
the damage occurring in this instance blocked by depletion of CDC25 (Toledo et 
al, 2011).  
 
In a perturbed cell cycle whereby DNA replication is block by aphidicolin the 
inhibition of Chk1 leads to destabilisation and collapse of stalled replication 
forks (Figure 6.9) which were generated by the inhibition of DNA polymerase by 
aphidicolin. Studies have shown that Chk1 is also important during perturbed S-
phase cycling where it acts to stabilise replication forks and supress the firing of 
late origins (Conti et al, 2007; Seiler et al, 2007; Zachos et al 2003; Zachos et al 
2005). Although CHIR-124 did cause destabilisation of stalled replication forks 
there was no evidence in this instance for the generation of new replication 
origins of firing during Chk1 inhibition as seen in previous studies.  
Calculation of EC50 values generated from dose-response curves showed that 
CHIR-124 had significant toxicity in all metastatic melanoma cell lines, with the 
calculated EC50 being less than that of DTIC or TMZ for all cell lines (Figure 
6.12). There was a broad variation in the relative toxicity of CHIR-124 (Figure 
6.13) with cell lines A375MM, Sk-Mel-2, Sk-Mel-103 and Sk-Mel-147 showing the 
greatest sensitivity after 72hrs treatment. In vivo analysis of the tumour growth 
rate of subcutaneously injected A375MM melanoma cells in CD1 nudes showed 
that CHIR-124 treatment caused a clear reduction in the tumour growth rate as 
compared to vehicle (Figure 6.14). This reduction was also greater than that 
seen in DTIC treated animals (Figure 6.15).  
 
This data suggests that CHIR-124 could have potential as a single agent in the 
treatment of advanced melanoma, especially in N-Ras mutant cell lines which 
were most sensitive. This could be of clinical importance as most new targeted 
therapies for melanoma are for the treatment of B-Raf mutated melanomas with 
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only one inhibitor of N-Ras currently in clinical trials (R115777) (Eggermont & 
Robert, 2011). CHIR-124 could also have potential in combination therapy with 
both known anti-cancer therapies and novel inhibitors of cell cycle proteins. 
Although not tested here it has been shown to increase the efficacy of known 
cytotoxic agents such as topoisomerase inhibitors in MDA-MB-435 breast cancer 
cells (Tse et al, 2007), IR in HCT 116 cells (Tao et al, 2009) and gemcitabine in a 
multicellular tumour spheroid model of pancreatic cancer (Dufau et al, 2012). In 
more recent studies CHIR-124 has been shown to increase the sensitivity to cell 
death induced by histone deacetylase inhibitors (Lee J et al, 2011) and Wee1 
(Carassa et al, 2012; Davies et al, 2011b). Furthermore recent studies have 
shown that chemo-resistance in melanoma cells could be, at least in part, 
through a MAPK-dependant alteration of Chk1 signalling. It has been shown that 
the p90 ribosomal S6 kinase, a direct downstream target of MAPK signalling from 
both N-Ras and B-Raf mutant melanomas, phosphorylates Chk1 on an inhibitory 
site, S280, both in vitro and in vivo (Ray-David et al, 2012). In addition inhibition 
of p90 ribosomal S6 kinase increased Chk1 activity in response to DNA damaging 
agents, and concurrently increased the sensitivity of melanoma cells to these 
agents (Ray-David et al, 2012). 
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7 Summary & Future Directions 
7.1 Summary 
One of the key aims of this thesis was to investigate the requirement of Chk1 in 
melanocyte cell survival and melanoma initiation, maintenance, and progression 
in vivo, which is described in Chapters 3 and 4 respectively.  
In order to address the first question I utilised a conditional knockout mouse 
model of Chk1 in combination with a melanocyte-specific Cre-recombinase. This 
allowed for the specific deletion of Chk1 in the melanocyte lineage during 
embryogenesis. Melanocytes were visualised using a reporter gene, LacZ, which 
was driven from a melanocyte-specific promoter.  
 
Using this model I showed that Chk1 expression is essential for the survival of 
melanocyte precursor cells, melanoblasts, during embryonic development. 
Homozygous deletion of Chk1 caused a complete loss of melanoblasts during 
development resulting in a non-pigmented adult mouse. IHC analysis showed 
that there were high levels of DNA damage, as marked by γH2AX, in these Chk1 
deleted melanoblasts. In addition I also showed that while homozygous deletion 
of Chk1 is severely detrimental to the survival of melanoblasts, hemizygous 
deletion has no effect on the phenotype of adult mice, with only a small but 
nevertheless significant decrease in melanoblast numbers during development. 
These data show that while complete Chk1 loss is not consistent with cell 
survival, loss of one copy of Chk1 is well tolerated demonstrating that one copy 
of Chk1 is mostly capable of performing the essential functions of Chk1 in 
melanocytes.  
 
While I have been able to show that Chk1 is essential for the survival of 
melanocyte precursor cells during development, which are the cells of origin for 
melanoma, in order to further determine the role of Chk1 in melanocytes during 
melanoma development I utilised another mouse model. In order to address the 
second question I used the aforementioned conditional knockout mouse model of 
Chk1 in combination with an inducible melanocyte-specific Cre-recombinase. 
This allows for spatially and temporally controlled deletion of Chk1 from 
melanocytes. These mice were crossed onto a mouse model of melanoma 
whereby an oncogenic N-Ras (Q61K) is expressed specifically in melanocytes on a 
Chapter 7  193 
 
p16Ink4a-deficient background. From these mice cell lines were generated which 
were subsequently used for allograft experiments in CD1 nude mice.  
 
Using this model I showed that complete loss of Chk1 during tumour 
development caused a profound reduction in the proliferation potential of 
melanoma tumour formation with a concurrent significant increase in survival 
time in these mice. In addition I also showed that hemizygous deletion of Chk1 
during tumour development exerts a more modest but nevertheless measurable 
effect on melanoma tumour formation, however with no demonstrable effect on 
survival time. Furthermore in metastatic models (tail-vein injected CD1 nudes) 
hemizygous deletion of Chk1 had a significant but transient effect on the 
metastatic growth rate, as demonstrated by the increase in survival time, but 
with the same metastatic burden at time of death. This data shows that 
reduction in Chk1 levels modestly effects both the primary tumour formation of 
melanoma in vivo, and the proliferation/survival of metastatic growths. In 
addition while hemizygous deletion has a slight effect, the complete loss of Chk1 
is severely detrimental for primary tumour formation of melanoma in vivo. 
Collectively these data show that Chk1 is essential for the maintenance and 
progression of melanoma in vivo.  
 
Another aim of this thesis was to examine the function of ATR/Chk1 signalling in 
melanoma cells, which is described in Chapter 5. 
 
The ATR/Chk1 pathway is activated by RPA-coated tracts of ssDNA which are 
generated in response to replicative stress, DNA damaging agents that directly 
cause single-stranded breaks and after resection of DNA DSBs, and is therefore 
important in the response to a wide variety of cellular stresses. Two of the cell 
cycle checkpoints that ATR/Chk1 are required for are the G2/M and S/M 
checkpoints; however they also play key roles in the intra-S checkpoint and the 
mitotic spindle checkpoint.  
 
In order to determine the functions of ATR/Chk1 signalling in melanoma cells I 
first assessed G2/M and S/M checkpoint proficiency in response to IR and 
replicative stress respectively. Interestingly, I demonstrate that in response to 
replicative stress, induced by inhibition of DNA polymerase upon aphidicolin 
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treatment, all melanoma cell lines tested were able to activate Chk1 and induce 
a cell cycle arrest such that no cells entered mitosis in the presence of DNA 
which was not fully replicated. However in response to DNA DSBs induced by IR, 
most but not all melanoma cell lines were able to activate Chk1 and induce a 
G2-phase blockage. In the cell lines which displayed a weaker G2/M checkpoint 
response the mechanism by which Chk1 function is altered in unclear. Several 
cell lines showed that activation of Chk1 was impaired, suggesting that the 
upstream signal is short-lived or that Chk1 itself is ‘turned off’ rapidly. However 
several other melanoma cell lines with as weak checkpoint responses showed 
strong activation of Chk1 as expected in response to IR, suggesting that the 
upstream signalling is intact but that the signal is somehow not transmitted 
appropriately downstream of Chk1. 
  
This data suggests that while the G2/M checkpoint is apparently dispensable for 
cell survival, the S/M checkpoint may not be. Other studies have also shown that 
DNA damage-induced checkpoint function of Chk1 can be disrupted in cells 
without affecting cell survival (Wilsker et al, 2008). In addition, although not 
fully understood mechanistically, this data also shows that despite functioning 
through presumably the same downstream cyclin/CDK targets the G2/M and S/M 
checkpoints can be distinguished from each other, with loss of G2/M checkpoint 
but maintenance of S/M checkpoint function in some melanoma cell lines. 
  
In addition I also analysed the importance of MRN complex signalling in Chk1 
activation following IR-induced DNA DSBs. The MRN complex is a key sensor of 
DNA DSBs and is important in activating the ATM/Chk2 pathway and for DNA 
strand resection, facilitating DNA repair and ATR/Chk1 activation. In melanoma 
cell lines that lacked expression of Mre11, with concurrent reductions in both 
Nbs1 and Rad50, I showed that the MRN complex is essential for activation of 
Chk2 following IR treatment but not for activation of Chk1. Although after 
transient transfection of Mre11 into these cell lines, I was able to show that the 
addition of Mre11, and presumed activation of the MRN complex, was able to 
enhance the activation of Chk1 following IR treatment, especially at later time 
points post-treatment. This is consistent with other recent studies that have 
shown that although the initial activation of Chk1 is not dependant on MRN 
complex signalling it does play a role in the maintenance of Chk1 activation 
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after IR-induced DNA damage (Buis et al, 2008; Kousholt et al, 2012, Sartori et 
al, 2007).  
 
The final aim of this thesis was to determine if inhibition of Chk1 is a viable 
therapeutic strategy in the treatment of advanced metastatic melanoma, a 
cancer that is largely refractory to current standard treatments, which is 
described in Chapter 6.  
 
Due to the well-established role of Chk1 in the DDR pathway and during 
unperturbed cell cycling many Chk1 inhibitors have been developed for cancer 
therapy. In order to assess the potential of Chk1 inhibition for melanoma therapy 
I used a specific allosteric inhibitor of Chk1, CHIR-124, which has been shown to 
have high selectivity for Chk1 over other related kinases.  
 
Firstly I showed that inhibition of Chk1 with CHIR-124 was effective at causing 
apoptotic cell death in a dose- and time-dependent manner in most metastatic 
melanoma cell lines, as demonstrated by cleavage of PARP and subsequent 
Annexin V staining. However there was one single cell line that did not induce 
apoptotic cell death in the presence of CHIR-124, with no cleavage of PARP or 
Annexin V staining, but rather becoming only PI positive after treatment 
suggesting another mechanism of cell death. This could be due to the mutant 
p53 status of this cell line; however it could also represent a cell line-specific 
phenotype as another p53 mutant cell line was also able to initiate apoptotic 
cell death.  
 
In order to elucidate mechanistically why Chk1 inhibition causes cell death I 
analysed the generation of DNA damage upon CHIR-124 treatment in otherwise 
unperturbed cycling cells. I was able to show that DNA damage, as marked by 
γH2AX, was generated specifically in S-phase cells, labelled by EdU 
incorporation, upon Chk1 inhibition which is in contrast to other DNA damaging 
agents that generate DNA damage non-selectively of cell cycle. I also showed, by 
pulse-labelling of S-phase cells with BrdU, that in the presence of CHIR-124 
melanoma cells could enter S-phase normally but once there normal DNA 
replication was inhibited resulting in DNA damage. In addition during a 
perturbed cell cycle, whereby S-phase is blocked by aphidicolin which causes 
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active replication forks to stall, Chk1 inhibition resulted in collapse of these 
stalled replication forks.  This is consistent with studies which have shown that 
Chk1 is important during unperturbed S-phase where active Chk1 is required to 
avoid deleterious DNA breakage even in the absence of exogenous DNA damaging 
agents (Lam et al, 2004, Petermann & Caldecott, 2006; Maya-Mendoza et al, 
2007), and also during perturbed S-phase cycling where it acts to stabilise 
replication forks and supress the firing of late origins (Conti et al, 2007; Seiler et 
al, 2007; Zachos et al, 2003; Zachos et al, 2005).  
 
I also showed via analysis of cell viability in response to a range of drug doses 
that CHIR-124 has significant toxicity in vitro in all metastatic melanoma cell 
lines, with the calculated EC50 being less than that of dacarbazine and 
temozolomide in each cell line; two chemotherapeutic alkylating agents used in 
the treatment of advanced melanoma.  However there was a broad range of 
relative toxicities to Chk1 inhibition between cell lines. Further in vivo analysis 
also showed that CHIR-124 treatment caused a measurable reduction in the 
tumour growth rate of subcutaneously injected metastatic melanoma cells in 
CD1 nude mice. This data suggests that Ch1 inhibition could have potential as a 
single agent treatment for advanced melanoma, especially in N-Ras mutant cell 
lines which were most sensitive to CHIR-124 treatment.  Recent studies have 
also demonstrated that Chk1 inhibition may have potential as a single agent 
treatment in some cancer types; including lymphoma, leukaemia and melanoma 
(Brooks et al, 2012; Davies et al, 2011a; Ferrao et al, 2012), with Chk1 activity 
recently being implicated in the chemo-resistant phenotype of melanoma cells 
to DNA damaging agents (Ray-David et al, 2012).  
 
7.2 Future Directions 
The work presented here demonstrates that Chk1 is essential for the survival of 
normal melanocytes during development in vivo. In addition, complete loss of 
Chk1 is severely detrimental for melanoma tumour growth in allograft nude 
mouse models, whilst Chk1 hemizygousity is also detrimental although to a lesser 
degree. However it is still unclear what role Chk1 may play in melanoma 
formation in a more physiologically relevant in vivo model.  Furthermore owing 
to the relatively rapid growth of implanted tumour cells in nude mouse studies it 
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is difficult to determine the role that Chk1 may play at different stages of 
tumour development. For instance would Chk1 deletion have a more or less 
profound effect on tumour initiation if deleted before the onset of a tumour, 
compared to its effect on tumour maintenance and progression if deleted at 
later stages of tumour development? If Chk1 was deleted once a tumour has 
formed, would this prevent further tumour progression, slow but not stop 
tumour progression, or cause regression of the primary tumour? In addition there 
is data to suggest that Chk1 may act as a dose-dependent tumour suppressor 
with Chk1 haplo- insufficiency promoting tumour development in some 
instances, whilst inhibiting tumour development in others. As such, how does 
hemizygousity for Chk1 at different stages of growth specifically affect 
melanoma tumour development?  
In addition other work presented in this thesis demonstrates that Chk1 inhibition 
alone can have cytotoxic effects in melanoma tumour cells both in vitro and in 
vivo, with cell death being associated with high levels of DNA damage induced in 
S-phase cells accompanied by collapse of replication forks. However I observed a 
broad range of sensitivity to the cytotoxic effects of Chk1 inhibition, with EC50 
values ranging from the nano-molar to micro-molar range. Although this data 
suggest that targeting Chk1 may have therapeutic potential it is still unclear how 
Chk1 inhibition mechanistically affects both tumour and normal cells, and how 
this initiates cell death. In addition it is also unclear what mechanisms may 
underlie any apparent selectivity and sensitivity to Chk1 inhibition, and how 
these could be manipulated for therapy. Collectively this could be of importance 
for the clinical application of Chk1 inhibitors; both in terms of understanding any 
potential side effects and to which tumour types Chk1 therapy should be 
targeted.  
As with data presented here whereby Chk1 loss severely inhibited melanoma 
tumour growth other studies have also shown that Chk1 deficiency inhibits 
tumour formation in other systems. In both mammary tumour formation and skin 
carcinogenesis studies (Fishler et al, 2010; Tho et al, 2012) Chk1 deficiency 
inhibited tumour formation, however these studies primarily examined tumour 
initiation. In this thesis Chk1 loss was induced one week after tumour cell 
implantation, in the mammary study Chk1 was constitutively deleted using a 
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mammary-specific Cre-recombinase (Fishler et al, 2010), and in the skin 
carcinogenesis study Chk1 was deleted prior to initiation with chemical 
carcinogens (Tho et al, 2012). In fact, if treatment with chemical carcinogens 
was delayed for some time after Chk1 deletion, which allowed for repopulation 
of the skin with Chk1 proficient cells, normal sensitivity was restored, 
highlighting the importance of Chk1 expression for tumour initiation (Tho et al, 
2012). 
While complete Chk1 loss therefore inhibits tumour growth, hemizygous deletion 
has more varied effects. In data presented here Chk1 hemizygousity had a 
detrimental effect on melanoma tumour formation although to a lesser degree 
than complete loss. However in contrast to this Chk1 hemizygousity in mammary 
tissue enhanced tumour formation on both a p53 null background (Fishler et al, 
2010) and a WNT-1 transgenic model (Liu et al, 2000). Whilst in skin 
carcinogenesis Chk1 hemizygousity had no effect on benign papilloma formation 
but did increase the propensity for conversion to carcinoma (Tho et al, 2012). It 
is interesting to note that while Chk1 hemizygousity in mice can affect tumour 
formation in combination with other oncogenic changes or chemical carcinogens, 
in the absence of such initiating stimuli it does not increase spontaneous 
development of cancer, but rather has modest effects on normal tissue 
homeostasis. For instance in the mammary gland Chk1 hemizygousity causes 
abnormal development of the tissue associated with cell cycle defects (Fishler et 
al, 2010; Liu et al, 2000), while in the haematopoietic system it causes cellular 
defects resulting in anaemia (Boles et al, 2010). This is consistent with data 
presented here whereby hemizygous loss of Chk1 from melanocytes during 
embryogenesis caused a slight but significant decrease in cell number but with 
no observable alteration to the coat phenotype of adult mice. This apparent 
difference in sensitivity to Chk1 loss between normal unperturbed cells and 
tumour cells could be explained by the increase in genomic instability seen in 
tumour cells during malignant progression. As a consequence of this tumour cells 
may be more sensitive to alterations in Chk1 levels, thereby affecting cell 
maintenance, and promoting malignant transformation. In addition this apparent 
selectivity could also be due to the high replicative rate of tumour cells versus 
normal cells, as Chk1 has seen shown to be important during S-phase of cycling 
cells. This could account for the more dramatic effect seen in the 
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haematopoietic system, as this is a normal cell type which is rapidly 
proliferating in humans. 
In data presented here Chk1 appears to be rate-limiting to melanoma tumour 
growth. If this was true in other systems it could be expected that Chk1 
expression and activation may alter during malignant progression. Studies have 
shown that, at least in some cell types, Chk1 expression does alter during cancer 
development in humans. In colorectal cancer Chk1 protein expression is used as 
a marker of cancer, with 100% of tumours at various stages staining positive for 
Chk1 (Madoz-Gurpide et al, 2007). In colorectal cancer it has been shown that 
there is a strong accumulation of Chk1, with an intense nuclear and cytoplasmic 
staining compared to normal tissue, with total Chk1 expression being up-
regulated in late stages (Madoz-Gurpide et al, 2007). In myc-amplified 
neuroblastoma cells and high-risk primary tumour samples both Chk1 mRNA 
levels and phosphorylated protein (S345) levels were constitutively increased 
compared to normal cell lines and low-risk primary tumours (Cole et al, 2011). 
This suggests that Chk1 is probably important during maintenance and 
progression of late stage tumours as well as for initiation, with Chk1 potentially 
being more important at later stages, as demonstrated by its increased 
expression and activity. Late stage tumours have high levels of genetic 
instability; Chk1 plays an important role in maintaining genomic stability. 
Therefore Chk1 could potentially be important to maintain the levels of genetic 
instability at levels which are compatible with tumour cell survival. However this 
increase in Chk1 expression and activity could also be a consequence of the 
increased DNA damage associated with advanced tumours. Therefore are 
changes in Chk1 levels causative or consequential to tumour development? It is 
interesting to note that Chk1 protein levels in the melanoma cells examined in 
this thesis are much lower than in HCT-116 cells, a colon-carcinoma cell line 
(Figure 5.9).  
Chk1 inhibition has been developed as a potential therapeutic target for cancer 
both in combination with standard chemotherapeutic agents and recently with 
more targeted selective partners such as Wee1 inhibitors (Carrassa et al, 2012; 
Davies et al, 2011b). In addition use as a single agent in some cancer types has 
been studied (Davies et al, 2011a; Ferrao et al, 2012). Chk1 inhibition as a 
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clinical modality initially came about as a targeted synthetic lethal approach in 
combination with standard chemotherapeutics. The rationale behind this 
approach was that most standard chemotherapeutics induce large amounts of 
DNA damage, which will subsequently activate Chk1. In this instance Chk1 
activation is thought to be protective triggering cell cycle arrest while the DNA 
damage is repaired. This is similar to the initial concept for PARP inhibition 
which was thought to protect cells following DNA damaging agents by activating 
DNA repair pathways, although the mechanism for PARP selectivity has recently 
shown to be more complex with PARP inhibition playing a role in increasing 
spontaneous DNA damage as well as blocking DNA repair (Murai et al, 2012). The 
philosophy behind those approaches is in contrast to other recent drug 
development strategies which have focused on targeting specific molecular 
alterations within cancer cells that are essential for their survival, such as 
Gleevec which targets the oncogenic bcr-abl kinase in CML.  
In data presented here it was demonstrated that Chk1 inhibition alone can have 
cytotoxic effects in melanoma cell lines both in vitro and in vivo, however with 
a wide range in sensitivity. One potential mechanism for the variations in 
sensitivity seen to Chk1 inhibition could be inherent differences in proficiency of 
DDR pathway signalling within melanoma cells. Chk1 is an important effector 
kinase in cell cycle checkpoints of the DDR pathway, and as such Chk1 inhibition 
has been shown to be more potent in tumours where other aspects of this 
pathway are deficient. For example, tumour cells deficient in Fanconi anaemia 
(FA) genes, which are responsible for the repair of cross-linked DNA lesions, are 
hyper-sensitive to Chk1 inhibition and siRNA knockdown in comparison to FA-
proficient cells (Chen et al, 2009). Silencing of FA genes resulted in hyper-
activation of Chk1, which when inhibited was associated with increased DNA and 
chromosomal breaks (Chen et al, 2009). The MRN complex is a key sensor of DNA 
DSBs, and is important in initiating cell cycle checkpoints and processing of the 
lesions to allow DNA repair. Recently it has been shown that the Mre11 protein, 
a component of the MRN complex, is critical for sensitivity to Chk1 inhibition 
with loss of Mre11 leading to resistance associated with decreased levels of 
ssDNA and DNA DSBs following Chk1 inhibition (Thompson et al, 2012). Although 
not completely consistent I did observe that one of the melanoma cell lines 
which was deficient for both Mre11 and Nbs1 expression, Sk-Mel-39, was also 
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more resistant to Chk1 inhibition as compared to other cell lines (Figure 6.13). 
However cell lines Sk-Mel-103 and Sk-Mel-147, which lack Mre11 expression or 
have low levels of Mre11 expression respectively, did not show this resistance. 
Another important component of the DDR pathway is p53. p53 is a potent 
inducer of cell death under conditions of DNA damage and a key regulator of the 
G1/S checkpoint. p53 is mutated or lost in many cancers which as a result lose 
G1/S checkpoint function which theoretically makes them more reliant of other 
checkpoints controlled by Chk1. Studies have shown that p53-deficient triple 
negative breast cancer cells are sensitive to Chk1 inhibition resulting in cell 
death (Ma et al, 2012). Other studies have shown that Chk1 inhibition 
potentiates the cytotoxic effects of DNA damaging agents in p53-deficient cells 
but not in p53-proficient cells of various tissue origins (Chen et al, 2006). 
However other findings show that p53 status does not necessary predict the 
efficacy of Chk1 inhibition (Zenvirt et al, 2010). Thus in experiments where Chk1 
inhibition was shown to abrogate cell cycle arrest following DNA damage, p53-
deficient cells were no more sensitive to Chk1 inhibition than p53-proficient 
cells (Zenvirt et al, 2010). In contrast, in myc-driven lymphoma cells in vitro and 
in vivo, p53 wild-type: Arf null cells were more sensitive to Chk1 inhibition than 
there p53 null: Arf wild-type counterparts (Ferrao et al, 2012). This is consistent 
with data presented here, whereby melanoma cell lines which were null or 
mutant for the CDKN2A locus, Sk-Mel-103 and Sk-Mel-147, were more sensitive to 
Chk1 inhibition than those with a wildtype CDKN2A locus, Sk-Mel-5, Sk-Mel-28 
and Sk-Mel-39 (Figure 6.13). This apparent discrepancy could be explained by 
recent data which suggests that sensitivity to Chk1 inhibition is due to loss of 
p21 expression, a downstream target of p53, rather than p53 itself (Origanti et 
al, 2012). In this study loss of p21 sensitised cells to Chk1 inhibition in 
combination with DNA damaging agents much more than p53 loss. In addition 
basal pools of p21, which are p53-independent, provided protection to 53 null 
cells following treatment (Origanti et al, 2012). 
Other potential mechanisms associated with sensitivity to Chk1 inhibition are 
high levels of endogenous DNA damage and replicative stress. In melanoma cell 
lines sensitivity to Chk1 inhibition correlated with the levels of endogenous DNA 
damage, an indicator of replicative stress, while normal melanocytes were only 
sensitive at much higher concentrations of drug (Brooks et al, 2012). In these 
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cells Chk1 inhibition promoted premature mitotic entry of aberrant S-phase cells 
resulting in a dysfunctional mitosis and cell death (Brooks et al, 2012). Similarly, 
in both myc-driven lymphoma and neuroblastoma cells, which exhibit high levels 
of DNA damage due to myc-induced replicative stress, Chk1 inhibition induced 
cytotoxic effects resulting in accumulation of DNA damage and cell death that 
was not seen in either normal B-cells or normal NC-cells respectively (Cole et al, 
2011; Ferrao et al, 2012). In myc-amplified neuroblastoma cells apoptosis was 
shown to be specifically induced during replication (Cole et al, 2011). Consistent 
with this, data presented in this thesis has also pointed to the idea that there is 
a replication associated mechanism for the cytotoxic effects of Chk1 inhibition, 
as DNA damage following Chk1 inhibition was specifically generated in S-phase 
cells. In addition Chk1 inhibition seemed to alter progression through S-phase 
with an increase in replication fork collapse. Studies have suggested that this 
may be due to uncontrolled CDK activity; however a mechanism is still unclear. 
It would be interesting to elucidate if sensitivity to Chk1 inhibition in melanoma 
cells, at least in part, is attributable to the proliferation rate of these cells; for 
instance are senescent melanocyte cells resistant to Chk1 inhibition? Data would 
suggest that while Chk1 loss causes acute cell death in a subset of cells within 
normal tissues there is no dramatic effect to the overall homeostasis of the 
tissue (Greenow et al, 2009; Tho et al, 2012). For instance in the small intestine 
Chk1 loss resulted in crypt cell death while in skin Chk1 loss resulted in cell 
death mainly within the hair follicle, however in both incidences there was no 
overt defect to the tissue structure (Greenow et al, 2009; Tho et al, 2012) 
suggesting that most cells in a tissue which are differentiated are not affected 
by Chk1 loss. Furthermore deletion of ATR in adult mice leads to the rapid 
appearance of age-related phenotypes including hair greying. These phenotypes 
were associated with a dramatic reduction in tissue-specific stem and progenitor 
cells, resulting in exhaustion of tissue renewal and homeostatic capacity 
(Ruzankina et al, 2007). This could be important for understanding the clinical 
application of Chk1 inhibitors, especially in terms of side effects. Collectively 
these data might suggest that Chk1 inhibition in cancer cells may act, either in 
combination with other drugs or due to genetic alterations already present, by 
increasing the genomic instability to such an extent that cell survival is no longer 
viable. 
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This concept has similar parallels to that of standard chemotherapeutics which 
have been proposed to exploit the mutator phenotype of cancer cells, however 
perhaps with a slightly more targeted rational. The mutator phenotype of cancer 
cells refers to the high levels of genetic instability seen in cancers which may 
facilitate cellular plasticity and adaptation allowing for the continued growth of 
cancer cells in otherwise detrimental conditions (Fox & Loeb, 2010). However a 
major consequence of this genetic instability is that many cancer cells may exist 
at a threshold of mutational load, beyond which cell survival is no longer 
possible. Most standard cancer therapies induce DNA damage which may in some 
situations at least push the cancer cells above this threshold resulting in cell 
death through lethal mutagenesis. Evidence that Chk1 may protect against such 
effects comes from recent data which shows that overexpression of Chk1, by 
addition of an extra allele, is protective and promotes transformation (Lopez-
Contreras et al, 2012). In vitro mouse embryonic fibroblasts (MEFs) expressing an 
extra allele of Chk1 were protected against agents that induce replicative stress, 
and furthermore against oncogene-induced replicative stress. This suppression of 
replicative stress was associated with increased efficiency of transformation 
(Lopez-Contreras et al, 2012). This suggests that targeting genomic instability 
and the inherent increased mutation rate of cancer cells could be a viable 
therapeutic strategy. Evidence for this comes from the observation that PARP 
inhibitors are more lethal in cancer cells which lack HR repair, than those that 
are proficient. Cancer cells which lack HR repair have a high rate of mutagenesis 
and genomic instability. In this instance inhibition of PARP, which is responsible 
for base excision repair, will presumably increase the mutation rate and thus 
genomic instability of these cells resulting in cell death (Audeh et al, 2010; 
McCabe et al, 2006).    
In addition to the work presented here I also carried out a limited in vitro 
analysis of Chk1 inhibition in combination with 5-flurouracil (5-FU) and with a 
selective PARP inhibitor (AZD2281). In this limited analysis, carried out on three 
metastatic melanoma cell lines, I did not see any synergy between the Chk1 
inhibitor CHIR-124 and 5-FU. In fact, in most cases the addition of 5-FU 
decreased the apparent sensitivity to CHIR-124. This is in contrast to a study 
which has shown that siRNA of Chk1 in HCT-116 cells is able to sensitize them to 
5-FU treatment (Ganzinelli et al, 2008). Analysis with PARP inhibition was less 
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clear with synergy seen in some but not all cell lines. Recent studies have shown 
that both Chk1 inhibitors and dual Chk1/2 inhibitors increase endogenous PARP 
activity, which is blocked by PARP1 inhibition resulting in increased cell death in 
a breast cancer cell lines (Mitchell et al, 2010; Tang et al, 2012). In addition 
there is other published data demonstrating that Chk1 inhibition increases the 
cytotoxic effects of other known genotoxins including IR, cisplatin, gemcitabine 
and topoisomerase inhibitors. It would be interesting to examine which 
combinations do show, if any, synergy with the Chk1 inhibitor CHIR-124 both in 
vitro and in vivo, in the context of melanoma? Interestingly a recent synergistic 
relation between Chk1 and its downstream target Wee1 has been discovered, 
with Wee1 inhibitors markedly increasing the cytotoxic effects of Chk1 inhibition 
in ovarian and neuroblastoma cells (Carrassa et al, 2012; Russell et al, 2012).  
In conclusion the work presented here suggests that Chk1 is important for the 
development of malignant melanoma, and that targeted Chk1 inhibitors may be 
a viable therapeutic application for the treatment of melanoma. However 
whether this is in combination with other drugs or in context with the specific 
genetic background of cancer types remains to be seen.  
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